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ABSTRACT OF DISSERTATION 
 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL RESVERATROL AND 
COMBRETASTATIN A4 DERIVATIVES AS POTENT ANTI-CANCER AGENTS 
Resveratrol has been reported as a potential anticancer agent but cannot be used as an 
antitumor drug due to its chemical and metabolic instability. We have designed and 
synthesized 184 novel compounds related to resveratrol in an attempt to produce more 
potent and drug-like molecules. We have identified a tetrazole analog of resveratrol, ST-
145(a) as a lead anticancer agent from the resveratrol analog series of compounds with a 
GI50 value of less than 10nM against almost all the human cancer cell lines in the 
National Cancer Institute’s screening panel.  
In a separate study, we tested the hypothesis that the limited bioavailability of resveratrol, 
can be improved by synthesizing analogs which would be glucuronidated at a lower rate 
than resveratrol itself. We demonstrated that ST-05 and ST-12(a) exhibit lower 
glucuronidation profiles when compared to resveratrol and that these synthesized 
stilbenoids likely represent useful scaffolds for the design of efficacious resveratrol 
analogs. 
We have also initiated a new discovery program to identify selective CB1 and CB2 
receptor ligands from a library of novel stilbene scaffolds structurally related to the 
resveratrol molecule. From the screened resveratrol analogs, two compounds were 
identified as selective CB2 and CB1 ligands. Compound ST-179 had 47-fold selectivity 
for CB2 (Ki = 284 nM) compared to CB1, while compound ST-160 was 2-fold selective 
for CB1 (Ki = 400 nM) compared to the CB2 receptor. These structural analogs have the 
potential for development as novel cannabinoid therapeutics for treatment of obesity 
and/or drug dependency.
 
Combretastatin A4 (CA-4) is one of the most potent antiangiogenic and antimitotic 
agents of natural origin. However, CA-4 suffers from chemical instability due to cis-trans 
isomerism in solution. To circumvent this problem, we have developed a facile procedure 
for the synthesis of novel 4,5-diaryl-2H-1,2,3-triazoles as CA-4 analogs to constrain the 
molecule to its cis-configuration. Twenty three triazoles were prepared as CA-4 analogs 
and submitted for anticancer screening. Among these CA-4 analogs, ST-467 and ST-
145(b) can be considered as lead anticancer agents from this series, and further 
investigation against various cancer cell types in vivo with this class of compound may 
provide novel therapeutic avenues for treatment. 
Keywords: combretastatin, resveratrol, triazole, tetrazole, cannabinoid 
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Chapter 1: 
Goals of the study and literature review 
 
1.1 Hypothesis: 
The central hypothesis of this work is that the anti-cancer activity, metabolic stability and 
chemical stability of resveratrol can be improved by structural modification of the 
stilbene molecule. The second hypothesis of this work was that the anti-cancer activity 
and chemical stability (cis-trans isomerization) of the related compound, combretastatin 
A4, can be improved by replacing the ethylene bridge with a heterocyclic ring system, 
thereby constraining the molecule to the cis configuration. 
1.2 Overall Aims: 
Cancer is the second most life threatening disease after cardiovascular disease, affecting 
more than six million people per year worldwide. Drastic changes in lifestyle during the 
beginning of 20th century have increased the risk of humans developing different types of 
cancers. Although to date, significant research has carried out to improve treatment of 
various forms of cancer, there is still a lack of effective chemotherapeutic treatment to 
cure most forms of cancer completely. In this respect, considerable effort has been 
focused on identifying molecules with anti-cancer properties from both natural and 
synthetic sources. Herein, two medicinal chemistry projects related to the natural product 
molecules resveratrol and combretastatin A4, both of which possess anticancer 
properties, are presented. 
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Resveratrol (3,5,4-trihydroxystilbene) is a well-known phytoalexin found in grapes, 
peanuts, red wine and other foods. It has been reported as a potential chemotherapeutic 
agent due to its striking inhibitory effects on cellular events associated with cancer 
initiation, promotion, and progression. In clinical studies, resveratrol has demonstrated 
the ability to reduce tumor cell proliferation in patients with colorectal cancer. However, 
resveratrol has some limitations which preclude its use in cancer treatment, since it 
cannot be used as a drug because of its chemical and metabolic instability. This project 
has been designed to improve the chemical and metabolic stability and the anti-cancer 
potency of the resveratrol molecule with structural modifications designed to make the 
molecule more drug like.  
Combretastatin A4 (CA-4), a natural product structurally related the resveratrol molecule 
was first isolated from the South African willow tree, combretum caffrum, by Pettit and 
co-workers (Pettit, Singh et al. 1995). It is one of the most potent antiangiogenic and 
antimitotic agents of natural origin. Combretastatin A4 is structurally and functionally 
similar to a well-known microtubule-targeting agent, colchicine. Its phosphate prodrug 
(CA-4P) is currently in phase 3 clinical trial for the treatment of anaplastic thyroid 
cancer, and it has successfully retarded tumor growth in a wide spectrum of tumor 
models. However, recent studies have reported the chemical instability of CA-4 due to 
cis-trans isomerization to the more thermodynamically stable, but less potent trans-CA-4 
isomer (Nathwani, Hughes et al. 2013). This project has been designed to improve the 
chemical stability and the anti-cancer potency of the resveratrol molecule with structural 
modifications designed to constrict the cis configuration of CA-4. 
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Figure 1.1 Structure of resveratrol and Combretastatin A4 
 
 
1.3 Introduction to cancer  
Cancer is the second most common cause of death in America after cardiovascular 
disease. About 567,628 Americans died of cancer in 2009 alone, almost 11,000 per week. 
About 23 % of deaths in the United States during 2008-2009 were caused by cancer 
(Heron 2012). The cost for the treatment of cancer in the US in 2009 was estimated to be 
$216.6 billion and was expected to double over the next few years. Thus, curing cancer is 
one of the biggest challenges the scientific community is facing in the 21st century. 
Cancer is a disease characterized by unrestrained growth and abnormal spread of cells. If 
the invasion of these abnormal cells to other tissues is not controlled, it may lead to death. 
This abnormality in the cells can be caused by both internal stimuli (hormones, immune 
system, inherited mutations and mutations from metabolism) and external stimuli 
(chemicals, radiation, infectious microorganisms). Both the internal and external factors 
may act together to initiate the development of cancer (Heron 2012). 
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1.4 Natural products as anti-cancer drugs 
Since 1940, a systematic search for novel natural products with interesting biological 
properties has been initiated by pharmaceutical organizations and health institutes all 
around the world. By 1958 Charles Beer had isolated a pure compound from the leaves of 
the Madagascar periwinkle that depleted white cells and named the compound vinblastine 
(Noble, Beer et al. 1959). During the same period, the Eli Lilly Company discovered that 
vinblastine prolonged the life of mice carrying the leukemia cell line P1534. Vinblastine 
is currently being used in the treatment of testicular teratoma and Hodgkin’s lymphoma 
(Gobbi, Broglia et al. 2003). Later, another Vinca alkaloid, vincristine was isolated which 
was used to treat a host of rare childhood cancers such as Wilms tumour, neuroblastoma, 
rhabdomyosarcoma and Ewing’s sarcoma (Johnson, Armstrong et al. 1963).  
 
N
H
N
OH
CO2Me
N
N
O OMe
R
HO
O
OMeO
R
Vinblastine Me
Vinccristine CHO
 
 
 
Figure 1.2 Structures of Vinblastine and Vincristine. 
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Reports of the use of Podophyllum peltatum (Mayapple) for the treatment of cancer 
around 950 AD from the “Leech book of Bald” intrigued the NCI to screen extracts from 
the plant, and thy discovered podophyllotoxin as a potent anticancer drug (Ma, Khan et 
al. 2005). However, due to high toxicity in clinical trials the drug was withdrawn. Further 
SAR studies focused on synthesizing glycoside analogues of podophyllotoxin; this 
approach yielded two successful drugs: Etoposide and Teniposide (Figure 1.3). 
Etoposide is currently being used to treat testicular and small cell lung cancers, 
Teniposide, on the other hand, is used to treat acute lymphoblastic leukemia and rare 
childhood cancers such as neuroblastoma (Ma, Khan et al. 2005). 
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Figure 1.3 Structures of Podophyllotoxin, Etoposide and Teniposide. 
  
In 1958, Monroe Wall discovered and isolated the natural product camptothecin from 
Carmptotheca acuminata, a tree native to China and Tibet. It was found to have potent 
antitumor activity against leukemia cell line L1210. The exact structure was elucidated in 
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1966, and its water soluble analogues, topotecan and irinotecan (Figure 1.4) are used in 
the treatment of colon and ovarian cancer, respectively (Thomas, Rahier et al. 2004).  
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Figure 1.4 Structures of Camptothecin, Topotecan and Irinotecan. 
 
 
The discovery of penicillium by Fleming in 1928 lead scientists to look into 
microorganisms as a source of useful natural products and this led to the discovery of 
several anticancer agents. In 1960, Dr. Faber discovered the anticancer properties of 
actinomycin D (Figure 1.5) and reported its potential for treating Wilms tumour in 
children (Farber, D'Angio et al. 1960). The discovery of actinomycin D introduced a new 
class of antitumor agents from microorganisms. 
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Figure 1.5: Structures of Actinomycin D and Mitomycin C. 
Mitomycin C was first isolated by Wakaki from Streptomyces caespitosus in 1958. It was 
found to be highly toxic towards cancer cells but lacked selectivity, causing bone-marrow 
depression, vomiting, and kidney, liver and heart toxicity. The toxicity of mitomycin C 
was attributed to its bio-reduced product, which can form covalent bonds to DNA, similar 
to alkylating agents (Nguy, Chiu et al. 1987).  
Anthracyclines are a more useful class of anticancer antibiotics. The Arcamone group 
first isolated them in the early 1960s, and they were found to possess potent antitumor 
properties. In the coming years, hundreds of analogues were synthesized and developed 
to yield drugs such as Doxorubicin and Daunorubicin, with a broad spectrum of 
anticancer activity (Arcamone, Franceschi et al. 1964).  
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Figure 1.6 Structures of Daunorubicin and Doxorubicin. 
Another area of developing anticancer agents is the use of hormone mimics. In the early 
1930s Dodd and coworkers reported that a dimer of p-propenyl phenol had potent 
oestrogenic activity and mimicked the activity of estrogen (Hasenbrink, Sievernich et al. 
2006). This lead to the synthesis of a series of dimeric structures, among which 
diethylstilbestrol was found to be a potent compound against breast cancer. Further 
modifications to the diethylstilbestrol structure led to the discovery of Tamoxifen (Early 
Breast Cancer Trialists' Collaborative 1992).  
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Figure 1.7 Structures of p-Propenyl phenol, Diethylstilbestrol, Tamoxifen and Glivec. 
The initial discoveries in the field of chemotherapy were mostly cytotoxic agents with 
little selectivity for cancer cells. However, as our understanding of cancer improved, 
complimented with computational docking studies, high throughput screening protocols 
and bioinformatics, chemotherapy is now becoming more selective in targeting cancer 
cells. 
By 2001, the first target-based cancer drug, Gleevec (Figure 1.7), was approved by the 
FDA for the treatment of chronic myelogenous leukemia (CML). If treated with Gleevec 
in the early stages of CML, nearly 100% of the diagnosed patients went into remission, 
and no major side effects were reported (Capdeville, Buchdunger et al. 2002). 
Cancer chemotherapy is used as the primary mode of treatment for cancer and is also 
utilized as an adjuvant to other treatment options. However, it often is associated with 
9 
 
side effects and poor selectivity. Throughout history, natural products have been a rich 
source of compounds with excellent pharmacological activities and few side effects. The 
huge structural diversity of natural products isolated from natural sources can serve as 
lead compounds for the discovery of new anticancer agents, and their potencies and drug 
likeness properties can be further optimized by appropriate chemical modifications. Most 
of the anticancer drugs currently available on the market are from natural sources 
(Gordaliza 2007). The search for potent and selective semi-synthetically derived 
anticancer agents from parent natural products continues to be an important part of drug 
discovery process. Currently, close to 30 molecules of natural origin are in various stages 
of clinical trials for the treatment of cancer. Researchers and pharmaceutical companies 
devoted to the search for new cancer drugs are exploring new natural products emerging 
from variable sources, with the hope of finding potent, selective, drug-like and non-toxic 
molecules.  
There are more than 100 types of malignancies that have been recognized to date. Almost 
any cell types can become cancerous (Heron 2012). In the last 50 years our understanding 
of cancer has improved greatly, but many forms of cancer still lack effective treatment 
options. In an effort to find anticancer drug leads, pharmaceutical companies often screen 
large chemical libraries which include natural products. Natural products are a rich 
source of complex molecules that are biologically relevant. The method used to develop 
new drugs from a prototype or a lead molecule of known biological activity is known as 
pharmacomodulation. The main aim of pharmacomodulation is to establish a correlation 
between the pharmacophore in the structure and its biological activity.  By understanding 
the structure activity relationships (SAR) of the natural product and its analogs, by semi-
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synthetically altering the functional groups in the molecule, additionally complimented 
with high throughput screening protocols, computational docking studies and 
bioinformatics, medicinal chemists can produce compounds that are far more effective as 
clinical agents in terms of potency and pharmacokinetic parameters. 
1.5 National Cancer institute (NCI) Anticancer screening program 
Screening natural products from different sources for activity against various human 
cancer cells gained momentum after the discovery of vinblastine in the 1950s. The 
National Cancer Institute (NCI) has been screening thousands of natural products and 
their derivatives and has been encouraging researchers to submit semi-synthetically 
produced derivatives for testing against its panel of 60 human tumor cell lines of nine 
different classifications (Rubinstein, Shoemaker et al. 1990). Numerous anticancer drugs 
have been discovered because of the NCI initiative, e.g. paclitaxel, docetaxel, irinotecan 
and topotecan (Shoemaker 2006). The successful discovery of these agents demonstrates 
the potential of natural products in the treatment of cancer. 
Since 1955, the NCI has employed both in vitro and in vivo screens to evaluate the 
activity of natural products, their analogs, and novel synthetic compounds. Up until 1990, 
the NCI used the P388 mouse leukemia cell line to assess the activity of submitted 
compounds (Boyd and Paull 1995). From 1991 onwards the NCI introduced a panel of 60 
human cancer cell lines of nine different classifications for its in vitro screens. The 
classifications represent human cancer lines from leukemia, non-small cell lung, colon, 
CNS, melanoma, ovarian, renal, prostate, and breast cancers. Five different 
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concentrations, viz. 10-4 M, 10-5 M, 10-6 M, 10-7 M and 10-8 M, of the compounds are 
used to evaluate their growth inhibition properties after 48 hours of exposure to cells in 
culture. The NCI employs an effective triage system for the submitted compounds based 
on duplicates already screened and single dose screening results, prior to selecting them 
for five dose testing. According to Rubinstein et al. anti-cancer activity screening studies 
involves a two stage process in which only the compounds showing more than 60% 
growth inhibition in at least eight of the 60 tumor cell line panel with a single dose of 
10µM  are selected for the second stage (five dose testing) (Rubinstein, Shoemaker et al. 
1990). The Sulforhodamine B (SRB) assay is used to quantify the cell growth and 
viability effects of the test compounds. SRB is a chemical which stains basic amino acids 
to afford a pink colored product in mild acidic conditions allowing colorimetric 
quantitation, which is proportional to the total biomass. The collected data, when 
compared to control cells, allows the determination of GI50 values (i.e. 50% Growth 
Inhibition, concentration of drug resulting in a 50% reduction in net protein increase 
compared to control cells), TGI values (Total Growth Inhibition, concentration of drug 
resulting in a 100% reduction in net protein increase compared with control cells) and 
LC50 values (Lethal Concentration, concentration of drug lethal to 50% of cells). The 
screens have identified many potent anticancer drugs, and on average, every year NCI 
screens close to 10,000 novel compounds against its 60 human cancer cells. We have 
utilized the NCI 60-cell cancer screen to gather large quantities of useful biological data 
for the synthesized molecules in this dissertation project against various human tumor 
cell lines.  
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Herein, two medicinal chemistry projects related to the natural product molecules 
resveratrol and combretastatin, which possess anticancer properties, are presented. The 
projects were designed to improve the chemical/metabolic stability and pharmacokinetic 
properties of the above-mentioned drug molecules.  
1.6 Introduction to resveratrol 
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Resveratrol  
Figure 1.8 Structure of resveratrol 
The use of resveratrol in an ayurvedic herbal preparation can be dated back to thousands 
of years ago. Darakchasava is an ayurvedic herbal preparation of which the main 
ingredient is Vitis vinifera L (Baur, Pearson et al. 2006). This ayurvedic medicine was 
prescribed to patients with cardiovascular ailments. High performance liquid 
chromatography studies on darakchasava revealed the active ingredient to be resveratrol 
(Paul, Masih et al. 1999).  Resveratrol (Figure 1.8) is a naturally occurring E-3,5,4’-
trihydroxystilbene that was first isolated from the roots of white hellebore in 1940 (Baur 
and Sinclair 2006). The phytoalexin (resveratrol) is produced by a wide variety of plants 
in response to injury, stress, microbial infection and UV irradiation (Aggarwal, Takada et 
al. 2004). Although, red grapes have the highest concentration of resveratrol (50-100 mg 
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per gram) in the plant kingdom, Resveratrol was found in more than 80 plant species  
(Figure 1.9) (Baur and Sinclair 2006).  
 
Figure 1.9 Sources of resveratrol from various plant species. 
Resveratrol received tremendous attention after it was credited for the cardio-protective 
effects of red wine, famously known as the ‘French paradox’ (Kopp 1998). In 1997, Jang 
and coworkers reported that the topical application of resveratrol reduced mouse skin 
tumors to 2%, triggering extensive research on resveratrol (Jang, Cai et al. 1997). Since 
then, hundreds of reports (Figure 1.10) have shown that resveratrol can be used to treat a 
wide variety of diseases including cancer. Resveratrol has been reported as a potential 
chemotherapeutic agent due to its striking inhibitory effects on cellular events associated 
with cancer initiation, promotion, and progression in vitro (Aggarwal, Bhardwaj et al. 
2004). In addition, there are several in vitro and in vivo reports on the biologically 
beneficial properties of resveratrol for coronary, hepatic, neurological, cardiovascular, 
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and inflammation conditions (Pace-Asciak, Rounova et al. 1996, Fauconneau, Waffo-
Teguo et al. 1997, Jang, Kang et al. 1999, Aggarwal, Bhardwaj et al. 2004, Kim, Zhu et 
al. 2006). Also, resveratrol synergistically enhanced the anti-HIV activity of zidovudine, 
and has antiviral effects against the herpes simplex virus (Docherty, Fu et al. 1999, 
Heredia, Davis et al. 2000). 
Below is a list of breakthrough findings on resveratrol’s biological properties. 
1) Resveratrol modulates low-density lipoprotein levels, reducing the risk for 
development of coronary heart disease (Frankel, Waterhouse et al. 1993). 
2) Resveratrol reduced mouse skin tumors by 98%, indicating its chemo-preventive 
effects (Jang, Cai et al. 1997). 
3) Resveratrol extends the life span of yeast, giving a boost to the sales of resveratrol 
supplements (Howitz, Bitterman et al. 2003). 
4) Resveratrol has a positive effect on obesity and diabetes (Baur, Pearson et al. 
2006) (Lagouge, Argmann et al. 2006). 
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Figure 1.10 Resveratrol citations appearing on Pubmed from 1978 to 2013. The PubMed 
database was searched using the key word ‘resveratrol’. 
 
1.6.1 Molecular targets of resveratrol: 
Extensive studies have been conducted to elucidate the mechanism of resveratrol as an 
anticancer agent. The studies revealed multiple molecular targets, which regulate cell 
growth, invasion, apoptosis, angiogenesis and metastasis. Resveratrol’s direct and 
indirect targets include tumor suppressors p53 and Rb; cell cycle regulator cyclins, 
CDKs, p21WAF1, p27KIP and INK and the checkpoint kinases ATM/ATR; transcription 
factors NFκB, AP-1, c- Jun, and c-Fos; angiogenic and metastatic factors, VEGF and 
matrix metalloprotease 2/9; cyclooxygenases for inflammation; and apoptotic and 
survival regulators Bax, Bak, PUMA, Noxa, TRAIL, APAF, survivin, Akt, Bcl2 and Bcl-
XL (Athar, Back et al. 2009). In addition to these targets, resveratrol is known to exhibit 
pro-oxidant activity in cancer cells causing apoptosis (Seve, Chimienti et al. 2005). 
Resveratrol is an ideal anticancer molecule due to its low toxicity and capacity to target 
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multiple molecular targets that may collectively promote cancerous cell growth and 
invasion. Since resveratrol is known to regulate multiple molecular targets and signaling 
pathways, it is important to elucidate the mechanism by which resveratrol influences 
these molecular targets. One assumption is that the resveratrol may act as an endogenous 
signaling molecule, or act through generation of mediators such as reactive oxygen 
species (ROS), or both (Athar, Back et al. 2009). The biological effects and molecular 
targets of resveratrol against various tumor cell lines are summarized in Table 1.1.  
Table 1.1 Effects of resveratrol on various human cancer cell lines. Adapted from (Athar, 
Back et al. 2009) 
Table 1.1 (continued) 
Cell Type Molecular target Cellular effects References 
Breast cancer 
T47D 
MDA-MB-231 
MDA-MB-468 
MCF-7 
p53, PTEN, p27, ROS, NO, 
QR, p21p70S6K, ppS6RP, 
Src-Stat3, pAkt, Bcl2, NF-
jB, calpain, MMP-9, cyclin 
D, Cdk4, ribonucleotide 
reductase, CYP1A1, 
telomerase 
Apoptosis 
Growth arrest 
Cell migration 
(Lee and Safe 2001, Pozo-
Guisado, Alvarez-Barrientos 
et al. 2002, Pozo-Guisado, 
Merino et al. 2005, Waite, 
Sinden et al. 2005, Lanzilli, 
Fuggetta et al. 2006, Alkhalaf 
2007) 
Prostate cancer 
LNCap 
PC-3 
DU145 
LAPC-4 
Caspases 3/9, p53, p21, 
p27, Bax, Bak, Bid, Bad, 
MKP5PI3K, pAKT, cyclins 
B/D1/E, Cdk1/4, Bcl2, Src-
Stat3, ROS 
Apoptosis, G0/G1-arrest 
Proliferation rate, cell 
viability 
(Awad, Burr et al. 2005, 
Aziz, Nihal et al. 2006, 
Benitez, Pozo-Guisado et 
al. 2007, Nonn, Duong et 
al. 2007) 
Colon cancer 
HT-29 
DLD1 
HCT116 
AMPK, ROS, cathepsin D, 
caspase-2, cytochrome c, 
ATF3 Cdk7, p34Cdc2 
Apoptosis, lysosome 
leakage, G2-arrest, Cell 
growth 
(Liang, Tsai et al. 2003, 
Hwang, Kwak et al. 2007, 
Trincheri, Nicotra et al. 
2007) 
Pancreatic cancer MIC-1, cytochrome c, Apoptosis (Mouria, Gukovskaya et al. 
2002, Golkar, Ding et al. 
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Table 1.1 (continued) 
CD18 
S2-013 
panc-1 
caspase-3 Src-Stat3, NF-jB Cell growth 2007) 
Leukemia 
HL-60 
NO Apoptosis, nuclear size, 
granularity  
Cell growth 
(Quiney, Dauzonne et al. 
2004, Stervbo, Vang et al. 
2006) 
Hepatoma 
HepG2 
NO Apoptosis, nuclear size, 
granularity  
Cell growth 
(Stervbo, Vang et al. 2006) 
B-cell Lymphoma 
LY1 
LY8 
LY18 
p27, p53, CD69 
BCL6, Myc, pAKT, pp70S6K 
Apoptosis, G0/G1-arrest 
glycolysis 
(Faber and Chiles 2006, 
Faber, Dufort et al. 2006) 
Osteosarcoma 
SJSA1 
pERK1/2, pp53(Ser15) Apoptosis 
Cell growth 
(Alkhalaf 2007) 
Acute myeloid leukemia  
OCIM2 
OCI/AML3 
IL-1b, NF-jB S-arrest, apoptosis (Estrov, Shishodia et al. 
2003) 
Thyroid cancer 
PTC 
FTC 
P53, p53(ser15), c-fos, c-
jun, p21 
Apoptosis (Shih, Davis et al. 2002) 
Gastric adenocarcinomas 
KATO-III 
RF-1 
PKC, PKCa G0/G1-arrest, apoptosis 
DNA synthesis 
(Atten, Attar et al. 2001) 
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1.6.2 Pharmacokinetics of resveratrol: 
Nearly all the reports claiming the biologically beneficial effects of resveratrol to date 
have been generated in vitro and in animal models. Thus, it is still unclear if these claims 
can be translated to humans. At higher doses, protective effects of resveratrol were 
observed. For example, a daily dose of 40 mg/kg increased the survival of mice with 
subcutaneous neuroblastomas from 0% to 70% (Chen, Tseng et al. 2004). However, in 
many in vivo studies, no notable chemopreventive effect of resveratrol was observed in 
animal models. For example, treatment with  1-5 mg/kg daily dose of resveratrol failed to 
affect the metastasis of breast cancer in mice, despite encouraging in vitro results. In one 
recent study, resveratrol acted as an ant-proliferative agent against ovarian cancer cells in 
vitro, but failed to exhibit this effect on the same cancerous cells in vivo (Bove, Lincoln et 
al. 2002). Overall, numerous in vitro studies clearly showed promising results, but the 
drug did not yield consistent results in vivo. 
The pharmacokinetic data of resveratrol reported in the literature is both confusing and 
contradicting. The high doses of resveratrol used in animal models (for example 100 ng -
1500 mg/Kg body weight) to achieve pharmacologically relevant concentration in plasma 
raises many questions about its translational effectiveness in humans. Resveratrol was 
found to have a short half-life of 8-10 min after oral administration, and was extensively 
metabolized to both sulfate and glucuronide phase 2 conjugates (Marier, Vachon et al. 
2002). In the case of intravenous administration, resveratrol was completely converted to 
sulfate conjugates within 30 min in humans (Walle, Hsieh et al. 2004). The maximum 
tolerated dose of resveratrol has not been comprehensively determined; however, 
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300mg/Kg (body weight) showed no toxicity in rats, but toxic effects related to the 
kidney have been observed at 1 gram/Kg (body weight) (Crowell, Korytko et al. 2004). 
Despite resveratrol’s low bioavailability, it was speculated that the in vivo efficacy of 
resveratrol could be attributed to its metabolites. However, when resveratrol-3-sulfate 
was tested in vitro it failed to activate SIRT1 and inhibit cyclooxygenase (Yu, Shin et al. 
2003). Another speculation is that the inactive metabolites of resveratrol could act as pool 
from which the resveratrol can be released into the tissues and stimulate the biological 
activity; however, no data on such findings have been reported. 
Because of the extremely low bioavailability and rapid clearance from the circulation, 
resveratrol could not be used as a drug. One approach to addressing this problem is to 
modify resveratrol’s structure to create analogs which would be metabolized at a slower 
rate than resveratrol itself (Greer, Madadi et al. 2014). Another approach is to synthesize 
potent resveratrol analogs that mimic its effect with improved bioavailability (Aggarwal, 
Takada et al. 2004). In the following chapters, both of these approaches have been tested. 
1.7 Introduction to Combretastatin A4 
Microtubules are believed to be one of the most promising targets for cancer 
chemotherapy since the tubulin interacting agent pacitaxel (Figure 1.13) was approved 
by the FDA for cancer treatment. Since then, the interest in tubulin targeting agents has 
significantly increased. Between 2007 and 2009, over 25% of the drug molecules that 
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entered clinical study were tubulin targeting agents (Butler 2008), and almost all of these 
drug molecules were natural products or analogs thereof.  
It is important to evaluate the role of tubulin in the life cycle of the cell in order to 
understand the mechanism of action of tubulin targeting anti-cancer agents. The 
cytoskeleton present in the cytoplasm of eukaryotic cells is responsible for the 
organization of constituents of the cell, maintains cell shape and the movement of the 
various organelles within the cell. There are three types of filaments or fibers that 
makeup the cytoskeleton: they are the microfilaments, the intermediate filaments and the 
microtubules. Microtubules comprise of αβ-tubulin heterodimers and play an important 
role in cell division, cellular transport, and cell mortality, maintaining cell polarity and 
cell signaling (Jordan, Hadfield et al. 1998, Zhou and Giannakakou 2005). Microtubule 
polymerization involves coordinated assembly of αβ-tubulin dimers followed by GTP 
hydrolysis. Each α and β subunit of the heterodimer has one GTP molecule bound to it; 
the GTP attached to the α subunit is irreversible, whereas the GTP molecule attached to 
the β subunit is reversibly hydrolyzed during polymerization (Nogales, Wolf et al. 1998). 
Compromised or non-coordinated microtubule functioning may lead to apoptosis. 
There are mainly three phases of microtubule polymerization 
1. Nucleation (an oligomer consisting of 6-12 α-β-tubulin heterodimers is formed) 
2. Polymer growth (a protofilament is formed where the GTP binds to αβ-tubulin 
dimers) 
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3. Steady-state equilibrium (addition and dissociation of tubulin subunits is 
balanced) 
Treadmilling and dynamic instability are the two types of microtubule dynamics 
observed. In the treadmilling dynamics the subunits from the minus end of the 
microtubule flow to the plus end; this dynamics doesn’t change the average length of the 
microtubules. On the other hand, dynamic instability is associated with alternative growth 
and shortening microtubule ends (Mitchison and Kirschner 1984). The transition from a 
growing phase to a shortening phase is termed as “catastrophe” and the transition from a 
shortening phase to a growing phase as “rescue”, Figure 1.13 illustrates the necessity for 
GTP hydrolysis for switching between catastrophe and rescue.  Microtubules are 
stabilized and destabilized by microtubule-associated proteins (MAP). MAPs such as 
plus and tracking proteins (TIP) interact with the microtubule ends to regulate the 
microtubule dynamics (Akhmanova and Steinmetz 2008). Since the microtubule 
dynamics play an important role in mitosis and basic cellular functions, microtubule 
targeting drugs are used in the treatment of various forms of cancer (Jordan and Wilson 
2004, Singh, Rathinasamy et al. 2008). 
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Figure 1.11 Microtubule dynamic instability, where the coexistence of polymerization 
and depolymerizing microtubules are imperative for dynamic stability. 
Anticancer agents that have polymerizing and depolymerizing effects on tubulin 
assembly are known as Microtubule-interfering Agents (MIA). Both polymerization and 
depolymerization impairs the proper function of microtubules and stagnates the cell cycle 
at G2/M phase leading to apoptosis (Li, Wu et al. 2009). Anticancer drugs such as 
colchicine, vinblastine and vincristine act by depolymerizing mechanism, whereas drugs 
such as paclitaxel and docetaxel act through a polymerizing effect. There are many 
tubulin binding sites for the depolymerizing agents, such as the colchicine and the 
vinblastine binding sites (Ravelli, Gigant et al. 2004, Gigant, Wang et al. 2005). 
Additionally, when depolymerization agents such as estramustine and LY290181 (Figure 
1.12) were treated with tubulin, they did not compete for the colchicine and vinblastine 
binding sites. Also, Chakraborti et al. using fluorescence spectroscopy, demonstrated that 
curcumin binds to tubulin at a site which is close to the vinblastine binding site 
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(Chakraborti, Das et al. 2011). This experiment suggests that each of these 
depolymerization agents have distinct binding site (Singh, Rathinasamy et al. 2008). 
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Figure 1.12 Structures of polymerizing and depolymerizing agents on tubulin assembly. 
Microtubule targeting agents act as anticancer agents by causing the cells to arrest at the 
G2/M stage of the cell cycle promoting apoptosis, and/or by their vascular disrupting 
action. However, the mechanism by which they act is poorly understood. The relationship 
between mitotic block and apoptosis caused by 2’,3,4,4’,5-pentamethoxy-trans-stilbene 
(PMS) (Figure 1.13) was studied by Li and co-workers. The experiments suggested that 
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hyper phosphorylation of CDC2 or JNK by Bcl-2/Bcl-xL and activation of Bim by JNK 
could be a link between mitotic block and apoptosis (Li, Wu et al. 2009). Also, caspase-8 
activation was observed during paclitaxel-induced apoptosis (Goncalves, Braguer et al. 
2000). 
Interestingly, there is also a strong correlation between microtubule targeting agents and 
their vascular disruption properties (Mason, Zhao et al. 2011). Anticancer agents that 
target the tumor vasculature are known as vascular-targeting agents (VTAs) and can be 
divided into two categories. They are 
(a) Vascular disrupting agents (VDAs). Example: Combretastatin A4. 
(b) Angiogenesis inhibiting agents (AIA). Example: Bevacizumab. 
VDAs like combretastatin A4 influence tubulin polymerization by damaging the 
proliferating endothelial cells of the cancer vasculature, thereby decreasing blood flow to 
the tumor cells leading to cell death. VDAs like combretastatin A4 also have potential 
curative activities in retinal and choroidal neovascularization related diseases, since 
angiogenesis plays a key role in these disease conditions (Nambu, Nambu et al. 2003, 
Jockovich, Suarez et al. 2007). 
A total of seventeen combretastatin compounds have been isolated from the South 
African bushwillow tree Combretum caffrum by Pettit and co-workers (Pettit, Singh et al. 
1995). Among these compounds, a cis-stilbene: Combretastatin A4 (3’-hydroxy-3,4,4’,5-
tetramethoxy-cis-stilbene; CA-4; Figure 1.13), has emerged as a potent anti-cancer agent 
with promising anti-mitotic and anti-angiogenic activity (Tron, Pirali et al. 2006). CA4 
functions as a microtubule targeting agent, interfering with microtubule dynamics and 
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perturbation of the mitotic cycle. Moreover, CA4 selectively inhibits the formation of 
new blood vessels in cancerous cells, sparing the normal cell population (Thorpe 2004). 
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H3CO
H3CO
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(C) PMS  
Figure 1.13 Structures of Combretastatin A4 (CA4), CA4P and PMS. 
CA4 is well known anticancer agent for inhibition of tubulin polymerization in vitro. 
CA4 binds to the β-tubulin at the colchicine binding site, promoting the disturbance of 
the dynamic equilibrium of microtubule formation (Mikstacka, Stefanski et al. 2013). 
Also, CA4 exerts its antitumor affects against multi-drug resistant (MDR) cancer cells 
(Chaudhary, Pandeya et al. 2007). However, CA4 itself cannot be used as a drug because 
of its poor water solubility leading to low bioavailability, and due to its chemical 
instability, since it forms the thermodynamically more stable and less potent trans CA4 
(Hsieh, Liou et al. 2005) isomer. The low bioavailability of CA4 was addressed by 
preparing the water soluble phosphate salt (disodium CA-4-3-O-phosphate) of CA4 
(CA4P). Currently, CA4P (Figure 1.13) has been moved into phase III clinical trial by 
the pharmaceutical company OXiGENE for the treatment of anaplastic thyroid cancer 
(Siemann, Chaplin et al. 2009). Another approach utilized for improving the 
bioavailability of CA4 was to prepare nitrothiophene ether-linked conjugates of CA4, 
which could function as bioreductively activated prodrugs (Thomson, Naylor et al. 2006). 
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Also, formulations that employ nanoparticles to selectively deliver CA4 and improve its 
bioavailability have also been reported (Calligaris, Verdier-Pinard et al. 2010). 
The chemical instability (isomerization) of CA4 has been addressed by designing and 
synthesizing a series of cis-constrained derivatives of CA4. Extensive studies have been 
conducted to stabilize CA4 by replacing the double bond bridge with heterocyclic ring 
systems such as β-lactam, azetidone, thiazoles, tetrazoles, imidazoles, pyrazoles, 
oxazolones, triazoles, and furanones (Shirai, Takayama et al. 1998, Tron, Pagliai et al. 
2005, Carr, Greene et al. 2010, Beale, Bond et al. 2012, Banimustafa, Kheirollahi et al. 
2013, Mikstacka, Stefanski et al. 2013, Demchuk, Samet et al. 2014).  
Our approach is to design and synthesize triazole modified CA4 analogues that are more 
water soluble and also incapable of undergoing cis-trans isomerization of CA4. 
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Chapter 2 
Synthesis of resveratrol analogues as anti-cancer agents 
2.1 Previous SAR studies on resveratrol analogues 
Resveratrol binds with multiple molecular targets in vitro, and exhibits cytotoxic effects 
against breast, skin, gastric, colon, esophageal, prostate, and pancreatic cancer cells, and 
leukemia cells (Jang, Cai et al. 1997, Aggarwal, Bhardwaj et al. 2004).  However, 
resveratrol has some limitations which preclude its use in cancer treatment, and it cannot 
be used as an antitumor drug due to its photosensitivity and metabolic instability 
(Goldberg, Ng et al. 1995). Literature results indicate that the in vivo effectiveness of 
resveratrol in animal models is limited by its poor systemic bioavailability (Athar, Back 
et al. 2009). Thus, there is a need for the design and synthesis of novel resveratrol 
analogs that retain the potent anti-cancer agents of the parent compound, have good 
chemical and metabolic stability, and are devoid of photosensitivity problems. 
Extensive structure activity relationship (SAR) studies on the resveratrol molecule for its 
anticancer activity and chemical/metabolic stability have been conducted on synthetically 
prepared derivatives and natural products which resemble resveratrol. The studies 
revealed that maintaining the stilbene skeleton is necessary for good metabolic stability 
and for retaining resveratrol’s medicinal properties. Also, replacing the extensively 
metabolized hydroxyl groups with methoxyl groups improves resveratrol’s 
bioavailability.  
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Wang and co-workers compared the anticancer effects of resveratrol and its natural 
derivatives pterostilbene, trans-3,5,4’ -trimethoxy-stilbene, pinostilbene and 
desoxyrhapontigenin against human prostate cancer cell line LNCaP (Figure 2.1). They 
reported that trans-3,5,4’ -trimethoxy-stilbene was the most effective compound among 
resveratrol and its natural derivatives, causing G2/M blockage in the cell cycle leading to 
apoptosis (Wang, Schoene et al. 2010).  
HO
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(A) Resveratrol (B) Desoxyrhapontigenin (C) 3,5,4' -trimethoxy-stilbene
(D) Pinostilben (E) Pterostilbene
H3CO
H3CO
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H3CO
(F) 3,4,5,4' -trimethoxy-stilbene
HO
HO
OH
OH
AcO
AcO
OAc
AcO
AcO
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(G) Piceatannol (H) 3,5,4' -triacetyl-stilbene (C)3,5-diacetyl resveratrol  
Figure 2.1 Structures of resveratrol and its O-methylated derivatives. 
Chen and co-workers synthesized and evaluated a series of methoxylated resveratrol 
derivatives for their anti-cancer properties against three different human cancer cell lines, 
i.e. K562, HT29, and HePG2. They reported that trans-3,5,4’ -trimethoxy-stilbene 
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(TMR) and trans-3,4,5,4’ -trimethoxy-stilbene (Figure 2.1) were the most effective anti-
cancer agents among the synthesized analogs and showed better cytotoxicity compared to 
resveratrol itself. SAR analysis revealed that methoxy substitutions at positions 3, 4, and 
5 on the A ring and at position 4’ of the B ring promoted cytotoxicity, and that 
incorporation of halogeno substituents such as bromo, chloro and fluoro, or nitro groups 
into the B ring was detrimental to anticancer activity (Chen, Hu et al. 2013).  
Dias et al. evaluated resveratrol, trans-3,5,4’ –trimethoxystilbene (TMR), piceatannol, 
pterostilbene, trans-3,5-diacetyl-4’ hydroxyl stilbene, and trans-3,5,4’-triacetylstilbene, 
and characterized their effects on PCa cells in vitro using a cell proliferation assay. Also, 
they compared the chemopreventative effects of oral resveratrol, trans-3,5,4’ –
trimethoxystilbene, piceatannol in LNCaP-Luc xenografts. Among all these stilbenes 
examined, trans-3,5,4’ –trimethoxystilbene was the most potent in inhibiting cell 
proliferation, and its permeability into the tumor tissues was the highest (Dias, Li et al. 
2013). 
H3CO
H3CO
OCH3
trans-3,5,4' -trimethoxy-stilbene
H3CO
OCH3 OCH3
cis-3,5,4' -trimethoxy-stilbene
Stable Unstable
Isomerization
 
Figure 2.2 Isomerization of cis-3,5,4’-trimethoxystilbene to trans-3,5,4’-
trimethoxystilbene. 
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Paul et al. compared the anticancer activity of trans-3,5,4’-trimethoxystilbene with cis-
3,5,4’-trimethoxystilbene against the colon cancer cell lines HT-29 and Caco-2. Also, in 
vivo studies using HT-29 xenografts in immunodeficient mice were conducted with both 
these isomers. Tumor volume was significantly lowered in groups of mice when trans-
3,5,4’-trimethoxystilbene was used compared to cis-3,5,4’-trimethoxystilbene, Also cis-
3,5,4’-trimethoxystilbene was found to be chemically unstable and isomerized to trans-
3,5,4’-trimethoxystilbene in solution (Paul, Mizuno et al. 2010). 
From these studies, it is evident that trans-3,5,4’-trimethoxystilbene (TMR) is the most 
potent and stable analog of resveratrol, and has better bioavailability than resveratrol. 
Trans-3,5,4’-trimethoxy-stilbene is a natural resveratrol analogue extracted from the 
plant species Pterobolium hexapetallum (Aggarwal, Bhardwaj et al. 2004) and the 
molecule has been reported to have anticancer and antiangiogenic activities (Belleri, 
Ribatti et al. 2005). The trimethoxylated substitution pattern on trans-3,5,4’-
trimethoxystilbene molecule might improve metabolic stability and intestinal absorption. 
Moreover, conversion of the phenolic substituents to methoxy substituents increases the 
lipophilicity and cell membrane permeability properties of the molecule and enhances 
bioavailability. 
2.2 Synthesis of (E)-stilbenes as resveratrol analogues  
Based on the structure-activity relationship analysis reported previously, it is evident that 
O-methylation of resveratrol leads to an enhanced cytotoxic activity. In our continuing 
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quest for improving the potencies of our newly identified lead anti-cancer agents, we 
have synthesized a wide range of such (E)-stilbene resveratrol analogs.  
R1 CHO PPh3
R2
Br
R1
R2
Aldehyde Wittig salt t rans stilbene
a
R1 = R2 = Aromatic ring  
Scheme 2.1 Synthesis of (E)-stilbenes as resveratrol analogues. Reagents and conditions: 
(a) 5% NaOMe, MeOH, reflux. 
The general procedure for the synthesis of trans 2,3-disubstituted stilbenes is illustrated 
in Scheme 2.1. Trans 2,3-disubstituted stilbenes were synthesized by reacting substituted 
benzyl carbaldehydes (1 mmol) with an appropriately substituted benzyl Wittig salt (1.2 
mmol) in 5% NaOMe in methanol. The reaction mixture was stirred at room temperature 
for about 2-3 hours for the reaction to come to completion and the final product crashed 
out of the solution. The resulting precipitate was filtered, washed with methanol, then 
water and dried to yield the desired compound in yields ranging from 60-75% (Scheme 
2.1). If necessary, further purification can be carried out by flash column 
chromatography. The minor cis-stilbene product could be separated during the filtration 
and methanol wash. A total of seventy four trans stilbenes were synthesized via this 
general procedure and their structures are presented in Table 2.1. 
 
Table 2.1: Structures of the synthesized trans-stilbenes and the starting materials (benzyl 
carbaldehyde and Wittig salt) used. 
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Table 2.1 (Continued) 
           Aldehyde         Wittig salt                  Stilbene 
1.  O
O
CHO
 Ph3P
Br
 
O
O
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2.  O
O
CHO
 Ph3P
Br
OCH3
 O
O
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OCH3
 
3.  O
O
CHO
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Br
OCH3
OCH3
OCH3  O
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OCH3
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4.  O
O
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O
 O
O
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5.  O
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 Ph3P
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O
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6.  O
O
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OEt
O
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7.  O
O
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 Ph3P
Br
Cl
 O
O
Cl
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8.  
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Cl
 
H3CO
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13.  
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18.  
CHOH3CO
H3CO  Ph3P
Br
O
 
H3CO
H3CO
O
ST-212  
19.  
CHOH3CO
H3CO  
Ph3P  O
O
ST-213  
20.  
CHOH3CO
H3CO  
Ph3P
Br
 
O
O
ST-214  
21.  
CHOH3CO
OCH3  
Ph3P
Br
Cl
 
Cl
ST-219
OMe
MeO
 
22.  
CHOH3CO
OCH3  
Ph3P
Br
F
 
F
ST-222
OMe
MeO
 
23.  
CHOH3CO
OCH3  
Ph3P
Br
OCH3
 
MeO
ST-223
OMe
MeO
 
24.  
CHOH3CO
OCH3  
Ph3P
Br
 
ST-224
OMe
MeO
 
36 
 
Table 2.1 (Continued) 
25.  
CHOH3CO
OCH3  
Ph3P
Br
 ST-225
OMe
MeO
 
26.  
CHOH3CO
OCH3
 
Ph3P
Br
O
 
OCH3
H3CO
O
ST-220  
27.  
CHOH3CO
OCH3  Ph3P
Br O
O
 
OCH3
OCH3
O
O
ST-221  
28.  
CHO
 
Ph3P
Br
OCH3
OCH3  
OCH3
H3CO
ST-226
 
29.  
CHO
 
Ph3P
Br
O
 
O ST-227
 
30.  
CHO
 
Ph3P
Br O
O
 
O
O
ST-228
 
37 
 
Table 2.1 (Continued) 
31.  
CHO
 Ph3P
Br
O
 
H3CO
ST-230
  
32.  
CHO
H3CO
H3CO
H3CO
 
Ph3P
Br
OCH3
OCH3  H3CO
OCH3
H3CO
OCH3
H3CO
ST-233  
33.  
CHO
H3CO
H3CO  
Ph3P
Br
OCH3
OCH3  
OCH3
H3CO
H3CO
OCH3
ST-234  
34.  
CHOH3CO
H3CO
H3CO  
Ph3P
Br
CN
 
H3CO
H3CO
CN
ST-315OCH3  
35.  
CHOH3CO
H3CO
H3CO  
Ph3P
Br
 
ST-199
H3CO
H3CO
H3CO
 
36.  
CHOCl
Cl  
Ph3P
Br
Cl
 
Cl
Cl
ST-301
Cl
 
38 
 
Table 2.1 (Continued) 
37.  
CHOCl
Cl  
Ph3P
Br
NO2
 
Cl
NO2
ST-302
Cl
 
38.  
CHOH3CO
 
Ph3P
Br
CN
 
H3CO
CN
ST-320  
39.  
CHOH3CO
 
Ph3P
Br
Br
 
H3CO
Br
ST-321  
40.  O
O
CHO
 Ph3P
Br
Br
 Br
ST-312
O
O
 
41.  
CHOCl
Cl  
Ph3P
Br
CN
 
Cl
CN
ST-313
Cl
 
42.  O
O
CHO
 
Ph3P
OCH3
OCH3
OCH3  
ST-309
H3CO
H3CO
H3CO
O
O
 
43.  
CHOH3CO
H3CO
H3CO
 
Ph3P
Br
Br
 
 
 
ST-316
H3CO
H3CO
H3CO
Br
 
44.  
CHO
 
 
Ph3P
Br
Br
 Br
ST-323  
39 
 
Table 2.1 (Continued) 
45.  
CHOCl
Cl  
Ph3P
Br
Br
 
ST-314
Cl
Cl
Br
 
46.  CHO
 
Ph3P
Br
OCH3
OCH3  
H3CO
H3CO ST-236  
47.  CHO
 
Ph3P
Br
O
 
O
ST-237  
48.  CHO
 
Ph3P
Br O
O
 
O
O
ST-238  
49.  CHO
 
Ph3P
Br
O
 
H3CO
ST-239  
50.  CHO
 Ph3P
Br
 
ST-240  
51.  CHO
 Ph3P
Br
 
ST-241  
52.  CHO
 Ph3P
F
 
F
ST-242  
40 
 
Table 2.1 (Continued) 
53.  CHO
 Ph3P
Br
Cl
 
Cl
ST-243  
54.  
CHO
 Ph3P
Br
O
 
O
OCH
ST-245
 
55.  
CHO
 Ph3P
Br O
O
 
OCH3
O
O
ST-246
 
56.  
CHO
 Ph3P
Br
O
 OCH
H3CO
ST-247
 
57.  
CHOH3CO
 
Ph3P
Br
 OCH3
ST-249  
58.  
CHOH3CO
 
Ph3P
Br
Cl
 
OCH3
ST-251
Cl
 
59.  CHOO
O  
Ph3P
Br
O
 
OEt
O
O
ST-268  
41 
 
Table 2.1 (Continued) 
60.  CHOO
O  
Ph3P
Br O
O
 
O
O
O
O
ST-269  
61.  CHOO
O  Ph3P
Br
O
 
OCH3O
O
ST-270  
62.  CHOO
O  
Ph3P
F
 
F
O
O
ST-273  
63.  CHOO
O  
Ph3P
Br
Cl
 
Cl
O
O
ST-274  
64.  CHOO
O  
Ph3P
Br
NO2
 O
O
NO2
ST-275  
65.  
CHOCl
Cl  Ph3P
Br
O
 
Cl
ST-295
OEt
Cl
 
66.  
CHOCl
Cl  Ph3P
Br
OCH3
OCH3
OCH3  
Cl
ST-297
OMe
Cl
OMe
OMe  
42 
 
Table 2.1 (Continued) 
67.  
CHOCl
Cl  
Ph3P
Br
OCH3
 Cl
ST-294
OMe
Cl
 
68.  
CHOCl
Cl  Ph3P
Br
 
Cl
ST-298
Cl
 
69.  
CHOOHC
 
Ph3P
Br
 
ST-283
 
70.  
CHOOHC
 Ph3P
Br
 
ST-284
 
71.  
CHOHO
O2N
O2N
 
Ph3P
Br
OCH3
OCH3
OCH3  
NI-ST-11
OH
H3CO
H3CO
H3CO
NO2
NO2  
72.  
CHOH3CO
O2N  Ph3P
Br
OCH3
OCH3
OCH3  
NI-ST-12
OCH
H3CO
H3CO
H3CO
NO2
 
43 
 
Table 2.1 (Continued) 
73.  
CHOHO
O2N
O2N
 
Ph3P
Br
OCH3
OCH3  
DNR-1
OH
H3CO
H3CO
NO2
NO2  
74.  
CHOH3CO
H3CO
 
 
Ph3P
Br
Cl
 
Cl
ST-208
OMe
OMe  
 
2.2.1 Analytical data for the synthesized trans-stilbene analogues 
ST-196 :  1H NMR (400 MHz, DMSO-d6): δ 3.68 (s, 3H, -OCH3), 3.84 (s, 6H, -OCH3), 
3.85 (s, 3H, -OCH3), 6.98 (s, 2H, -ArH), 7.34 (d, J =7.2 Hz, 2H, ArH), 7.72 (d, J =8.4 
Hz, 2H, ArH), 7.968 (d, J =8 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 52.4, 
56.3, 60.5, 60.5, 104.76, 126.8, 127.0, 128.4, 130.1, 131.9, 132.6, 142.4, 153.5, 166.4 
ppm. 
ST-192 :  1H NMR (400 MHz, DMSO-d6): δ1.32 (t, J =12.8 Hz, 3H, -CH3), 4.03 (d, J 
=6.8 Hz, 2H, -CH2), 6.02 (s, 2H, -CH2), 6.91 (d, J =6.8 Hz, 3H, ArH), 6.96-7.02 (m, 3H, 
ArH), 7.22 (s,1H, ArH), 7.47 (d, J =7.6 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 15.0, 63.4, 101.4, 105.5, 108.7, 115.0, 121.5, 126.2, 126.7, 127.9, 130.1, 
132.4, 147.0, 148.2, 158.4 ppm. 
ST-191 :  1H NMR (400 MHz, DMSO-d6): δ6.04 (s, 2H, -CH2), 6.92 (d, J =8 Hz, 1H, 
ArH), ), 7.02 (d, J =9.2 Hz, 1H, ArH), 7.12 (s,2H, ArH), 7.18 (t, J =17.6 Hz, 2H, ArH), 
7.26 (d, J =1.2 Hz, 1H, ArH), 7.06-7.57 (m, 2H, ArH) ppm. 13C NMR (100 MHz, 
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DMSO-d6): 101.5, 105.6, 108.8, 115.8, 116.0, 122.0, 125.9, 128.4, 128.5, 128.5, 131.9, 
134.3, 147.3, 148.3 ppm. 
ST-193 :  1H NMR (400 MHz, DMSO-d6): δ6.04 (s, 2H, -CH2), 6.92 (d, J =7.6 Hz, 1H, 
ArH), ), 7.04 (d, J =9.2 Hz, 1H, ArH), 7.12 (d, J =16.4 Hz, 1H, ArH), 7.21 (d, J =16.4 
Hz, 1H, ArH), 7.27 (d, J =1.2 Hz, 1H, ArH), 7.41 (d, J =8.8 Hz, 2H, ArH), 7.57 (d, J 
=8.8 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 101.6, 105.8, 108.8, 122.3, 
125.7, 128.2, 129.0, 129.5, 131.7, 131.9, 136.6, 147.5, 148.3 ppm. 
ST-188 :  1H NMR (400 MHz, DMSO-d6): δ 2.38 (s,3H, CH3), 6.04 (s, 2H, -CH2), 6.92 
(d, J =8 Hz, 1H, ArH), ), 7.05-7.01 (m, 2H, ArH), 7.14-7.19 (m, 3H, ArH), 7.28 (d, J 
=16.0 Hz, 1H, ArH), 7.33 (d, J =1.6 Hz, 1H, ArH), 7.61 (d, J =6.8 Hz, 1H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 19.9, 101.5, 106.0, 108.7, 122.1, 124.6, 125.2, 
126.5, 127.6, 129.8, 130.7, 132.3, 135.7, 136.4, 147.3, 148.3 ppm. 
ST-186: 1H NMR (400 MHz, DMSO-d6): δ 3.76 (s, 3H, -OCH3), 6.02 (s, 2H, -ArH), 
6.88-6.93 (m, 3H, ArH), 6.97-7.04 (m, 3H, ArH), 7.23 (s, 1H, -ArH), 7.49 (d, J =8.8 Hz, 
2H, ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 55.5, 55.6, 101.4, 105.5, 108.8, 114.5, 
121.6, 126.3, 126.7, 127.9, 130.3, 132.3, 147.0, 148.2, 159.1 ppm. 
ST-198 :  1H NMR (400 MHz, DMSO-d6): δ 3.64 (s, 3H, -OCH3), 3.74 (s, 3H, -OCH3), 
3.79 (s, 6H, -OCH3), 6.85 (s, 2H, -ArH), 6.91 (d, J =8.8 Hz, 2H, ArH), 6.97 (d, J =16.4 
Hz, 1H, ArH), 7.11 (d, J =16.4 Hz, 1H, ArH), 7.11 (d, J =8.8 Hz, 1H, ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 55.56, 56.29, 60.50, 103.99, 114.64, 126.73, 127.87, 
128.03, 130.20, 133.56, 137.42, 153.48, 159.29 ppm. 
45 
 
ST-194 :  1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.83 (s, 6H, -OCH3), 
6.93 (s, 2H, -ArH), 6.93 (s, 2H, -ArH), 7.21 (s, 2H, -ArH), 7.43 (d, J =8.4 Hz, 2H, ArH), 
7.60 (d, J =8.4 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.3, 60.5, 104.4, 
126.8, 128.3, 129.1, 129.9, 132.1, 132.9, 136.5, 137.9, 153.5 ppm. 
ST-190 :  1H NMR (400 MHz, DMSO-d6): δ 3.84 (s, 3H, -OCH3), 6.05 (s, 2H, -CH2), 
6.94 (d, J =8 Hz, 1H, ArH), 7.08 (d, J =16.4 Hz, 1H, ArH), 7.36 (d, J =16.8 Hz, 2H, 
ArH), 7.68 (d, J =8.8 Hz, 2H, ArH), 7.94 (d, J =8.4 Hz, 2H, ArH) ppm. 13C NMR (100 
MHz, DMSO-d6): 52.4, 101.6, 105.9, 108.8, 122.8, 125.8, 126.7, 128.2, 130.0, 131.5, 
142.5, 147.9, 148.3, 166.4 ppm. 
ST-195 :  1H NMR (400 MHz, DMSO-d6): δ 1.33 (t, J =14.0 Hz, 3H, -CH3), 3.66 (s, 3H, 
-OCH3), 3.82 (s, 6H, -OCH3), 4.04 (dd, J =20.8 Hz, J =6.8 Hz,  2H, -CH2), 6.88 (s, 2H, -
ArH), 6.93 (d, J =8.8 Hz, 2H, ArH), 7.03 (d, J =16.4 Hz, 1H, ArH), 7.17 (d, J =16.4 Hz, 
1H, ArH), 7.51 (d, J =8.4 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 15.0, 
56.2, 60.4, 63.4, 103.9, 115.0, 126.6, 127.8, 128.0, 130.0, 133.5, 137.3, 153.4, 158.5 
ppm. 
ST-200 :  1H NMR (400 MHz, DMSO-d6): δ 2.41 (s, 3H, -CH3), 3.68 (s, 3H, -OCH3), 
3.84 (s, 6H, -OCH3), 6.94 (s, 2H, -ArH), 7.05 (d, J =16 Hz, 1H, ArH), 7.19-7.16 (m, 3H, 
ArH), 7.37 (d, J =16.4 Hz, 1H, ArH), 7.63 (d, J =9.6 Hz, 1H, ArH) ppm. 13C NMR (100 
MHz, DMSO-d6): 20.0, 56.3, 60.5, 104.5, 125.5, 125.9, 126.5, 127.7, 130.4, 130.7, 
133.4, 135.8, 136.4, 137.8, 153.5 ppm. 
ST-197:  1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.83 (s, 6H, -OCH3), 
6.92 (s, 2H, -ArH), 7.11-7.25 (m, 4H, ArH), 7.19-7.16 (m, 3H, ArH), 7.62 (dd, J =14.8 
46 
 
Hz, J =6.0Hz, 2H, -CH2) ppm. 13C NMR (100 MHz, DMSO-d6): 56.3, 60.5, 104.3, 
115.9, 116.1, 127.0, 128.5, 128.6, 128.9, 128.9, 133.1, 134.2, 134.2, 137.7, 153.4, 160.7, 
163.2 ppm. 
ST-203 :  1H NMR (400 MHz, DMSO-d6): δ 3.78 (s, 6H, -OCH3), 3.85 (s, 3H, -OCH3), 
6.46 (s, 1H, -ArH), 6.83 (s, 2H, ArH), 7.35 (s, 2H, ArH), 7.73 (d, J =8 Hz, 2H, ArH), 
7.96 (d, J =8 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 52.4, 55.6, 100.9, 
105.3, 127.1, 128.2, 128.7, 130.0, 131.7, 139.0, 142.2, 161.1, 166.4 ppm. 
ST-209 :  1H NMR (400 MHz, DMSO-d6): δ 1.33 (t, J =11.2 Hz, 3H, -CH3), 3.75 (s, 3H, 
-OCH3), 3.81 (s, 3H, -OCH3), 4.03 (d, J =6.4 Hz, 2H, -CH2), 6.90-6.92 (m, 3H, -ArH), 
7.02-7.05 (m, 3H, -ArH), 7.20 (s, 1H, -ArH), 7.49 (d, J =8.0 Hz, 2H, ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 15.1, 55.9, 63.4, 109.4, 112.2, 115.0, 119.9, 126.4, 126.5, 
127.8, 130.3, 130.8, 148.8, 149.3, 158.3 ppm. 
ST-210:  1H NMR (400 MHz, DMSO-d6): δ 3.78 (s, 3H, -OCH3), 3.83 (s, 3H, -OCH3), ), 
3.85 (s, 3H, -OCH3), 6.98 (d, J =8.4 Hz, 1H, ArH), 7.16 (d, J =9.6 Hz, 1H, ArH), 7.24 (d, 
J =16.4 Hz, 1H, ArH), 7.29 (d, J =1.6 Hz, 1H, ArH), 7.37 (d, J =16.4 Hz, 1H, ArH), 7.71 
(d, J =8.4 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 52.4, 55.9, 109.8, 112.1, 
1210.0, 125.4, 126.6, 128.1, 1293.9, 130.0, 131.8, 142.7, 149.4, 149.7, 166.4 ppm. 
ST-212 :  1H NMR (400 MHz, DMSO-d6): δ 3.76 (s, 3H, -OCH3), 3.76 (s, 3H, -OCH3), 
3.81 (s, 3H, -OCH3), 6.94-6.91 (m, 3H, ArH), 7.10-6.98 (m, 3H, ArH), 7.20 (s, 1H, -
ArH), 7.51 (d, J =8.4 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.5, 55.9, 
55.9, 109.4, 112.2, 114.5, 119.9, 126.3, 126.5, 127.8, 130.4, 130.7, 148.8, 149.3, 159.0 
ppm. 
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ST-211:  1H NMR (400 MHz, DMSO-d6): δ 3.76 (s, 3H, -OCH3), 3.82 (s, 3H, -OCH3), 
6.95 (d, J =8.4 Hz, 1H, ArH), 7.07-7.23 (m, 6H, ArH), 7.59 (t, J =14 Hz, 2H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 55.9, 55.9, 109.6, 112.1, 115.8, 116.0, 120.3, 
125.5, 128.3, 128.3, 128.8, 130.3, 134.4, 149.1, 149.3 ppm. 
ST-213 :  1H NMR (400 MHz, DMSO-d6): δ 2.32 (s, 3H, -CH3), 3.76 (s, 3H, -OCH3), 
3.82 (s, 3H, -OCH3), 6.95 (d, J =8.4 Hz, 1H, ArH), 7.04-7.26 (m, 6H, ArH), 7.35 (d, J =8 
Hz, 1H, ArH), 7.39 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 21.4, 55.9, 55.9, 
109.6, 112.2, 120.2, 123.8, 126.7, 127.0, 128.3, 128.6, 128.9, 130.4, 137.7, 138.1, 149.1, 
149.3 ppm. 
ST-214 :  1H NMR (400 MHz, DMSO-d6): δ 2.33 (s, 3H, -CH3), 3.77 (s, 3H, -OCH3), 
3.81 (s, 3H, -OCH3), 6.94 (d, J =8 Hz, 1H, ArH), 7.02-7.25 (m, 6H, ArH), 7.34 (d, J =8 
Hz, 1H, ArH), 7.41 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 20.9, 55.7, 55.9, 
101.3, 116.2, 124.2, 125.8, 126.5, 127.6, 128.5, 128.7, 129.9, 132.8, 134.3, 136.1, 149.7, 
151.4 ppm. 
ST-220:  1H NMR (400 MHz, DMSO-d6): δ 1.35 (t, J =11.2 Hz, 3H, -CH3), 3.74 (s, 3H, 
-OCH3), 3.80 (s, 3H, -OCH3), 4.02 (d, J =6.4 Hz, 2H, -CH2), 6.90-6.92 (m, 3H, -ArH), 
7.02-7.04 (m, 3H, -ArH), 7.21 (s, 1H, -ArH), 7.48 (d, J =8.0 Hz, 2H, ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 15.3, 55.8, 63.4, 109.4, 112.2, 115.0, 119.9, 126.4, 126.5, 
127.8, 130.3, 130.8, 148.9, 149.1, 158.5 ppm. 
ST-121 :  1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.85 (s, 3H, -OCH3), 
3.87 (s, 3H, -OCH3), 6.97 (s, 2H, -ArH), 7.36 (d, J =7.2 Hz, 2H, ArH), 7.71 (d, J =8.0 
Hz, 2H, ArH), 7.98 (d, J =8.4 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 51.1, 
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54.3, 57.5, 60.1, 101.1, 123.8, 127.0, 128.4, 131.1, 131.8, 137.1, 142.8, 150.1, 161.6 
ppm. 
ST-226:  1H NMR (400 MHz, DMSO-d6): δ 3.77 (s, 6H, -OCH3), 6.46 (d, J =6.4 Hz, 2H, 
-CH2), 6.83 (s, 1H, ArH), 7.23-7.37 (m, 5H, -ArH), 7.73-7.86 (m, 6H, -ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 55.6, 100.9, 105.3, 127.1, 128.2, 128.5, 128.7, 130.0, 
131.7, 139.0, 142.2, 152.1 ppm. 
ST-227 :  1H NMR (400 MHz, DMSO-d6): δ 1.33 (t, J =12.4 Hz, 3H, -CH3), 4.04 (dd, J 
=20.8 Hz, J =6.8 Hz,  2H, -CH2), 6.88 (d, J =6.8 Hz, 2H, -CH2), 6.93 (d, J =8.8 Hz, 2H, 
ArH), 7.25-7.38 (m, 6H, -ArH), 7.71-7.77 (m, 4H, -ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 15.3, 56.2, 103.9, 115.0, 126.6, 126.8, 127.8, 128.0, 130.0, 131.1, 132.5, 
133.5, 137.3, 153.4, 154.5 ppm. 
ST-228:  1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 6.97 (s, 2H, -ArH), 
7.36 (d, J =7.2 Hz, 2H, ArH), 7.71 (d, J =8.0 Hz, 2H, ArH), 7.98 (d, J =8.4 Hz, 2H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 51.1, 101.1, 111.2, 115.4, 120.6, 123.8, 127.0, 
127.4, 127.8, 128.4, 131.1, 137.1, 142.8, 150.1, 161.6 ppm. 
ST-230:  1H NMR (400 MHz, DMSO-d6): δ 3.73 (s, 3H, -OCH3), 6.97 (d, J =7.2 Hz, 2H, 
ArH), 7.36 (d, J =7.2 Hz, 2H, ArH), 7.46-7.53 (m, 11H, -ArH) ppm. 13C NMR (100 
MHz, DMSO-d6): 55.8, 111.5, 125.3, 125.6, 126.7, 129.5, 130.2, 131.4, 140.5, 142.3, 
158.3 ppm. 
ST-237 :  1H NMR (400 MHz, DMSO-d6): δ 1.34 (t, J =13.6 Hz, 3H, -CH3), 4.06 (dd, J 
=20.8 Hz, J =6.8 Hz,  2H, -CH2), 6.96 (d, J =8.4 Hz, 2H, ArH), 7.23-7.37 (m, 2H, -ArH), 
7.46-7.50 (m, 2H, -ArH), 7.58 (d, J =8.4 Hz, 2H, ArH), 7.82-7.90 (m, 3H, -ArH), 6.37 (s, 
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1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 15.1, 63.5, 115.1, 123.9, 126.1, 126.4, 
126.8, 128.0, 128.1, 128.3, 128.5, 129.1, 129.9, 132.7, 133.7, 135.4, 158.7 ppm. 
ST-233 :  1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.78 (s, 6H, -OCH3), 
3.83 (s, 6H, -OCH3), 6.40 (s, 1H, -ArH), 6.77 (d, J =2 Hz, 2H, ArH), 6.92 (s, 2H, ArH), 
7.13-7.24 (m, 2H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.6, 56.2, 60.5, 100.3, 
104.3, 104.6, 128.2, 129.5, 133.0, 137.7, 139.6, 153.4, 161.0 ppm. 
ST-234:  1H NMR (400 MHz, DMSO-d6): δ 3.73 (s, 12H, -OCH3), 6.43 (s, 2H, -ArH), 
6.77 (d, J =8 Hz, 2H, ArH), 6.92 (s, 4H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 
55.6, 99.6, 105.2, 127.4, 140.2, 158.4 ppm. 
ST-238:  1H NMR (400 MHz, DMSO-d6): δ 3.73 (s, 3H, -OCH3), 7.18-7.30 (m, 3H, 
ArH), 7.45-7.55 (m, 3H, ArH), 7.75 (d, J =7.6 Hz, 1H, ArH), 7.87-7.90 (m, 3H, ArH), 
8.01 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.6, 121.5, 124.7, 125.4, 
126.7, 126.8, 127.4, 128.0, 128.3, 128.6, 130.2, 130.8, 132.1, 133.7, 135.3, 136.5, 140.1 
ppm. 
ST-239 :  1H NMR (400 MHz, DMSO-d6): δ 3.75 (s, 3H, -OCH3), 6.81 (d, J =8.4 Hz, 
2H, ArH), 7.25-7.36 (m, 2H, -ArH), 7.45-7.59 (m, 2H, -ArH), 7.61 (d, J =8.0 Hz, 2H, 
ArH), 7.80-7.97 (m, 4H, -ArH), 6.37 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-
d6): 55.5, 110.4, 122.4, 125.2, 125.4, 126.1, 128.2, 128.3, 128.3, 128.8, 129.1, 129.5, 
132.8, 132.9, 133.2, 152.3 ppm. 
ST-240:  1H NMR (400 MHz, DMSO-d6): δ 2.43 (s, 3H, -CH3), 7.08-7.26 (m, 3H, ArH), 
7.45-7.52 (m, 3H, ArH), 7.71 (d, J =8 Hz, 1H, ArH), 7.84-7.99 (m, 4H, ArH) ppm. 13C 
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NMR (100 MHz, DMSO-d6): 19.7, 119.5, 121.5, 124.1, 125.7, 126.8, 126.9, 128.0, 
128.3, 128.6, 131.1, 132.9, 133.4, 133.9, 134.3, 134.4, 135.3 ppm. 
ST-241:  1H NMR (400 MHz, DMSO-d6): δ 2.45 (s, 3H, -CH3), 7.19-7.31 (m, 3H, ArH), 
7.48-7.59 (m, 3H, ArH), 7.73 (d, J =7.6 Hz, 1H, ArH), 7.89-7.92 (m, 3H, ArH), 8.03 (s, 
1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 20.03, 124.25, 125.5, 126.4, 126.6, 
126.8, 126.9, 128.0, 128.3, 128.6, 130.1, 130.8, 133.0, 133.7, 135.3, 136.0, 136.2 ppm. 
ST-242:  1H NMR (400 MHz, DMSO-d6): δ 6.82 (d, J =8.0 Hz, 2H, ArH), 7.22-7.35 (m, 
2H, -ArH), 7.46-7.61 (m, 2H, -ArH), 7.72 (d, J =8.4 Hz, 2H, ArH), 7.82-7.999 (m, 4H, -
ArH), 6.65 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 113.5, 122.4, 125.2, 
125.4, 125.5, 127.2, 128.2, 128.3, 128.8, 129.1, 129.5, 132.8, 133.7, 135.4, 159.5 ppm. 
ST-243:  1H NMR (400 MHz, DMSO-d6): δ 7.19-7.31 (m, 3H, ArH), 7.48-7.59 (m, 3H, 
ArH), 7.73 (d, J =7.6 Hz, 1H, ArH), 7.89-7.92 (m, 3H, ArH), 8.03 (s, 1H, ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 111.7, 125.5, 126.4, 126.6, 126.8, 126.9, 128.0, 128.3, 
128.6, 130.1, 131.8, 133.1, 133.5, 134.3, 135.0, 154.2 ppm. 
ST-245:  1H NMR (400 MHz, DMSO-d6): δ 1.34 (t, J =11.2 Hz, 3H, -CH3), 3.99 (s, 3H, 
-OCH3), 4.05 (dd, J =20.4 Hz, J =6.8 Hz,  2H, -CH2), 6.95 (d, J =8.4 Hz, 2H, ArH), 7.02 
(d, J =7.6 Hz, 1H, ArH), 7.11 (d, J =16 Hz, 1H, ArH), 7.51-7.65 (m, 4H, -ArH), 7.75-
7.82 (m, 2H, -ArH), 8.21 (d, J =8.0 Hz, 1H, ArH), 8.35 (d, J =8.4 Hz, 1H, ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 15.3, 55.8, 63.4, 109.4, 112.2, 115.0, 119.9, 126.4, 126.5, 
127.8, 130.3, 130.8, 148.9, 149.1, 158.5 ppm. 
ST-246:  1H NMR (400 MHz, DMSO-d6): δ 3.64 (s, 3H, -OCH3), 3.75 (s, 3H, -OCH3), 
6.37 (s, 1H, -ArH), 6.74 (d, J =1.6 Hz, 2H, ArH), 6.89 (s, 1H, ArH), 7.16 (dd, J =42 Hz, J 
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=16.4 Hz,  2H, -CH2) ppm. 13C NMR (100 MHz, DMSO-d6): 55.6, 56.2, 60.5, 100.3, 
104.3, 104.6, 128.2, 129.5, 133.0, 137.7, 139.6, 153.4, 161.0 ppm. 
ST-247:  1H NMR (400 MHz, DMSO-d6): δ  3.65 (s, 3H, -OCH3), 3.67 (s, 3H, -OCH3), 
6.75 (d, J =8.0 Hz, 2H, ArH), 7.12 (d, J =8.4 Hz, 1H, ArH), 7.11 (d, J =8.4 Hz, 1H, 
ArH), 7.51-7.65 (m, 4H, -ArH), 7.75-7.82 (m, 2H, -ArH), 8.19 (d, J =8.4 Hz, 1H, ArH), 
8.24 (d, J =8.0 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.8, 55.9, 104.6, 
112.2, 116.1, 120.4, 126.4, 126.5, 127.8, 130.3, 131.4, 144.1, 145.5, 158.5 ppm. 
ST-268:  1H NMR (400 MHz, DMSO-d6): δ 1.35 (t, J =12.4 Hz, 3H, -CH3), 4.01 (dd, J 
=16.4 Hz, J =8.0 Hz,  2H, -CH2), 4.15 (s, 4H, -CH2), 6.85 (d, J =8.8 Hz, 1H, ArH), 7.06-
7.13 (m, 4H, ArH), 7.15 (t, J =17.6 Hz, 2H, ArH), 7.56-7.60 (m, 2H, ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 15.1, 59.1, 64.4, 64.6, 115.1, 115.8, 116.0, 117.6, 120.2, 
125.9, 128.2, 128.3, 128.4, 128.5, 131.9, 134.3, 145.1, 149.1 ppm. 
ST-269 :  1H NMR (400 MHz, DMSO-d6): δ 3.85 (s, 3H, -OCH3), 4.26(s, 4H, -CH2), 
6.88 (d, J =8.4 Hz, 1H, ArH), 7.10-7.18 (m, 3H, ArH), 7.32 (d, J =16.4 Hz, 1H, ArH), 
7.69 (d, J =8.4 Hz, 2H, ArH), 7.93 (d, J =8.4 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 52.4, 64.4, 64.6, 115.5, 117.7, 120.7, 125.8, 126.7, 128.2, 130.0, 130.5, 
131.3, 142.5, 143.9, 144.2, 166.4 ppm. 
ST-270:  1H NMR (400 MHz, DMSO-d6): δ 3.76 (s, 3H, -OCH3), 4.24 (s, 4H, -CH2), 
6.83 (d, J =8 Hz, 1H, ArH), 6.93 (d, J =8.4 Hz, 2H, ArH), 6.97-7.07 (m, 4H, ArH), 7.49 
(d, J =8.8 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.5, 64.4, 64.5, 114.5, 
114.8, 117.6, 119.9, 126.0, 126.7, 127.9, 130.3, 131.4, 143.2, 143.9, 159.1 ppm.   
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ST-273:  1H NMR (400 MHz, DMSO-d6): δ 4.25 (s, 4H, -CH2), 6.85 (d, J =8.8 Hz, 1H, 
ArH), 7.07-7.11 (m, 4H, ArH), 7.18 (t, J =17.6 Hz, 2H, ArH), 7.57-7.61 (m, 2H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 64.4, 64.6, 115.1, 115.8, 116.0, 117.6, 120.2, 
125.9, 128.2, 128.3, 128.4, 128.5, 130.9, 134.3, 143.6, 143.9 ppm. 
ST-274:  1H NMR (400 MHz, DMSO-d6): δ 4.25 (s, 4H, -CH2), 6.84 (d, J =8.4 Hz, 1H, 
ArH), 7.05-7.17 (m, 4H, ArH), 7.40 (d, J =8.4 Hz, 2H, ArH), 7.57 (d, J =8.8 Hz, 2H, 
ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 64.4, 64.6, 115.2, 117.6120.4, 1255.7, 
128.2, 129.0, 129.2, 130.8, 131.8, 136.9, 136.6, 143.8, 143.9 ppm. 
ST-275:  1H NMR (400 MHz, DMSO-d6): δ 4.19 (s, 4H, -CH2), 6.79 (d, J =8.8 Hz, 1H, 
ArH), 7.10-7.15 (m, 4H, ArH), 7.21 (t, J =17.6 Hz, 2H, ArH), 7.59-7.63 (m, 2H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 64.7, 64.7, 113.2, 115.8, 116.1, 119.8, 123.7, 
123.9, 128.5, 129.1, 129.4, 129.5, 131.5, 136.3, 144.4, 146.5 ppm. 
ST-295:  1H NMR (400 MHz, DMSO-d6): δ 1.32 (t, J =12.8 Hz, 3H, -CH3), 4.04 (d, J 
=6.4 Hz, 2H, -CH2), 6.94 (d, J =8.4 Hz, 2H, ArH), 7.07 (d, J =16.4 Hz, 1H, ArH), 7.32 
(d, J =16.4 Hz, 1H, ArH), 7.50-7.59 (m, 4H, ArH), 7.82 (s, 1H, ArH) ppm. 13C NMR 
(100 MHz, DMSO-d6): 15.1, 63.5, 115.0, 1238, 126.5, 128.0, 128.5, 129.4, 130.9, 131.1, 
131.8, 138.9, 159.1 ppm. 
ST-297:  1H NMR (400 MHz, DMSO-d6): δ 3.68 (s, 3H, -OCH3), 3.82 (s, 6H, -OCH3), 
6.93 (s, 2H, ArH), 7.23 (d, J =16.4 Hz, 1H, ArH), 7.33 (d, J =16.4 Hz, 1H, ArH), 7.56 (d, 
J =8.4 Hz, 1H, ArH), 7.63 (d, J =8.4 Hz, 1H, ArH), 7.85 (s, 1H, ArH) ppm. 13C NMR 
(100 MHz, DMSO-d6): 56.3, 60.5, 104.6, 125.6, 126.7, 128.2, 129.7, 131.2, 131.4, 131.9, 
132.6, 138.1, 138.6, 153.4 ppm. 
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ST-294:  1H NMR (400 MHz, DMSO-d6): δ 3.77 (s, 3H, -OCH3), 6.96 (d, J =8.4 Hz, 2H, 
ArH), 7.08 (d, J =16.4 Hz, 1H, ArH), 7.32 (d, J =16.4 Hz, 1H, ArH), 7.52-7.58 (m, 4H, 
ArH), 7.81 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.5, 114.6, 123.9, 
126.5, 128.0, 128.5, 129.4, 129.5, 130.8, 131.1, 131.8, 138.8, 159.8 ppm. 
ST-298:  1H NMR (400 MHz, DMSO-d6): δ 2.33 (s, 3H, -CH3), 7.12 (d, J =7.2 Hz, 1H, 
ArH), 7.24-7.42 (m, 4H, ArH), 7.61 (dd, J =8.4 Hz, J =15.2 Hz, 2H, ArH), 7.88 (s, 1H, 
ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 21.4, 124.5, 126.1, 126.9, 127.6, 128.4, 
129.1, 129.3, 131.2, 131.3, 136.8, 138.2, 138.5 ppm. 
ST-290:  1H NMR (400 MHz, DMSO-d6): δ 7.22 (s, 1H, ArH), 7.91-7.93 (m, 3H, ArH), 
7.88 (s, 1H, ArH), 8.30-8.34 (m, 3H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 106.7, 
108.0, 117.9, 121.9, 124.8, 126.7, 137.5, 140.2, 146.1, 147.4, 149.6 ppm. 
ST-283:  1H NMR (400 MHz, DMSO-d6): δ 2.33 (s, 6H, ArH), 7.46 (d, J =6.8 Hz, 2H, 
ArH), 7.24-7.28 (m, 6H, ArH), 7.38-7.44 (m, 4H, ArH), 7.60 (s, 4H, ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 19.8, 121.5, 123.5, 124.1, 125.5, 126.4, 127.4, 127.6, 
128.2, 128.8, 135.2 ppm. 
ST-284:  1H NMR (400 MHz, DMSO-d6): δ 2.42 (s, 6H, ArH), 7.12-7.21 (m, 8H, ArH), 
7.46 (d, J =16.4 Hz, 2H, ArH), 7.64-7.69 (m, 6H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 19.2, 124.2, 124.8, 124.9, 125.5, 126.4, 127.4, 127.4, 128.6, 129.5, 136.7 
ppm. 
NI-ST-11: 1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.82 (s, 6H, -OCH3), 
6.93 (s, 2H, -ArH), 7.32 (s, 2H, -ArH), 8.41 (s, 2H, -ArH) ppm. 13C NMR (100 MHz, 
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DMSO-d6): 56.7, 56.8, 61.0, 104.9, 124.8, 127.5, 129.1, 131.5, 133.2, 138.5, 141.4, 
146.0, 154.0 ppm. 
NI-ST-12: 1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.82 (s, 6H, -OCH3), 
3.94 (s, 3H, -OCH3), 6.92 (s, 2H, -ArH), 7.24 (s, 2H, -ArH), 7.34 (d, J =8.0 Hz, 1H, 
ArH), 7.85 (d, J =8.0 Hz, 1H, ArH), 8.09 (s, 1H, -ArH), 8.52 (s, 2H, -ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 56.6, 60.2, 103.6, 112.4, 114.6, 124.6, 127.4, 127.5, 130.5, 
131.2, 134.5, 140.4, 145.4, 149.5, 152.3 ppm. 
DNR-1; 1H NMR (400 MHz, DMSO-d6): δ 3.76 (s, 6H, -OCH3), 6.33 (s, 1H, -ArH), 
6.71 (s, 2H, -ArH), 6.83 (d, 1H, -ArH, J = 16.4 Hz), 7.12 (d, 1H, -ArH J = 16 Hz), 8.10 
(s, 2H, -ArH) ppm. 13C NMR (DMSO-d6, ppm): δ 55.5, 99.6, 104.2, 110.0, 113.5, 124.2, 
128.1, 128.5, 140.7, 143.6, 159.7, 161.0 ppm. 
ST-208 :  1H NMR (400 MHz, DMSO-d6): δ 3.77 (s, 3H, -OCH3), 3.81 (s, 3H, -OCH3), 
6.94 (d, 1H, -ArH J = 8 Hz), 7.09 (d, 1H, -ArH J = 9.6 Hz), 7.15 (s, 1H, -ArH), 7.19 (s, 
1H, -ArH), 7.24 (d, J =1.6 Hz, 1H, ArH), 7.41 (d, 2H, -ArH J = 8 Hz), 7.59 (d, 2H, -ArH 
J = 8.4Hz) ppm. 13C NMR (100 MHz, DMSO-d6): 55.9, 109.6, 112.1, 120.6, 125.3, 
128.1, 129.1, 129.7, 130.1, 131.8, 136.8, 149.3 ppm. 
2.3 Synthesis of (E)-3,5,4’-trimethoxy resveratrol analogues with substitutions at the 
C2 position on the stilbene. 
 
2.3.1 Prior studies with this scaffold 
Structure-activity relationship studies on the resveratrol molecule identified trans-3,5,4’-
trimethoxy-resveratrol as a lead drug candidate and further SAR studies revealed that 
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various substitutions at the C2 position on trans-3,5,4’ -trimethoxy-resveratrol led to 
enhanced cytotoxic activity against a variety of tumor cell lines (Figure 2.3). 
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(D) (E)-3-(2,4-dimethoxy-6-(4-
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(E) (E)-3-(2,4-dimethoxy-6-(4-methoxystyryl)phenyl)
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(F) N-((E)-2-cyano-3-(2,4-dimethoxy-6-(4-
methoxystyryl)phenyl)acryloyl)nicotinamide  
Figure 2.3 Structures of trans-3,5,4’-trimethoxystilbene and its potent analogs. 
In 2006, Huang et al. reported that O-methylation of resveratrol caused an increase in 
cytotoxicity and that introduction of a formyl group (B) or an alkyl amine moiety (C) at 
the C2 position on the trans-3,5,4’-trimethoxystilbene scaffold (A) led to an enhanced 
cytotoxic activity (Huang, Ruan et al. 2007). In related studies, Ruan et al. have reported 
the antitumor activity of resveratrol derivatives possessing a chalcone moiety (Figure 
2.3. Structure D); these analogues exhibited potent anti-proliferative and antitubulin 
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activities, and compound D inhibited the growth of cancer cell lines HepG2, B16-F10, 
and A549 with IC50 values of 0.2, 0.1, and 1.4 μg/mL, respectively.(Ruan, Lu et al. 
2011). Recently, Raun and co-workers reported compounds E and F to be the most potent 
among the trans-3,5,4’-trimethoxystilbene acrylamides amine derivatives. Compounds E 
had the best cytotoxicity against the HuH-7 cell line and its IC50 was 4.5 μmol/L; and 
compound F had the best anti-tumor activity against the K562 cell line with an IC50 of 
2.9 μmol/L. 
2.3.2 Chemistry and analytical data 
Based on the structure-activity relationship analysis of the above mentioned literature, it 
is evident that substitutions at the C2 position of the trans-3,5,4’-trimethoxystilbene 
scaffold (Figure 2.3, A) leads to enhanced cytotoxic activity along with increased tubulin 
binding capacity. In this respect, we have synthesized a range of trans-3,5,4’-trimethoxy 
resveratrol analogs with substitutions at the C2 position. We designed and synthesized a 
series of novel trans-3,5,4’-trimethoxy resveratrol analogs incorporating an α,β-
unsaturated double bond conjugated to different five, and six membered heterocyclic and 
bicyclic quinuclidinone ring systems Scheme 2.2 and Scheme 2.3. Also, we synthesized 
a series of 3,5,4’-trimethoxy resveratrol analogs with acrylonitrile substitutions at the C2 
position Scheme 2.3. 
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Scheme 2.2 Synthesis of resveratrol analogs with heterocyclic ring substitutions at the C2 
position. (a) MeI, K2CO3, acetone; (a) POCl3, DMF,  0 oC, 69% yield; (b) barbituric acid 
or thiobarbituric acid,  methanol, RT, 6 hrs, 95-96% yield; (c) five membered active 
methylene compound, NH4OAc, AcOH, MWI, 1-2 min, 94-97% yield; (d) isobarbituric 
acid, ethanol, reflux, 4 hrs, 60% yield. 
 
The procedure for synthesizing compound RES-11 involves O-methylating the hydroxyl 
groups on resveratrol with MeI/ K2CO3 in acetone followed by formylation of (E)-1,3-
dimethoxy-5-(4-methoxystyryl) benzene in the presence of a slight excess of POCl3 in 
DMF at 0 0C for 30 min yielding trans-2-formyl-3,4′,5-trimethoxy stilbene (RES-11). 
(RES-11): 1H NMR (DMSO-d6):3.78 (s, 3H), 3.90 (s, 3H), 3.92 (s, 3H), 6.63 (s, 1H), 
6.91 (s, 1H), 6.97 (d, 2H, J = 7.9 Hz), 7.21 (d, 1H, J = 16.2 Hz), 7.50 (d, 2H, J =7.9 Hz), 
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7.95 (d, 1H, J = 16.2 Hz), 10.41 (s, 1H) ppm. 13C-NMR (DMSO-d6): 55.8, 56.1, 101.2, 
102.5, 109.8, 114.3, 129.4, 130.5, 131.4, 139.7, 162.5, 167.8, 193.5 ppm. 
 The novel resveratrol analogs (RES-09 to RES-27) were then prepared by aldol 
condensation of RES-11 with an appropriate active methylene compound, utilizing a 
variety of reaction conditions, i.e., ammonium acetate in acetic acid under microwave 
irradiation (MWI) conditions, by refluxing the reactants in ethanol, or by stirring the 
reaction at ambient temperature in methanol. The synthetic routes to the resveratrol 
analogs RES-09 to RES-27 are illustrated in Scheme 2.2. 
RES-09: 1HNMR (DMSO-d6): δ 3.72-3.86 (m, 9H, 3 -OCH3), 6.38 (d, 1H, J=24 Hz, 
C6H), 6.79 (d, 1H, C4H), 6.81-6.96 (m, 3H, C8H, C11H, C13H), 7.11 (s, 1H, C7H, 
C15H), 7.43-7.48 (m, 3H) ppm.13C-NMR (DMSO-d6): δ 55.3, 55.5, 55.8, 55.8, 56.1, 
97.3, 97.7, 102.2, 111.4, 113.8, 124.6, 127.6, 127.5, 129.1, 129.7, 129.9, 131.8, 132.4, 
139.5, 159.0, 159.8, 162.6, 167.3, 169.8 ppm; mp: 146-148 oC.  
RES-10: 1H NMR (DMSO-d6):  δ  3.78 (d, 6H, -OCH3), 3.84 (s, 3H,  -OCH3), 6.25(s, 
1H, C6H), 6.73 (s, 1H,- Ar), 6.78 (d, 1H, J=1.8Hz,  C4H), 6.89 (d, 2H, C7H ,C8H, J=8.7 
Hz), 6.95 (d, 2H, C11H,C13H,  J=4.5 Hz), 7.35 (d, 2H, J=8.7) ppm. 13C-NMR (DMSO-
d6): δ  56.4, 55.7, 55.9,100.6, 101.7, 109.4, 114.5, 123.4, 129.7, 130.2, 131.4, 136.7, 
148.4, 158.7, 158.9,160.4, 166.5, 166.9, 175.4  ppm; mp: 187-189oC. 
RES-80: 1H NMR (DMSO-d6):  δ  2.74 (s, 3H, -CH3), 3.20 (s, 3H,  -CH3), 3.64 (s, 3H, -
OCH3), 3.76 (s, 3H,  -OCH3), 3.78 (s, 3H,  -OCH3), 4.00 (s, 1H, ArH), 4.59 (s, 1H,- 
ArH), 6.32 (s, 1H, -ArH), 6.58 (s, 1H, ArH), 6.98 (s, 1H, ArH), 7.04 (d, 2H, J=8.4, ArH), 
7.50 (d, 2H, J=8.4, ArH) ppm. 13C-NMR (DMSO-d6): δ  27.91, 28.5, 48.5, 55.7, 55.7, 
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55.8, 95.5, 99.4, 114.9, 127.0, 128.4, 147.1, 149.9, 151.9, 155.3, 159.5, 161.4.  ppm; mp: 
156-158oC. 
RES-14: 1HNMR (DMSO-d6): δ  3.57 (d, 6H, -OCH3), 3.61 (s, 3H,  -OCH3), 6.35 (d, 
1H, J=24 Hz, C6H), 6.75 (d, 1H, C4H), 6.82-6.94 (m, 3H, C8H, C11H, C13H), 7.17 (s, 
2H, C7H, C15H), 7.39-7.48 (m, 2H) ppm.13C-NMR (DMSO-d6): δ 55.6, 55.8, 56.2, 
100.5, 102.3, 109.4, 114.3, 122.4, 124.5, 127.5, 130.4, 136.7, 154.3, 158.6, 159.1, 161.3, 
163.6.ppm; mp: 123-125 oC. 
RES-27: molecular formula: C22H23NST-624; 1H NMR (DMSO-d6):  δ 2.84 (s, 3H, -
NCH3), 3.81 (d, 6H, -OCH3), 3.89 (s, 3H,  -OCH3), 6.39(s, 1H, C6H), 6.75 (s, 1H, =CH), 
6.79 (d, 1H, J=1.8Hz,  C4H), 6.85 (d, 2H, C7H ,C8H, J=8.7 Hz), 6.99 (d, 2H, 
C11H,C13H,  J=4.5 Hz), 7.38 (d, 2H, C10H,C14H, J=8.7) ppm. 13C-NMR (DMSO-d6): 
δ 29.9,  55.6,  55.7, 55.8, 97.5, 100.9, 106.3, 113.7,114.3, 114.4, 124.2, 128.1, 128.5, 
129.8, 130.7, 135.3, 138.9, 158.8, 159.7, 160.8, 167.9, 176.2 ppm; mp: 162-165oC.  
RES-13: 1HNMR (DMSO-d6): δ 3.81-3.93 (m, 9H, 3 x -OCH3),6.51 (s, 1H, C6H), 6.93-
6.98 (m, 4H, C4H, C8H, C11H, C13H ), 6.27 (d, 1H, C7H ),7.45 (d, 2H, J=12.0 Hz, 
C10H, C14H), 8.34 (d, 1H, J=2 Hz, C15H), 11.21  (s, 1H, NH) ppm. 13CNMR (DMSO-
d6): δ 55.6, 55.9, 56.1, 101.4, 114.3, 120.4, 126.4, 129.8, 131.4, 131.6, 137.5, 139.6, 
157.5, 159.4, 161.3, 165.6, 175.9. ppm; mp: 112-114 oC. 
RES-16: 1HNMR (DMSO-d6): δ 3.77 (s, 3H, -OCH3), 3.91 (s, 3H, -OCH3), 3.93 (s, 3H, 
-OCH3),6.54 (s, 1H, C6H), 6.61 (d, 1H, C7H ), 6.81-6.87 (m, 4H, C4H, C8H, C11H, 
C13H ), 7.24 (d, 2H, J=12.0 Hz, C10H, C14H), 8.22 (d, 1H, J=2 Hz, C15H) 
60 
 
ppm. 13CNMR (DMSO-d6): δ 54.6, 55.1, 100.4, 102.4, 112.4, 116.0, 127.9, 130.4, 131.3, 
136.7, 154.3, 160.7, 161.3, 167.6. ppm; mp: 143-144 oC. 
RES-23: Molecular formula: C21H19NO4S2; 1HNMR (DMSO-d6): δ 3.70-3.83 (m, 9H, 3 
-OCH3), 6.31 (d, 1H, J=20.1 Hz, C6H), 6.78 (d, 1H, C4H), 6.86-6.98 (m, 3H, C8H, 
C11H, C13H), 7.11 (s, 2H, C7H, C15H), 7.41-7.48 (m, 2H) ppm.13C-NMR (DMSO-d6): 
δ 55.4, 55.5, 55.6, 55.9, 56.0, 97.8, 97.9, 103.2, 113.7, 114.6, 123.7, 126.9, 128.6, 128.7, 
129.1, 129.8, 132.6, 139.5, 159.0, 159.8, 162.3, 167.6, 169.0 ppm; mp: 130-135 oC.  
RES-18: Molecular formula: C22H20N2O6; 1HNMR (DMSO-d6): δ 3.81-3.93 (m, 9H, 3 x 
-OCH3),6.57 (s, 1H, C6H), 6.96-6.99 (m, 4H, C4H, C8H, C11H, C13H ), 6.15 (d, 1H, 
C7H ),7.54 (d, 2H, J=8.5 Hz, C10H, C14H), 8.32 (d, 1H, J=2 Hz, C15H), 11.0 (s, 1H,  
NH), 11.36  (s, 1H, NH) ppm. 13CNMR (DMSO-d6): δ 53.3, 55.5, 55.6, 55.9, 55.9, 56.2, 
56.3, 97.55, 97.6, 102.1, 102.4, 114.5, 115.6, 121.3, 124.2, 128.6, 129.9, 131.9, 139.7, 
149.7, 150.7 159.4, 159.7, 161.3, 162.4, 163.4 ppm; mp: 141-146 oC. 
RES-17: 1HNMR (DMSO-d6): δ 3.63 (s, 3H, -OCH3), 3.82 (s, 3H, -OCH3), 3.85 (s, 3H, 
-OCH3),6.55 (s, 1H, C6H), 6.64 (d, 1H, C4H), 6.87-6.96 (m, 3H, C8H, C11H, C13H), 
7.12 (d, 1H, C7H ),7.35 (d, 2H, J=12.0 Hz, C10H, C14H), 8.34 (d, 1H, J=2 Hz, C15H) 
ppm. 13CNMR (DMSO-d6): δ 54.6, 54.7, 55.2, 110.4, 115.8, 121.3, 127.7, 128.6, 131.4, 
131.8, 138.3, 139.9, 147.5, 156.8, 162.3, 165.6, 169.5 ppm; mp: 157-159 oC. 
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Scheme 2.3 Synthesis of resveratrol analogs with bicyclic and acrylonitrile substitutions 
at the C2 position (a) Quinuclidinone, 20% NaOH, EtOH, reflux; (b) NH2OH.HCl, 
AcONa, EtOH; (c) Phenylacetonitrile, NaOMe, EtOH, 6hrs reflux. 
The synthetic procedure for synthesizing compounds ST-98-ST-139 is shown in Scheme 
2.3. Trans-2-formyl-3,4′,5-trimethoxystilbene (RES-11) (1 mmol) and an appropriate 
phenylacetonitrile (1.1 mmol) were dissolved in 10 volumes of EtOH. 50% w/v aq. 
NaOMe was then added and mixture was refluxed for 6 hrs. The reaction was monitored 
by TLC (Thin Layer Chromatography). Once the reaction was completed the organic 
solvent was rota evaporated and purified by flash column chromatography with an 
EA/hexane solvent system, to afford analogs (ST-98)-(ST-139) in yields ranging from 
60-90%.  
ST-98: 1H NMR (DMSO-d6): δ 3.71 (s, 3H, -OCH3), 3.75 (s, 3H, -OCH3), 3.82 (s, 3H,  -
OCH3), 3.85 (s, 6H, -OCH3), 3.89 (s, 3H, -OCH3), 6.61 (s, 1H, ArH), 6.94 (d, J=8.4 Hz, 
2H), 7.00 (S, 3H, ArH), 7.08 (d, J=16 Hz, 2H), 7.28 (d, J=16 Hz, 2H), 7.49 (d, J=8.4 Hz, 
1H),  7.98 (s, 1H, ArH) ppm. 13C-NMR (DMSO-d6): δ 55.1, 55.3, 55.8, 56.1, 56.4, 98.2, 
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101.5, 104.7, 108.1, 110.5, 115.4, 117.6, 114.2, 121.4, 127.6, 131.7, 134.2, 159.7, 160.7, 
162.8 166.7 ppm. 
ST-127: 1H NMR (DMSO-d6): δ 3.74 (s, 3H, -OCH3), 3.81 (s, 6H, -OCH3), 3.84 (s, 3H,  
-OCH3), 3.89 (s, 3H, -OCH3), 6.60 (s, 1H, ArH), 6.93 (d, J=8.4 Hz, 2H), 6.97 (s, 1H, 
ArH), 7.03-7.07 (m, 2H), 7.28 (m, 2H), 7.33 (s, 1H, ArH), 7.47 (d, J=8.4 Hz, 2H), 7.89 
(s, 1H, ArH) ppm. 13C-NMR (DMSO-d6): δ 55.3, 55.4, 56.2, 56.4, 56.8, 56.9, 97.5, 
100.8, 104.7, 108.4, 111.5, 111.8, 114.5, 124.7, 129.5, 131.4, 134.8, 138.4, 147.5, 149.6, 
158.7, 163.8, 164.5 ppm. 
ST-99: 1H NMR (DMSO-d6): δ 3.75 (s, 3H, -OCH3), 3.81 (s, 9H, -OCH3), 3.89 (s, 3H,  -
OCH3), 6.61 (d, J=7.2 Hz, 2H), 6.87 (d, J=1.6 Hz, 2H), 6.94 (d, J=8.8 Hz, 2H), 6.98 (d, 
J=1.2 Hz, 1H),  7.07 (d, 1H, J=16.0 Hz, ArH), 7.27 (d, 1H, J=16.0 Hz, ArH),7.49 (d, 1H, 
J=8.4 Hz, ArH), 8.03 (s, 1H, ArH) ppm. 13C-NMR (DMSO-d6): δ 55.2, 55.8, 55.9, 99.5, 
100.5, 101.7, 109.5, 118.6, 120.5, 114.2, 127.4, 131.4, 136.3, 158.5, 160.7, 161.5. ppm. 
ST-100: 1H NMR (DMSO-d6): δ 3.75 (s, 3H, -OCH3), 3.81 (s, 6H, -OCH3), 3.89 (s, 3H,  
-OCH3), 6.60 (S, 1H, ArH), 6.91-7.07 (m, 6H, J= 64.8 Hz ArH), 7.22 (d, 1H, J= 16.4 Hz, 
ArH), 7.45 (d, 2H, ArH ,J= 8.4 Hz), 7.68 (d, 2H, ArH and J= 8 Hz), 7.83 (s, 1H, 
ArH). 13C-NMR (DMSO-d6): δ 55.6, 55.9, 55.9, 56.1, 98.2, 102.2, 114.7, 115.5, 117.2, 
117.6, 123.7, 126.1, 128.5, 129.6, 129.7, 129.9, 131.6, 133.8, 138.9, 139.4, 158.9, 159.7, 
161.6  ppm. 
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ST-128: 1H NMR (DMSO-d6): δ 3.78 (s, 3H, -OCH3), 3.86 (s, 3H, -OCH3), 3.88 (s, 3H,  
-OCH3), 6.18 (s, 1H, ArH), 6.75 (d, J=8.6 Hz, 2H), 6.83 (s, 2H, ArH), 7.12 (d, 1H, 
J=16.0 Hz, ArH), 7.28 (d, 1H, J=16.0 Hz, ArH), 7.43-7.50 (m, 6H, ArH), 7.77 (d, 2H, J= 
8.4 Hz, ArH), 8.01 (s, 1H, ArH). 13C-NMR (DMSO-d6): δ 55.7, 55.2, 56.4, 99.1, 101.2, 
114.7, 117.3, 117.9, 118.9, 124.8, 126.6, 127.6, 128.2, 129.5, 129.8, 131.9, 135.4, 138.5, 
140.2, 158.6, 158.8, 162.4  ppm. 
ST-139: 1H NMR (DMSO-d6): δ 3.74 (s, 3H, -OCH3), 3.82 (s, 3H, -OCH3), 3.89 (s, 3H,  
-OCH3), 6.13 (s, 1H, ArH), 6.93 (d, J=8.8 Hz, 2H), 6.98 (s, 2H, ArH), 7.08 (d, 1H, 
J=16.4 Hz, ArH), 7.22 (d, 1H, J=16.4 Hz, ArH), 7.45-7.51 (m, 6H, ArH), 7.76 (d, 2H, J= 
7.2 Hz, ArH), 7.98 (s, 1H, ArH). 13C-NMR (DMSO-d6): δ 55.5, 55.9, 56.1, 98.2, 102.2, 
114.7, 115.5, 117.1, 117.59, 123.6, 126.0, 128.4, 129.5, 129.6, 129.9, 131.9, 133.8, 138.9, 
139.4, 158.8, 159.6, 161.6  ppm. 
For preparing compound ST-54, E-2,4-dimethoxy-6-(4-methoxystyryl)benzaldehyde 
(RES-11) and quinuclidinone (1.2 mmol) were added to 10 volumes of methanol and the 
resulting mixture stirred at room temperature. The final product ST-54,  crashed out of 
the solution once the reaction was complete in 1-2 hrs. The final product was filtered and 
recrystallized from methanol to afford ST-54 in 80% yield. In the next step, compound 
ST-54 (1mmol), hydroxylamine HCl (1.1 mmol) and sodium acetate (1.5 mmol) were 
dissolved in 10 volumes of ethanol and the mixture was heated under reflux for 6 hrs. A 
white precipitate was formed, which was later filtered off to afford ST-57 in 65% yield 
(Scheme 2.3).ST-54: 1H NMR (DMSO-d6): δ 1.96 (d, J=3 Hz, 4H), 2.63 (s, 1H), 2.90–
2.92 (m, 4H), 3.72–3.82 (m, 6H), 3.86 (s, 3H), 6.39 (d, J=3 Hz, 1H), 6.78 (d, J=3 Hz, 
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1H), 6.86 (d, J=9 Hz, 2H), 6.95 (d, J=6 Hz, 2H), 7.26 (s, 1H), 7.38 (d, J=6 Hz, 2H) ppm 
.13C NMR (DMSO-d6): δ 26.1, 41.0, 48.2, 49.7, 55.6, 55.7, 55.9, 97.9, 101.6, 114.3, 
123.9, 125.4, 127.9, 128.0, 129.8, 130.2, 138.4, 158.8, 159.5, 160.9 ppm. mp: 178–180 
°C. 
ST-57: 1H NMR (DMSO-d6): δ 1.98 (d, J=3 Hz, 4H), 2.43 (s, 1H), 2.73–2.76 (m, 4H), 
3.79–3.84 (m, 6H), 4.13 (s, 3H), 6.46 (d, J=4 Hz, 1H), 6.84 (d, J=4.4 Hz, 1H), 6.89 (d, 
J=9 Hz, 2H), 6.93 (d, J=6 Hz, 2H), 7.28 (s, 1H), 7.41 (d, J=8.4 Hz, 2H) ppm.13C NMR 
(DMSO-d6): δ 26.1, 41.0, 48.2, 49.7, 55.6, 55.7, 55.9, 97.9, 101.6, 114.3, 123.9, 125.4, 
127.9, 128.0, 129.8, 130.2, 138.4, 158.8, 159.5, 160.9 ppm. mp: 142–145 °C. 
X-ray crystallographic data for the representative compounds RES-27, RES-17 and 
RES-54 were obtained which confirmed the Z-geometry (Figure 2.4) in these analogs 
(Madadi, Reddy et al. 2010, Madadi, Parkin et al. 2012). 
 
65 
 
 
Figure. 2.4 Crystal structures of compounds RES-27, RES-17 and RES-54. 
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Scheme 2.4 Synthesis of resveratrol analogs with hydroxamine, benzylalcohol, bromo, 
cyano and imidazole substitutions at the C2 position (a) NH4OH, NaOAc, ethanol, reflux 
4hrs; (b) NaBH4, methanol; (c) imidazole, neat, MW 180 0C, 5min (f) N-
bromosuccinamide, CHCl3; (g) Aq.NH3, I2, THF. 
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Scheme 2.5: Synthesis of resveratrol analogs with methyl, benzylalcohol and bromo 
substitutions at the C2 position (a) MeI, K2CO3, acetone, reflux 12hrs. (c) N-
bromosuccinamide, CHCl3; (e) NaBH4, methanol. 
  
We wanted to compare the anti-cancer activity of C2 conjugated five and six-membered 
heterocyclic and bicyclic quinuclidinone ring systems with simpler and smaller 
functionalities. Below are the analytical data and reaction conditions for the synthesized 
compounds: 
ST-138:  1H NMR (400 MHz, DMSO-d6): δ 3.32 (s, 3H, -CH3), 6.22 (d, J =2 Hz, 1H, 
ArH), 6.45 (d, J =2 Hz, 1H, ArH), 6.74 (d, J =8.4 Hz, 2H, ArH), 6.82 (d, J =16 Hz, 2H, 
ArH), 7.12 (d, J =16 Hz, 2H, ArH), 7.41 (d, J =7.2 Hz, 8.8H, ArH), 8.91 (s, 1H, -OH), 
9.09 (s, 1H, -OH), 9.53 (s, 1H, -OH) ppm. 13C NMR (100 MHz, DMSO-d6): 11.2, 103.0, 
112.8, 115.9, 123.9, 128.2, 128.8, 129.4, 138.1, 155.8, 156.4, 157.5 ppm. 
ST-76: δ 6.38 (s, 1H, ArH), 6.63 (s, 1H, ArH), 6.79 (d, J =5.6 Hz, 2H, ArH), 6.96 (d, J 
=16.4 Hz, 1H, ArH), 7.18 (d, J =16 Hz, 1H, ArH), 7.41 (d, J =6 Hz, 2H, ArH), 9.44 (s, 
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1H, -OH), 9.62 (s, 1H, -OH), 9.99 (s, 1H, -OH) ppm. 13C NMR (100 MHz, DMSO-d6): 
101.2, 102.8, 104.4, 110.0, 116.0, 124.5, 128.1, 128.5, 131.2, 138.5, 155.3, 157.5, 158.0 
ppm. 
ST-75: δ 6.58 (s, 1H, ArH), 6.72 (s, 1H, ArH), 6.80 (d, J =5.6 Hz, 2H, ArH), 6.92 (d, J 
=16.4 Hz, 1H, ArH), 7.06 (d, J =16 Hz, 1H, ArH), 7.52 (d, J =6 Hz, 2H, ArH), 9.19 (s, 
1H, -CHO), 9.95 (s, 1H, -OH), 10.45 (s, 1H, -OH), 10.66 (s, 1H, -OH) ppm. 13C NMR 
(100 MHz, DMSO-d6): 98.7, 101.8, 103.3, 116.7, 116.0, 124.5, 128.1, 128.5, 134.4, 
138.5, 157.5, 157.9, 193.1 ppm. 
ST-82: δ 3.59 (s, 2H, -CH2), 6.10 (s, 1H, ArH), 6.46 (s, 1H, ArH), 6.77 (d, J =9.2 Hz, 
2H, ArH), 6.81 (s, 1H, ArH), 7.19 (d, J =16.0 Hz, 1H, ArH), 7.40 (d, J =8.4 Hz, 1H, 
ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 43.9, 101.9, 103.0, 109.5, 111.5, 115.5, 
123.1, 127.9, 128.3, 129.6, 138.2, 157.0, 157.2, 158.8 ppm. 
ST-05: E-2,4-Dimethoxy-6-(4-methoxystyryl)benzaldehyde (RES-11) (1mmol), 
hydroxylamine HCl (1.1 mmol) and sodium acetate (1.5 mmol) were dissolved in 10ml 
of ethanol and the resulting mixture was heated under reflux for 4 hrs. A white precipitate 
was formed, which was later filtered off to afford ST-05 in 80% yield. 1H NMR (DMSO-
d6): δ 3.77 (s, 3H, -OCH3), 3.81 (s, 3H, -OCH3), 3.85 (s, 3H, -OCH3), 6.54 (s, 1H, -
ArH), 6.89 (s, 1H, -ArH), 6.93-6.96 (d, 2H, -ArH; J = 8.4 Hz), 7.11-7.15 (d, 1H, -ArH; J 
= 16.4 Hz), 7.45-7.47 (d, 2H, -ArH; J = 8 Hz), 7.59-7.63 (d, 1H, -ArH; J = 16.4Hz), 8.30 
(s, 1H, -ArH), 11.15 (s, 1H, -OH) ppm. 13C-NMR (DMSO-d6): δ 55.6, 55.8, 55.3, 98.0, 
102.7, 110.0, 112.6, 114.6, 126.4, 128.3, 130.1, 130.5, 138.7, 145.2, 159.4, 159.7, 161.0 
ppm. 
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ST-130: E-2,4-Dimethoxy-6-(4-methoxystyryl)benzaldehyde (RES-11) (1mmol) was 
dissolved in methanol and cooled to 0 0C and LiBH4(1.0 mmol) was added. The reaction 
mixture was allowed to stir for 1 hr at ambient temperature. The reaction was monitored 
by TLC, and after consumption of the starting materials, the reaction mixture was 
concentrated and extracted into ethyl acetate followed by concentration on a rotary 
evaporator. Flash column chromatography was carried out using an EA/hexane solvent 
system to afford ST-130 in 85% yield. (ST-130): 1H NMR (CDCl3): δ 3.83 (s, 3H, -
OCH3), 3.85 (s, 3H, -OCH3), 3.86 (s, 3H,  -OCH3), 4.79 (s, 2H, CH2), 6.41 (s, 2H, 
CH2), 6.72 (d, J=2.0 Hz, 1H), 6.91 (d, 2H, J=8.8 Hz, ArH), 6.98 (d, 1H, J=16.0 Hz, 
ArH), 7.36 (d, 1H, J=16.0 Hz, ArH), 7.47 (d, 2H, J= 8.4 Hz, ArH) ppm. 13C-NMR 
(DMSO-d6): δ 56.1, 56.7, 56.8, 58.6, 99.4, 99.8, 101.2, 114.5, 121.3, 124.5, 125.4, 129.7, 
131.2, 136.4, 153.4, 156.7, 159.6  ppm. 
ST-131: Compound ST-130 (1mmol) and imidazole (5mmol) were added to a synthetic 
microwave vial and irradiated for 2 min at 80 0C using a Biotage Initiator synthetic 
microwave. The reaction was monitored by TLC. After the starting material had 
completely disappeared, ethyl acetate was added and the excess imidazole was washed 
out with water. The ethyl acetate solvent was removed on a rotavaporator to yield ST-131 
in 95 % yield. 1H NMR (DMSO-d6): δ 3.78 (s, 3H, -OCH3), 3.83 (s, 3H, -OCH3),3.85 (s, 
3H, -OCH3), 5.29 (s, 2H, -CH2), 6.55-6.56(d, J=2 Hz, 1H, ArH), 6.79 (S, 1H, ArH), 
6.86-6.87(d, J=2Hz, 1H, ArH), 6.94-6.97(d, J=8.4 Hz, 2H, ArH), 7.12-7.16 (d, J=16 Hz, 
1H, ArH), 7.41-7.46 (d, J=16.4 Hz, 1H, ArH), 7.57 (s, 1H, ArH), 7.61-7.63 (d, J= 8.8 Hz, 
2H, ArH) ppm. 13C-NMR (DMSO-d6): δ 55.6, 55.7, 56.3, 98.2, 102.1, 110.0, 114.6, 
115.3, 119.3, 122.6, 128.5, 128.7, 129.9, 131.9, 137.3, 139.3, 159.3, 159.7, 160.7 ppm. 
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ST-62: To a solution of trans-2-formyl-3,4′,5-trimethoxystilbene (RES-11) (1.4 mmol) in 
CHCl3 (need volume), was added drop-wise at 0-5 0C N-bromosuccinimide (1.7 mmol). 
The reaction mixture was stirred for 2 hrs and was monitored by TLC. After compound 
RES-11 was consumed the mixture was added to 10 volumes of water and then extracted 
with 4 volumes of CH2Cl2. Removal of impurities from the product was achieved by 
column chromatography using a silica gel column and an ethyl acetate/hexane solvent 
system to afford ST-62 in 65% yield. 1H NMR (CDCl3): δ 3.83 (s, 3H), δ 3.86 (s, 3H), δ 
3.88 (s, 3H), 6.41 (s, 1H), 6.79 (s, 1H), 6.89 (d, 2H, J=8.8 Hz, ArH), 6.94 (d, 1H, J=16.0 
Hz, ArH), 7.37 (d, 1H, J=16.0 Hz, ArH), 7.50 (d, 2H, J=8.8 Hz, ArH) ppm; 13C-NMR 
(CDCl3): δ 55.1, 55.8, 100.3, 104.6, 105.1, 114.2, 127.4, 137.8, 157.9, 160.2 ppm.  
ST-59: Trans-2-formyl-3,4′,5-trimethoxystilbene (RES-11)(1 mmol) was dissolved in 
1ml of THF and 10 ml of 28% aqueous NH3 solution. Iodine (1.1 mmol) was added and 
the mixture stirred at room temperature for 1hr. The reaction mixture was quenched with 
Na2S2O3 followed by extraction with diethyl ether to afford the nitrile product ST-59 in 
55% yield. 1H NMR (CDCl3): δ 3.79 (s, 3H), δ 3.82 (s, 3H, -OCH3), δ 3.83 (s, 3H, -
OCH3), 6.46 (s, 3H, -OCH3), 6.82 (s, 1H), 6.87 (d, 2H, J=8.8 Hz, ArH), 6.97 (d, 1H, 
J=16.0 Hz, ArH), 7.39 (d, 1H, J=16.0 Hz, ArH), 7.52 (d, 2H, J=8.8 Hz, ArH) ppm; 13C-
NMR (CDCl3): δ 56.4, 56.7, 56.9, 98.6, 99.8, 103.2, 114.5, 121.3, 124.5, 125.4, 128.7, 
131.2, 136.4, 154.4, 156.7, 160.6  ppm. 
ST-132(a): (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene (1 mmol) was dissolved in 
10 volumes of  anhydrous acetone. MeI (2 eq) and K2CO3 (5 eq) were added to the 
solution and the mixture refluxed overnight to afford (E)-1,5-dimethoxy-3-(4-
methoxystyryl)-2-methylbenzene (ST-132(a)) along with a mixture of unidentified 
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methylated products. The resveratrol analog (ST-132(a)) was isolated by silica gel 
chromatography utilizing ethyl acetate/hexane as eluting solvent in 40 % yield. (ST-
132(a)): molecular formula: C18H20O3; 1H NMR (DMSO-d6): δ 3.82-3.85 (t, J= 13.6 Hz, 
9H, -OCH3), 6.40-6.41(d, J= 2.4 Hz, 1H, ArH), 6.72-6.73(d, J= 2.4 Hz, 1H, ArH), 6.90-
6.94 (m, J=18 Hz, 3H, ArH), 7.21-7.25 (d, J=16 Hz, 1H, ArH), 7.45-7.48 (d, J= 8.8 Hz, 
1H, ArH) ppm. 13C-NMR (DMSO-d6): δ 10.9, 55.3, 55.4, 55.6, 97.7, 101.2, 114.1, 117.1, 
124.9, 127.8, 129.9, 130.4, 138.1, 158.3, 158.6, 159.3. ppm. mp: 55-57 oC. 
2.4 Synthesis of (Z)-2,3-diaryl substituted acrylonitriles as anticancer agents. 
2.4.1 Prior studies with this scaffold 
In 2011, Tarleton and coworkers serendipitously discovered a family of 2-
phenylacrylonitriles (Figure 2.5, A) with potent growth inhibition properties against a 
panel of ten human cancer cell lines: HT29 and SW480 (colon cancer), MCF-7 (breast 
cancer), A2780 (ovarian cancer), H460 (lung cancer), A431 (skin cancer), DU145 
(prostate cancer), BEC-2 (neuroblastoma), SJ-G2 (glioblastoma), and MIA (pancreatic 
cancer) (Tarleton, Gilbert et al. 2011). They reported (Z)-2-(3,4-dichlorophenyl)-3-(4-
nitrophenyl)acrylonitrile (Figure 2.5, A)  as the lead compound from their studies with a 
GI50 value of 0.127 µM against the (ER+ve) human breast cancer cell line, MCF-7 with a 
543-fold selectivity towards MCF-7 cells compared with nine other non-breast derived 
cancer cell lines.  
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Cl
Cl
NO2
CN
S
CNR
N
CN
(A) 2-phenylacrylonitriles (B) (Z)-benzothiophene acrylonitriles
OCH3
OCH3
OCH3
N
CN
OCH3
OCH3
(C) (Z)-3-(quinolin-2-yl)-2-(3,4,5-
trimethoxyphenyl)acrylonitrile
(D) (Z)-2-(3,5-dimethoxyphenyl)-3-(quinolin-2-
yl)acrylonitrile  
Figure 2.5 Structures of literature reported potent anti-cancer agents in the       
phenylacrylonitrile series. 
Recently, our laboratory has reported on a series of (Z)-benzothiophene acrylonitrile 
analogues (Figure 2.5, B) as potent anti-cancer agents with GI50 values generally in the 
range 10–100 nM against a panel of 60 human cancer cell lines. Of interest, these 
compounds are also able to overcome cell-associated P-glycoprotein mediated resistance, 
since they were equipotent in inhibiting OVCAR8 and NCI/ADR-RES cell growth 
(Penthala, Sonar et al. 2013). 
Also, our laboratory has synthesized and evaluated a series of (Z)-quinolinyl acrylonitrile 
derivatives (Figure 2.5, C, D) as anticancer agents against a panel of 60 human cancer 
cell lines. Of these compounds, (Z)-3-(quinolin-2-yl)-2-(3,4,5-
trimethoxyphenyl)acrylonitrile (Figure 2.5, C) showed potent cytotoxicity against MDA-
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MB-435 melanoma and NCI-H522 non-small cell lung cancer line with GI50 values of 33 
nM and 37 nM, respectively. (Z)-2-(3,5-Dimethoxyphenyl)-3-(quinolin-2-
yl)acrylonitrile (Figure 2.5, D) also displayed potent growth inhibitory activity against 
NCI-H522 non-small cell lung cancer lines with a GI50 value of 94 nM (Penthala, 
Janganati et al. 2014). 
NC
R R
(G) (E)-diarylacrylonitriles(E) (E)-diaryl stilbenes
CN
(F) (Z)-diarylacrylonitriles
RRR
R
 
Figure 2.6 Scaffolds of reported potent anticancer agents in the stilbene and 
phenylacrylonitrile  series. 
Of interest, Ohsumi et al. had reported (E)-substituted diarylacrylonitrile analogs (Figure 
2.6, G)  as effective anti-cancer agents against murine solid tumors, but failed to mention 
or compare the activity of their Z-isomers (Ohsumi, Nakagawa et al. 1998). In the current 
work the stilbene structural fragments present in resveratrol are modified by introducing a 
cyano group on the double bond bridge and incorporating methoxy substituents into the 
phenyl rings to improve the compound’s potency. Also, a small structure-anticancer 
activity relationship (SAR) study was performed by comparing the GI50 and TGI values 
from the cytotoxic assay of the synthesized substituted stilbenes (Figure 2.6, E) and 
(E/Z)-substituted diarylacrylonitriles analogs (Table 2.2). 
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2.4.2 Chemistry and analytical data 
R1 CHO CN
R2 R1
R2
Aldehyde Phenylacetonitrile Diarylacrylonitrile
a
R1 = R2 = Aromatic ring
CN
 
Scheme 2.6 Synthesis of (Z)-2,3-diaryl substituted acrylonitriles; reagents and conditions: 
(a) 5% NaOMe, MeOH, reflux. 
A series of (Z)-substituted diarylacrylonitrile analogs (Table 2.2) were synthesized by 
reacting substituted benzyl carbaldehydes with their corresponding substituted 
phenylacetonitriles in 5% sodium methoxide/methanol. The reaction mixture was stirred 
at room temperature for 2-3 hours. On completion of the reaction, the desired product 
crashed out of the solution. The precipitate was filtered off, washed with water and dried 
to yield the final compound in yields ranging from 70-95 % (Scheme 2.6). Compounds 
with (Z)-geometry can convert to their corresponding (E)-isomer under certain reaction 
conditions. This conversion is also dependent on the nature of substituents and 
functionalities (electron donating or accepting) on the aryl rings. However, base-
catalyzed condensation reactions have been reported to form exclusively Z-isomer 
products (Penthala, Sonar et al. 2013). 
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Table 2.2 Structures of the synthesized diarylacrylonitrile products and the starting 
materials (aldehyde and phenylacetonitrile precursors) utilized in their preparation 
 
Table 2.2 (continued) 
 Aldehyde precursor Phenylacetonitrile 
precursor 
Diarylacrylonitrile product 
1.  CHO
 
O
O CN  
CN
O
O
ST-215  
2.  
CHO
MeO
MeO
NO2
 
O
O CN  
OCH3
OCH3
CN
O2N
ST-218
O
O  
3.  CHOO
O  
CN
 
NC
O
O
ST-254  
4.  
             
CHOO
O  
CN
MeO
 
OCH3
NC
O
O
ST-252
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Table 2.2 (continued) 
5.  CHOO
O  
CN
MeO
MeO
MeO
 
 
 
NC
OCH3
OCH3
OCH3
O
O
ST-253
 
6.  CHOO
O  
CN
F3C
 
ST-255
O
O NC
CF3
 
7.  CHOO
O  
CN
MeO
MeO
 
NC
OCH3
OCH3
O
O
ST-257
 
8.  CHOO
O  
CN
O2N
 
NC
NO2
O
O
ST-258  
9.  CHO
 
CN
O2N
 
NO2
NC
ST-259  
10.  CHO
 
CN
MeO
MeO
 OCH3
NC
OCH3
ST-260
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Table 2.2 (continued) 
11.  CHO
 
CN
MeO
MeO
MeO
 NC
OCH3
OCH3
OCH3ST-261
 
12.  CHO
 
CN
MeO
 
 
 
 
OCH3
NC
ST-262
 
13.  CHO
 
CN
 
 
 
 
ST-263
NC
 
14.  CHO
 
CN
F3C
 
ST-264
CF3
NC
 
15.  
CHOMeO
 
O
O CN  O
O
CN
ST-179
OCH3
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Table 2.2 (continued) 
16.  
S
CHO
 
O
O CN  O
O
CN
ST-180
S
 
17.  
N
MeO CHO
 
 
O
O CN  NO
O
CN
ST-181
OCH3
 
18.  CHO
 
O
O CN  
O
O
CN
ST-216  
19.  N CHO
 
O
O CN  NO
O
CN
ST-183  
20.  
CHOO
O  
MeO
CN
MeO  
O
O
OCH3
OCH3
CN
ST-185  
21.  
CHOO
O  
CN
MeO
MeO
MeO
 O
O
OCH3
OCH3
CN
ST-160
OCH3
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Table 2.2 (continued) 
22.  
CHOO
O  
CN
MeO
MeO
 
 
O
O
OCH3
CN
ST-155
OCH3
 
23.  
CHOO
O  
O
O CN  O
O
CN
O
O
ST-161  
24.  
CHO
MeO
MeO
MeO
 
O
O CN  
O
O
OCH3
OCH3
CN
OCH3
ST-162  
25.  
CHO
MeO
MeO
 
O
O CN  
O
O
OCH3
CN
OCH3
ST-164  
26.  
MeO CHO
 
O
O CN  O
O
OCH3CN
ST-163  
27.  
MeO CHO
MeO  
O
O CN  O
O
OCH3
OCH3
CN
ST-165  
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Table 2.2 (continued) 
28.  
MeO CHO
O2N  
O
O CN  O
O
OCH3CN
NO2
ST-166  
29.  
O2N CHO
 
O
O CN  O
O
NO2CN
ST-167  
30.  
CHO
Br
Br
 
O
O CN  
O
O
Br
CN
Br
ST-168  
31.  Cl
Cl
CN
 
O
O CN  O
O
CN
ST-169
Cl
Cl
 
32.  
Cl CHO
Cl  
O
O CN  
O
O
CN
Cl
ST-170
Cl
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Table 2.2 (continued) 
33.  
CHO
F
F
 
O
O CN  
O
O
F
CN
F
ST-171  
34.  
Br CHO
F  
O
O CN  
O
O
CN
F
ST-172
Br
 
35.  
MeO CHO
OMe  
O
O CN  O
O
CN
ST-173
OCH3
OCH3
 
36.  
Cl CHO
Cl  
O
O CN  O
O
CN
ST-174
Cl
Cl
 
37.  O
CHO  
O
O CN  O
O
CN
ST-175
O
 
38.  
N
CHO
Cl  
 
 
O
O CN  
NO
O
CN
ST-176
Cl
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Table 2.2 (continued) 
39.  
MeO CHO
MeO Cl  
O
O CN  O
O
CN
ST-177
OCH3
Cl
OCH3
 
40.  
CHO
 
O
O CN  O
O
CN
ST-178  
41.  
O2N CHO
 
CN
MeO
MeO
MeO
 
NC
OCH3
OCH3
OCH3
TMR-01
O2N
 
42.  
CHO
O2N  
CN
MeO
MeO
MeO
 NC
OCH3
O2N
OCH3
OCH3
TMR-03  
43.  
MeO CHO
O2N  
CN
MeO
MeO
MeO
 
NC
OCH3
OCH3
OCH3
TMR-04
O2N
H3CO
 
44.  
MeO CHO
 MeO
CN
 
O
O
CN
ST-153
OCH3
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Table 2.2 (continued) 
45.  
CHOO
O  
F
F
CN
 
O
O
CN
ST-184
F
F
 
46.  O
CHO  
MeO
CN
 
H3CO
CN
ST-288
O
 
47.  O
CHO  
CN
MeO
MeO
MeO
 H3CO
CN
ST-287
O
H3CO
OCH3
 
48.  
O2N CHO
 
 
 
O2N
CN
 O
O
CN
ST-156
NO2
 
49.  N CHO
 
CN
MeO
MeO
MeO
 
NH3CO
CN
ST-486
H3CO
OCH3  
50.  CHOO
O  
MeO
CN
MeO  
H3CO
CN
ST-479
O
O
H3CO
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Table 2.2 (continued) 
51.  
CHO
Br
Br  
CN
OMe  CN
ST-152
H3CO
Br
Br
 
52.  
MeO CHO
O2N  
HO
CN
 OCH3
NO2
HO
CN
ST-521
 
53.  
O2N CHO
 
CN
MeO
MeO
 
CN
H3CO
H3CO
NO2
ST-101  
54.  
Cl CHO
Cl  
MeO
CN
MeO  
CN
H3CO
H3CO
Cl
Cl
ST-527
 
55.  
CHO
MeO
MeO
 
MeO
CN
 
CN
H3CO
OCH3
OCH3
ST-124
 
56.  
CHO
MeO
MeO
MeO
 
MeO
CN
 
CN
H3CO
OCH
OCH3
OCH3ST-126
 
57.  
MeO CHO
HO  
MeO
CN
MeO
MeO
 
CN
H3CO
H3CO
OCH
OH
H3CO
ST-145
 
84 
 
Table 2.2 (continued) 
58.  
CHO
MeO
MeO
 
MeO
CN
MeO
MeO
 
CN
H3CO
H3CO
OCH3
H3CO
OCH3
ST-147
 
59.  
MeO CHO
 MeO
CN
MeO
MeO
 
CN
H3CO
H3CO
H3CO
OCH
ST-148
 
60.  
CHO
MeO
MeO
MeO
 
MeO
CN
MeO
MeO
 
CN
H3CO
H3CO
H3CO
OCH
OCH3
OCH3
ST-149
 
61.  
CHO
HO
MeO
 
MeO
CN
MeO  
 
CN
H3CO
H3CO
OCH
OHST-507
 
62.  - - 
H3CO OCH3
NC
OCH3
OH
ST-507(A) * 
63.  - - 
H3CO OCH3
NC
OCH3
OH
ST-510
H3CO
* 
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Table 2.2 (continued) 
64.  O
CHO  
CN
 
ST-289
O
CN
 
65.  O
CHO  
O2N
CN
 
O2N
ST-290
O
CN
 
66.  O
CHO
 
CN
Cl
F  ST-526 S
CN
Cl
F
 
67.  
N
H
N
CHO  
MeO
CN
MeO
MeO
 ST-488
NH
N
CN
H3CO
H3CO
H3CO
 
 
68.  
CHO
MeO
MeO  
HO
CN
 
H3CO
H3CO
OH
NC
ST-512  
69.  
MeO CHO
MeO
MeO  
HO
CN
 
H3CO
H3CO
OH
NC
ST-514
H3CO
 
70.  
CHO
 
HO
CN
 OH
ST-516
NC
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Table 2.2 (continued) 
71.  
CHOO
O  
HO
CN
 OHNC
ST-517
O
O
 
72.  
MeO CHO
 HO
CN
 OHNC
ST-520
MeO
 
73.  
MeO CHO
O2N  
HO
CN
 OHNC
ST-521
MeO
O2N
 
74.  
N CHO
 
MeO
CN
MeO
MeO
 
N
OMe
NC
ST-486
OMe
OMe  
 
* Synthetic route presented in Scheme 2.7. 
 
ST-215: 1H NMR (400 MHz, DMSO-d6): δ 6.13 (s, 2H, -ArH), 7.55 (t, J =14.8 Hz, 2H, 
ArH), 7.61-7.65 (m, 2H, ArH), 7.85 (d, J =7.2 Hz, 2H, ArH), 7.91 (t, J =13.6 Hz, 2H, 
ArH), 8.07 (d, J =8.4 Hz, 2H, ArH), 8.11 (d, J =8.4 Hz, 2H, ArH), 8.21 (s, 1H, -ArH), 
8.47 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 111.3, 115.5, 121.4, 126.2, 
126.3, 127.4, 128.1, 128.2, 128.9, 129.6, 129.7, 130.8, 131.8, 133.1, 134.4, 134.3, 141.5, 
145.8 ppm. 
ST-218: 1H NMR (400 MHz, DMSO-d6): δ 3.86 (s, 3H, -OCH3), 4.06 (s, 3H, -OCH3), 
6.12 (s, 2H, -ArH), 7.05 (d, J =8.0 Hz, 1H, ArH), 7.20 (d, J =7.6 Hz, 1H, ArH), 7.39 (s, 
1H, -ArH), 7.56 (d, J =8.4 Hz, 1H, ArH), 7.95 (s, 1H, -ArH), 8.23 (d, J =10.8 Hz, 1H, 
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ArH), 8.42 (d, J =1.2 Hz, 1H, ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 57.5, 57.6, 
102.2, 105.5, 105.6, 109.0, 110.2, 115.4, 115.5, 118.1, 121.1, 126.3, 126.6, 128.0, 134.9, 
135.0, 138.7, 138.8, 139.3, 148.7, 148.8, 153.6 ppm. 
ST-252: 1H NMR (400 MHz, DMSO-d6): δ 3.71 (s, 3H, -OCH3), 4.31 (d, J =5.6 Hz, 4H, 
-CH2), 7.12 (d, J =8.8 Hz, 1H, ArH), 7.54 (d, J =8 Hz, 1H, ArH), 7.58 (s, 1H, ArH), 
7.70-7.79 (m, 2H, ArH), 7.98 (d, J =12.8 Hz, 2H, ArH), 8.06 (s, 1H, -ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 64.4, 64.9, 107.9, 117.9, 118.0, 118.1, 118.7, 123.8, 123.8, 
123.9, 125.9, 126.0, 127.3, 128.4, 129.5, 134.4, 142.6, 144.4, 149.8, 151.3 ppm. 
ST-253: 1H NMR (400 MHz, DMSO-d6): δ 3.32 (s, 3H, -OCH3), 3.70 (s, 3H, -OCH3), 
3.86 (s, 6H, -OCH3), 4.25 (s, 4H, -ArH), 6.97 (s, 2H, -ArH), 7.09 (d, J =7.6 Hz, 1H, 
ArH), 7.44 (d, J =8.4 Hz, 1H, ArH), 7.58 (s, 1H, -ArH), 7.91 (s, 1H, -ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 56.54, 60.60, 102.36, 103.64, 107.95, 108.03, 109.24, 
118.74, 126.18, 128.29, 130.05, 138.67, 142.56, 148.24, 149.74, 153.67 ppm. 
ST-254: 1H NMR (400 MHz, DMSO-d6): δ 4.31 (d, J =5.6 Hz, 4H, -CH2), 7.03 (d, J 
=7.6 Hz, 1H, ArH), 7.34-7.51 (m, 4H, ArH), 7.56 (s, 1H, ArH), 7.72 (d, J =7.6 Hz, 2H, 
ArH), 7.90 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 64.4, 64.9, 107.9, 
117.9, 118.0, 118.1, 118.7, 123.8, 123.8, 123.9, 125.9, 126.0, 127.3, 129.3, 129.5, 134.4, 
142.6, 142.7, 143.8, 146.2 ppm. 
ST-255: 1H NMR (400 MHz, DMSO-d6): δ 4.30 (d, J =5.6 Hz, 4H, -CH2), 7.03 (d, J 
=8.8 Hz, 1H, ArH), 7.51 (d, J =8 Hz, 1H, ArH), 7.58 (s, 1H, ArH), 7.69-7.767 (m, 2H, 
ArH), 7.98 (d, J =12.8 Hz, 2H, ArH), 8.06 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, 
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DMSO-d6): 64.4, 64.9, 107.9, 117.9, 118.0, 118.1, 118.7, 123.8, 123.8, 123.9, 125.9, 
126.0, 127.3, 129.3, 129.5, 134.4, 142.6, 142.7, 143.8, 146.2 ppm. 
ST-258: 1H NMR (400 MHz, DMSO-d6): δ 4.11 (s, 4H, -ArH), 7.12 (d, J =8.4 Hz, 1H, 
ArH), 7.19 (d, J =9.2 Hz, 1H, ArH), 7.41 (d, J =1.2 Hz, 1H, ArH), 8.01-8.07 (m, 4H, 
ArH), 8.31 (d, J =9.2 Hz, 2H, ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 102.4, 105.9, 
109.1, 114.0, 1177.6, 121.9, 124.4, 127.7, 130.4, 138.8, 138.9, 140.6, 148.0, 149.1, 151.1 
ppm. 
ST-259: 1H NMR (400 MHz, DMSO-d6): δ 7.49 (d, J =8.8 Hz, 2H, ArH), 7.69-7.75 (m, 
2H, ArH), 7.82 (t, J =14.0 Hz, 2H, ArH), 8.01 (t, J =14.0 Hz, 2H, ArH), 8.13 (d, J =8.8 
Hz, 2H, ArH), 8.34 (s, 1H, -ArH), 8.35 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-
d6): 109.2, 118.1, 122.5, 123.0, 125.2, 125.3, 125.7, 126.1, 127.5, 127.6, 128.1, 128.2, 
128.4, 129.0, 129.1, 129.2, 130.1, 130.3, 130.6, 130.8, 131.2, 131.4, 131.4, 132.6, 133.5, 
138.4, 144.2, 149.9 ppm. 
ST-260: 1H NMR (400 MHz, DMSO-d6): δ 3.71 (s, 3H, -OCH3), 3.75 (s, 3H, -OCH3), 
7.07 (d, J =8.4 Hz, 1H, ArH), 7.31 (d, J =8.0 Hz, 1H, ArH), 7.62-7.66 (m, 4H, ArH), 7.95 
(d, J =7.2 Hz, 1H, ArH), 7.95-8.01 (m, 2H, ArH), 8.15 (m, 1H, ArH), 8.21 (s, 1H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 56.07, 56.35, 102.26, 106.24, 109.02, 114.71, 
118.10, 121.53, 124.76, 125.91, 127.06, 127.13, 127.41, 128.05, 129.01, 130.66, 131.47, 
132.08, 133.48, 141.05, 148.81, 148.86 ppm. 
ST-261: 1H NMR (400 MHz, DMSO-d6): δ 3.74 (s, 3H, -OCH3), 3.90 (s, 6H, -OCH3), 
7.16 (s, 2H, -ArH), 7.84 (t, J =14 Hz, 1H, ArH), 7.91 (d, J =8.4 Hz, 1H, ArH), 8.04 (t, J 
=19.6 Hz, 2H, ArH), 8.22 (s, 1H, -ArH), 8.53 (d, J =8.4 Hz, 1H, ArH) ppm. 13C NMR 
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(100 MHz, DMSO-d6): 56.6, 60.6, 104.4, 114.9, 117.8, 123.0, 128.0, 128.1, 128.3, 129.3, 
129.7, 130.8, 137.5, 139.5, 140.7, 147.6, 152.3, 153.6 ppm. 
ST-262: 1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 3H, -OCH3), 7.49 (t, J =14.8 Hz, 2H, 
ArH), 7.54-7.58 (m, 2H, ArH), 7.79 (d, J =8.0 Hz, 2H, ArH), 7.91 (t, J =8.4 Hz, 2H, 
ArH), 8.02 (d, J =8.0 Hz, 2H, ArH), 8.19 (d, J =8.0 Hz, 2H, ArH), 8.27 (s, 1H, -ArH), 
8.31 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.3, 112.4, 114.5, 121.4, 
122.2, 126.8, 127.4, 128.1, 128.2, 128.9, 129.6, 129.7, 130.8, 132.3, 133.0, 135.1, 135.4, 
143.3, 147.3 ppm. 
ST-263: 1H NMR (400 MHz, DMSO-d6): δ 7.47 (t, J =14.4 Hz, 1H, ArH), 7.54 (t, J 
=14.8 Hz, 2H, ArH), 7.60-7.63 (m, 2H, ArH), 7.83 (d, J =7.2 Hz, 2H, ArH), 7.99 (t, J 
=13.6 Hz, 2H, ArH), 8.07 (d, J =8.4 Hz, 2H, ArH), 8.13 (d, J =8.4 Hz, 2H, ArH), 8.21 (s, 
1H, -ArH), 8.43 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 110.9, 118.5, 
125.4, 126.2, 126.3, 127.4, 128.1, 128.2, 128.9, 129.6, 129.7, 130.8, 131.8, 133.0, 134.0, 
134.3, 143.3, 143.4 ppm. 
ST-264: 1H NMR (400 MHz, DMSO-d6): δ 7.61 (t, J =13.6 Hz, 2H, ArH), 7.74-7.82 (m, 
2H, ArH), 7.98 (t, J =14.4 Hz, 2H, ArH), 8.07 (t, J =16.8 Hz, 2H, ArH), 8.13 (d, J =8.8 
Hz, 2H, ArH), 8.38 (s, 1H, -ArH), 8.45 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-
d6): 109.2, 118.1, 122.5, 123.0, 125.2, 125.3, 125.7, 126.1, 127.5, 127.6, 128.1, 128.2, 
128.4, 129.0, 129.1, 129.2, 130.2, 130.3, 130.6, 130.8, 130.9, 131.4, 131.4, 132.9, 134.2, 
135.4, 145.1, 145.2 ppm. 
ST-179: 1H NMR (400 MHz, DMSO-d6): δ 3.85(s, 3H, -OCH3),  6.09 (s, 2H, -ArH), 
7.59 (d, J =14.2 Hz, 2H, ArH), 7.59-7.63 (m, 2H, ArH), 7.81 (d, J =8.0 Hz, 2H, ArH), 
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7.91 (t, J =14.8 Hz, 2H, ArH), 7.98 (d, J =8.0 Hz, 2H, ArH), 8.02 (d, J =8.0 Hz, 2H, 
ArH), 8.12 (s, 1H, -ArH), 8.24 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 
56.52, 109.2, 112.1, 118.4, 121.2, 123.3, 125.4, 126.1, 128.2, 128.9, 129.6, 129.7, 130.8, 
131.8, 133.1, 134.4, 141.5, 142.4 ppm. 
ST-181: 1H NMR (400 MHz, DMSO-d6): δ 3.81 (s, 3H, -OCH3), 6.11 (s, 2H, -CH2), 
6.56 (t, J =4 Hz, 1H, ArH), 6.82 (s, 1H, ArH), 7.11 (d, J =7.6 Hz, 1H, ArH), 7.46 (d, J 
=7.6 Hz, 1H, ArH), 7.59 (d, J =8 Hz, 1H, ArH), 7.96 (s, 1H, -ArH) ppm. 13C NMR (100 
MHz, DMSO-d6): 55.0, 101.0, 102.3, 104.2, 107.7, 108.8, 118.6, 126.4, 128.1, 136.3, 
142.3, 148.2, 148.9, 155.1 ppm. 
ST-216: 1H NMR (400 MHz, DMSO-d6): δ 6.08 (s, 2H, -CH2), 7.47-7.52 (m, 4H, ArH), 
7.60-7.71 (m, 5H, ArH), 8.07 (d, J =8.4 Hz, 2H, ArH), 8.13 (d, J =8.4 Hz, 2H, ArH 
ppm. 13C NMR (100 MHz, DMSO-d6): 108.1, 112.3, 114.3, 114.6, 116.7, 125.4, 126.2, 
126.3, 127.4, 127.8, 128.1, 128.5, 129.6, 129.7, 130.8, 131.8, 133.1, 133.2, 134.3, 141.0, 
142.8 ppm. 
ST-185: 1H NMR (400 MHz, DMSO-d6): δ 3.76 (s, 3H, -OCH3), 3.81 (s, 3H, -OCH3), 
6.19 (s, 2H, -ArH), 7.12 (d, J =8.0 Hz, 1H, ArH), 7.16 (d, J =8.4 Hz, 1H, ArH), 7.30 (s, 
1H, -ArH), 7.39 (s, 1H, -ArH), 7.79 (s, 1H, -ArH) ppm.  13C NMR (100 MHz, DMSO-
d6): 55.6, 56.1, 102.2, 105.5, 106.0, 109.0, 109.8, 118.71, 120.7, 128.5, 129.7, 132. 4, 
141.1, 148.6, 153.4 ppm. 
ST-156: 1H NMR (400 MHz, DMSO-d6): δ 6.11 (s, 2H, -ArH), 7.10 (d, J =8.4 Hz, 1H, 
ArH), 7.15 (d, J =8.8 Hz, 1H, ArH), 7.41 (d, J =4.0 Hz, 1H, ArH), 8.11-8.15 (m, 4H, 
ArH), 8.31 (d, J =8.0 Hz, 2H, ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 101.4, 102.1, 
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105.9, 109.1, 114.0, 1177.6, 121.9, 124.4, 127.7, 130.4, 138.8, 138.9, 140.6, 148.0, 149.1, 
151.1 ppm. 
ST-145: 1H NMR (400 MHz, DMSO-d6): δ 3.69 (s, 3H, -OCH3), 3.86 (s, 9H, -OCH3), 
6.97 (s, 2H, -ArH),    7.07-7.09 (d, J =8.4 Hz, 1H, ArH), 7.38 (d, J =8.4 Hz, 1H, ArH), 
7.51 (S, 1H, ArH), 7.84 (S, 1H, ArH), 9.42 (S, 1H, -OH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 56.08, 56.52, 60.58, 103.52, 107.09, 112.39, 115.61, 118.88, 122.96, 130.37, 
138.45, 143.00, 146.93, 150.50, 153.63 ppm. HRMS (ESI): m/z calcd for C19H19NO5 
[M-H] 342.1341; found 342.1331. 
ST-507: yellow solid; 1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 3H, -OCH3), 3.84(s, 
3H, -OCH3), 3.85(s, 3H, -OCH3),  7.04-7.07 (t, J =15.2 Hz, 2H, ArH), 7.20 (dd, J =2, 8.8 
Hz, 1H, ArH), 7.29 (S, 1H, ArH), 7.35 (dd, J =1.6, 8.4 Hz, 1H, ArH), 7.49 (S, 1H, ArH), 
7.77(S, 1H, ArH), 9.38 (S, 1H, -OH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.93, 
55.96, 56.02, 56.13, 56.16, 56.23, 107.16, 108.79, 112.23, 112.34, 112.39, 115.41, 
115.65, 118.94, 118.97, 119.08, 122.75, 127.20, 127.29, 141.15, 141.37, 146.90, 149.53, 
149.91, 150.22 ppm. 
ST-198: 1H NMR (400 MHz, DMSO-d6): δ 3.64 (s, 3H, -OCH3), 3.74 (s, 3H, -OCH3), 
3.79 (s, 6H, -OCH3), 6.85 (s, 2H, -ArH), 6.91 (d, J =8.8 Hz, 2H, ArH), 6.97 (d, J =16.4 
Hz, 1H, ArH), 7.11 (d, J =16.4 Hz, 1H, ArH), 7.11 (d, J =8.8 Hz, 1H, ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 55.56, 56.29, 60.50, 103.99, 114.64, 126.73, 127.87, 
128.03, 130.20, 133.56, 137.42, 153.48, 159.29 ppm. 
ST-148: 1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.81 (s, 3H, -OCH3), 
3.83 (s, 6H, -OCH3), 6.96 (s, 2H, -ArH), 7.07 (d, J =8.4 Hz, 1H, ArH), 7.89-7.91(m, 3H, 
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ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.88, 56.2, 60.59, 103.58, 107.54, 114.92, 
118.89, 126.72, 130.22, 131.47, 138.56, 142.59, 153.65, 161.48 ppm. 
ST-147: 1H NMR (400 MHz, DMSO-d6): δ 3.71 (s, 3H, -OCH3), 3.80 (s, 6H, -OCH3), 
3.87 (s, 6H, -OCH3), 6.65 (s, 1H, -ArH), 7.01 (s, 2H, -ArH), 7.12 (d, J =2 Hz, 2H, ArH), 
7.96 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.32, 57.05, 61.10, 103.39, 
104.39, 107.97, 111.57, 118.82, 130.18, 136.34, 139.49, 143.28, 154.16, 161.49 ppm. 
ST-124: 1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 6H, -OCH3), 3.81 (s, 3H, -OCH3), 
3.71 (s, 6H, -OCH3), 6.62 (s, 1H, -ArH), 7.05-7.10 (m, 4H, ArH), 7.69 (d, J =8.8 Hz, 2H, 
ArH), 7.84 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.1, 55.4, 55.6, 111.4, 
114.5, 115.9, 118.8, 126.7, 134.2, 135.1, 138.6, 142.9, 147.1, 149.1 ppm. 
ST-126: 1H NMR (400 MHz, DMSO-d6): δ 3.58 (s, 3H, -OCH3), 3.63 (s, 3H, -OCH3), 
3.71 (s, 6H, -OCH3), 7.12 (s, 2H, -ArH), 7.15 (d, J =8.0 Hz, 2H, ArH), 7.21 (d, J =8.8 
Hz, 2H, ArH), 7.36 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.88, 55.2, 
56.9, 101.5, 104.5, 114.9, 118.8, 126.7, 134.2, 135.1, 138.6, 142.9, 154.5, 155.8 ppm. 
ST-177: 1H NMR (400 MHz, DMSO-d6): δ 3.84 (s, 3H, -OCH3), 3.86 (s, 3H, -OCH3), 
6.13 (s, 2H, -ArH), 6.67 (d, J =8.4 Hz, 2H, ArH), 7.00 (d, J =8.0 Hz, 1H, ArH), 7.12- (d, 
J =8.4 Hz, 1H, ArH), 7.25 (s, 1H, -ArH), 7.78 (s, 1H, -ArH), 7.92 (d, J =8.8 Hz, 1H, 
ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.99, 56.31, 98.79, 120.11, 105.75, 
106.09, 108.38, 109.08, 115.85, 118.84, 120.48, 129.02, 129.40, 136.61, 148.34, 148.68, 
159.61, 163.15 ppm. 
ST-178: 1H NMR (400 MHz, DMSO-d6): δ 6.14 (s, 2H, -CH2), 7.07 (d, J =8.4 Hz, 1H, 
ArH), 7.31 (d, J =8.0 Hz, 1H, ArH), 7.62-7.66 (m, 4H, ArH), 7.95 (d, J =7.2 Hz, 1H, 
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ArH), 8.01 (m, 2H, ArH), 8.16 (m, 1H, ArH), 8.61 (s, 1H, ArH) ppm. 13C NMR (100 
MHz, DMSO-d6): 102.26, 106.24, 109.02, 114.71, 118.10, 121.53, 124.76, 125.91, 
127.06, 127.13, 127.41, 128.05, 129.01, 130.66, 131.47, 132.08, 133.48, 140.07, 148.80, 
148.95 ppm. 
ST-180: 1H NMR (400 MHz, DMSO-d6): δ 6.12 (s, 2H, -CH2), 7.03 (d, J =8.0 Hz, 1H, 
ArH), 7.21 (d, J =8.4 Hz, 1H, ArH), 7.43-7.46 (m, 4H, ArH), 7.95 (s, 2H, ArH), 8.05 (d, 
J =7.6 Hz, 1H, ArH), 8.28 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 102.30, 
105.61, 109.02, 109.14, 118.16, 121.23, 123.15, 125.12, 125.66 127.08, 127.89, 131.72, 
1234.80, 137.98, 138.59, 140.67, 148.84, 148.89 ppm. 
ST-160: 1H NMR (400 MHz, DMSO-d6): δ 3.32 (s, 3H, -OCH3), 3.70 (s, 3H, -OCH3), 
3.86 (s, 6H, -OCH3), 6.14 (s, 2H, -ArH), 6.97 (s, 2H, -ArH), 7.09 (d, J =7.6 Hz, 1H, 
ArH), 7.44 (d, J =8.4 Hz, 1H, ArH), 7.58 (s, 1H, -ArH), 7.91 (s, 1H, -ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 56.54, 60.60, 102.36, 103.64, 107.95, 108.03, 109.24, 
118.74, 126.18, 128.29, 130.05, 138.67, 142.56, 148.24, 149.74, 153.67 ppm. 
ST-163: 1H NMR (400 MHz, DMSO-d6): δ 3.83 (s, 3H, -OCH3), 6.09 (s, 2H, -ArH), 
7.01 (d, J =8.4 Hz, 1H, ArH), 7.07 (d, J =8.8 Hz, 2H, ArH), 7.15 (d, J =10.4 Hz, 1H, 
ArH), 7.36 (d, J =1.6 Hz, 1H, ArH),7.83 (s, 1H, -ArH), 7.88 (d, J =8.8 Hz, 1H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 56.54, 60.60, 102.36, 103.64, 107.95, 108.03, 
109.24, 118.74, 126.18, 128.29, 130.05, 138.67, 142.56, 148.24, 149.74, 153.67 ppm. 
ST-173: 1H NMR (400 MHz, DMSO-d6): δ 3.84 (s, 3H, -OCH3), 3.86 (s, 3H, -OCH3), 
6.09 (s, 2H, -ArH), 6.67 (d, J =8.4 Hz, 2H, ArH), 7.00 (d, J =8.0 Hz, 2H, ArH), 7.12- (d, 
J =8.4 Hz, 1H, ArH), 7.25 (s, 1H, -ArH), 7.78 (s, 1H, -ArH), 7.92 (d, J =8.8 Hz, 1H, 
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ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.99, 56.31, 98.79, 120.11, 105.75, 
106.09, 108.38, 109.08, 115.85, 118.84, 120.48, 129.02, 129.40, 136.61, 148.34, 148.68, 
159.61, 163.15 ppm. 
ST-162: 1H NMR (400 MHz, DMSO-d6): δ 3.74 (s, 3H, -OCH3), 3.82 (s, 6H, -OCH3), 
6.11 (s, 2H, -ArH), 7.03 (d, J =7.6 Hz, 1H, ArH), 7.18 (d, J =8.0 Hz, 1H, ArH), 7.31 (s, 
2H, -ArH), 7.39 (s, 1H, -ArH), 7.87 (s, 1H, -ArH) ppm.  13C NMR (100 MHz, DMSO-
d6): 56.26, 56.37, 60.60, 102.22, 105.56, 107.08, 109.00, 109.08, 118.71, 120.87, 128.50, 
129.57, 139.74, 141.61, 148.62, 148.78, 153.24 ppm. 
ST-521: 1H NMR (400 MHz, DMSO-d6): δ 3.95 (s, 3H, -OCH3), 6.13 (d, J =8.4 Hz, 2H, 
ArH), 7.21 (d, J =8.4 Hz, 2H, ArH), 7.27 (S, 1H, ArH), 7.44 (d, J =9.2 Hz, 1H, ArH), 
8.06 (d, J =8.4 Hz, 1H, ArH), 8.26 (S, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 
57.3, 112.3, 112.7, 115.1, 119.2, 119.9, 124.3, 126.3, 127.5, 128.8, 133.8, 139.5, 151.7, 
174.8 ppm. 
ST-149: 1H NMR (400 MHz, DMSO-d6): δ 3.71-3.75 (m, 6H, -OCH3), 3.84 (s, 6H, -
OCH3), 3.87 (s, 6H, -OCH3), 7.00 (s, 2H, -ArH), 7.32 (s, 2H, ArH), 7.94 (s, 1H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 60.5, 60.6, 103.6, 107.2, 109.4, 118.7, 129.4, 
129.8, 138.8, 139.9, 142.8, 153.2, 153.6 ppm. 
ST-152: 1H NMR (400 MHz, DMSO-d6): δ 3.88 (s, 3H, -OCH3), 7.07 (t, J =15.2 Hz, 1H, 
ArH), 7.17 (d, J =8.4 Hz, 1H, ArH), 7.49 (d, J =7.2 Hz, 2H, ArH), 7.65 (s, 1H, ArH), 
7.97 (s, 1H, ArH), 8.08 (s, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.3, 111.4, 
112.5, 117.5, 121.4, 123.2, 123.8, 130.3, 130.8, 131.8, 135.1, 138.0, 143.2, 157.0 ppm. 
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ST-153: 1H NMR (400 MHz, DMSO-d6): δ 3.80 (s, 3H, -OCH3), 6.13 (s, 2H, -ArH), 
7.06 (t, J =18 Hz, 3H, ArH), 7.41 (d, J =9.6 Hz, 1H, ArH), 7.55 (s, 1H, -ArH), 7.65 (d, J 
=8.4 Hz, 2H, ArH), 7.79 (s, 1H, -ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 55.7, 
55.85, 102.2, 107.7, 107.8, 107.9, 109.2, 115.0, 115.2, 118.8, 125.8, 126.7, 127.4, 128.5, 
140.7, 140.8, 148.1, 149.4, 160.2 ppm. 
ST-164: 1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 6H, -OCH3), 6.11 (s, 2H, -ArH), 
6.62 (s, 1H, -ArH), 7.05 (d, J =7.6 Hz, 1H, ArH), 7.10 (s, 2H, -ArH), 7.21 (d, J =7.6 Hz, 
1H, ArH), 7.39 (s, 1H, -ArH), 7.85 (s, 1H, -ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 
55.7, 102.2, 102.7, 105.7, 107.3, 109.0, 110.6, 118.3, 121.1, 128.3, 135.9, 141.4, 148.7, 
148.8, 160.9 ppm. 
ST-165: 1H NMR (400 MHz, DMSO-d6): δ 3.80 (s, 3H, -OCH3), 3.83 (s, 3H, -OCH3), 
6.10 (s, 2H, -ArH), 7.03 (d, J =8 Hz, 1H, ArH), 7.11 (d, J =8.4 Hz, 1H, ArH), 7.18 (d, J 
=10.4 Hz, 1H, ArH), 7.37 (d, J =2 Hz, 1H, ArH), 7.52 (d, J =10 Hz, 1H, ArH), 7.62 (d, J 
=1.6 Hz, 1H, ArH),  7.83 (s, 1H, -ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 55.7, 
55.8, 56.0, 56.1, 102.1, 105.5, 105.5, 107.1, 109.0, 112.1, 119.0, 120.5, 123.7, 126.8, 
128.8, 141.6, 141.7, 148.3, 148.3, 148.9, 151.1 ppm. 
ST-168: 1H NMR (400 MHz, DMSO-d6): δ 6.14 (s, 2H, -ArH), 7.17 (d, J =8.4 Hz, 1H, 
ArH), 7.28 (t, J =16.0 Hz, 2H, ArH), 7.41 (d, J =8.4 Hz, 1H, ArH), 7.51-7.56 (m, 3H, 
ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 101.3, 106.2, 107.8, 107.9, 109.4, 112.7, 
112.9, 117.6, 124.6, 124.8, 126.3, 126.9, 127.3, 130.5, 148.4, 150.6, 151.0, 158.5, 158.6 
ppm. 
96 
 
ST-486: 1H NMR (400 MHz, DMSO-d6): δ 3.74 (s, 3H, -OCH3), 3.90 (s, 6H, -OCH3), 
7.16 (s, 2H, -ArH), 7.84 (t, J =14 Hz, 1H, ArH), 7.91 (d, J =8.4 Hz, 2H, ArH), 8.04 (t, J 
=19.6 Hz, 2H, ArH), 8.22 (s, 1H, -ArH), 8.53 (d, J =8.4 Hz, 1H, ArH) ppm. 13C NMR 
(100 MHz, DMSO-d6): 56.6, 60.6, 104.4, 114.9, 117.8, 123.0, 128.0, 128.1, 128.3, 129.3, 
129.7, 130.8, 137.5, 139.5, 140.7, 147.6, 152.3, 153.6 ppm. 
ST-479: 1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 3H, -OCH3), 3.84 (s, 3H, -OCH3), 
4.31 (d, J =4 Hz, 4H, ArH), 7.01 (d, J =8.0 Hz, 1H, ArH), 7.05 (d, J =8.4 Hz, 1H, ArH), 
7.22 (d, J =8.4 Hz, 1H, ArH), 7.28 (s, 1H, -ArH), 7.44 (d, J =8.4 Hz, 1H, ArH), 7.52 (s, 
1H, -ArH), 7.80 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.0, 56.1, 64.4, 
64.8, 107.9, 108.9, 112.2, 117.7, 117.9, 118.8, 119.1, 123.5, 127.0, 127.6, 140.5, 143.7, 
145.8, 149.5, 150.0 ppm. HRMS (ESI): m/z calcd for C19H18NO4 [M-H] 324.1236; 
found 324.1224. 
ST-161: 1H NMR (400 MHz, DMSO-d6): δ 6.10 (s, 2H, -ArH), 6.13 (s, 2H, -ArH), 7.04 
(d, J =8.4 Hz, 1H, ArH), 7.09 (d, J =8.4 Hz, 1H, ArH), 7.17 (d, J =8.4 Hz, 1H, ArH), 
7.37 (d, J =1.6 Hz, 1H, ArH), 7.42 (d, J =8.0 Hz, 1H, ArH), 7.54 (s, 2H, -ArH), 7.82 (s, 
1H, -ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 102.1, 12.3, 105.5, 105.6, 107.6, 
107.8, 107.9, 109.0, 109.2, 118.7, 120.7, 125.9, 128.3, 128.6, 141.2, 141.3, 148.1, 148.4, 
148.7, 149.5 ppm. 
ST-156: 1H NMR (400 MHz, DMSO-d6): δ 6.17 (s, 2H, -ArH), 7.15 (d, J =8.0 Hz, 1H, 
ArH), 7.55 (d, J =8.4 Hz, 1H, ArH), 7.65 (d, J =1.6 Hz, 1H, ArH), 7.99 (d, J =9.2 Hz, 
1H, ArH), 8.19 (s, 1H, -ArH), 8.34 (d, J =8.8 Hz, 1H, ArH) ppm.  13C NMR (100 MHz, 
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DMSO-d6): 102.6, 105.8, 108.1, 108.2, 109.4, 118.1, 124.7, 127.0, 127.5, 127.7, 140.8, 
146.3, 146.4, 147.4, 148.3, 150.7 ppm. 
ST-175: 1H NMR (400 MHz, DMSO-d6): δ 6.19 (s, 2H, -ArH), 7.23 (s, 1H, -ArH), 7.26 
(s, 1H, -ArH), 7.29 (d, J =7.6 Hz, 1H, ArH), 7.32 (s, 1H, -ArH), 7.51 (d, J =7.6 Hz, 2H, 
ArH), 7.56 (d, J =8.0 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 102.9, 108.7, 
118.2, 121.7, 129.6, 131.5, 138.8, 144.3, 145.9, 153.6 ppm. 
ST-287: 1H NMR (400 MHz, DMSO-d6): δ 3.88 (s, 3H, -OCH3), 3.93 (s, 6H, -OCH3), 
6.81 (s, 2H, -ArH), 7.23 (s, 1H, -ArH), 7.26 (s, 2H, -ArH), 7.32 (s, 1H, -ArH), 7.52 (s, 
1H, -ArH), 7.95 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.2, 56.3, 60.9, 
102.9, 108.7, 110.1, 118.2, 121.7, 129.6, 131.5, 138.8, 144.3, 145.8, 145.9, 153.6 ppm. 
ST-288: 1H NMR (400 MHz, DMSO-d6): δ 3.84 (s, 3H, -OCH3), 6.95 (d, J =8.0 Hz, 2H, 
ArH), 7.21 (s, 1H, -ArH), 7.28 (s, 1H, ArH), 7.50 (s, 1H, -ArH), 7.56 (d, J =9.2 Hz, 2H, 
ArH), 7.91 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.3, 55.4, 108.7, 
109.8, 114.4, 118.3, 121.9, 126.4, 126.8, 129.9, 144.2, 145.3, 145.4, 160.1 ppm. 
ST-166: 1H NMR (400 MHz, DMSO-d6): δ 4.00 (s, 3H, -OCH3), 6.12 (s, 2H, -ArH), 
7.05 (d, J =8.0 Hz, 1H, ArH), 7.20 (d, J =7.6 Hz, 1H, ArH), 7.39 (s, 1H, -ArH), 7.56 (d, J 
=8.4 Hz, 1H, ArH), 7.95 (s, 1H, -ArH), 8.23 (d, J =10.8 Hz, 1H, ArH), 8.42 (d, J =1.2 
Hz, 1H, ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 57.6, 102.2, 105.5, 105.6, 109.0, 
110.2, 115.4, 115.5, 118.1, 121.1, 126.3, 126.6, 128.0, 134.9, 135.0, 138.7, 138.8, 139.3, 
148.7, 148.8, 153.6 ppm. 
ST-172: 1H NMR (400 MHz, DMSO-d6): δ 6.12 (s, 2H, -ArH), 7.06 (d, J =8.0 Hz, 1H, 
ArH), 7.20 (d, J =10.4 Hz, 1H, ArH), 7.39 (d, J =2 Hz, 1H, ArH), 7.56 (t, J =17.2 Hz, 
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1H, ArH), 7.91-7.97 (m, 2H, -ArH), 8.23 (dd, J =8.8 Hz, J =2.4 Hz, 1H, ArH) ppm.  13C 
NMR (100 MHz, DMSO-d6): 102.3, 105.7, 105.8, 108.9, 109.0, 109.1, 111.4, 117.6, 
117.9, 117.9, 121.9, 127.9, 130.5, 130.6, 130.7, 132.6, 134.5, 134.6, 138.7, 148.7, 149.0, 
158.0, 160.5 ppm. 
ST-167: 1H NMR (400 MHz, DMSO-d6): δ 6.13 (s, 2H, -ArH), 7.08 (d, J =8.4 Hz, 1H, 
ArH), 7.28 (d, J =9.2 Hz, 1H, ArH), 7.47 (d, J =1.2 Hz, 1H, ArH), 8.08-8.10 (m, 4H, 
ArH), 8.36 (d, J =9.2 Hz, 2H, ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 102.4, 105.9, 
109.1, 114.0, 1177.6, 121.9, 124.4, 127.7, 130.4, 138.8, 138.9, 140.6, 148.0, 148.8, 149.4 
ppm. 
ST-184: 1H NMR (400 MHz, DMSO-d6): δ 6.17 (s, 2H, -ArH), 7.13 (d, J =8.0 Hz, 1H, 
ArH), 7.29 (t, J =16.4 Hz, 2H, ArH), 7.46 (d, J =6.8 Hz, 1H, ArH), 7.55-7.63 (m, 3H, 
ArH) ppm.  13C NMR (100 MHz, DMSO-d6): 94.0, 102.6, 107.8, 107.9, 109.4, 112.7, 
112.9, 117.6, 126.9, 127.3, 130.5, 148.4, 150.6, 151.0, 158.5, 158.6, 160.9, 161.0 ppm. 
ST-101: 1H NMR (400 MHz, DMSO-d6): δ 3.81 (s, 6H, -OCH3), 6.71 (s, 1H, -ArH), 
7.21 (s, 2H, -ArH), 8.04 (d, J =9.2 Hz, 2H, ArH), 8.25 (s, 1H, -ArH), 8.37 (d, J =8.8 Hz, 
2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.8, 99.5, 99.6, 105.4, 118.5, 124.5, 
125.6, 125.8, 132.4, 136.5, 140.8, 147.1 ppm. 
TMR-01: 1H NMR (400 MHz, DMSO-d6): δ 3.72 (s, 3H, -OCH3), 3.87 (s, 6H, -OCH3), 
7.06 (s, 2H, -ArH), 8.12 (d, J =8.8 Hz, 2H, ArH), 8.17 (s, 1H, -ArH), 8.38 (d, J =8.4 Hz, 
2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.5, 60.6, 104.2, 114.3, 117.6, 124.5, 
130.5, 139.5, 140.25, 140.4, 148.1, 153.7 ppm. 
99 
 
TMR-03: 1H NMR (400 MHz, DMSO-d6): δ 3.72 (s, 3H, -OCH3), 3.87 (s, 6H, -OCH3), 
7.05 (s, 2H, -ArH), 7.83 (t, J =16 Hz, 1H, ArH), 8.19 (s, 1H, -ArH), 8.29 (d, J =8.4 Hz, 
1H, ArH), 8.36 (d, J =8.0 Hz, 1H, ArH), 8.73 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 56.5, 60.6, 104.0, 113.1, 117.7, 124.3, 125.0, 129.0, 131.0, 134.9, 135.7, 
139.3, 140.1, 148.4, 153.7 ppm. 
TMR-04: 1H NMR (400 MHz, DMSO-d6): δ 3.71 (s, 3H, -OCH3), 3.86 (s, 6H, -OCH3), 
4.01 (s, 3H, -OCH3), 7.01 (s, 2H, -ArH), 7.60 (d, J =9.2 Hz, 1H, ArH), 8.07 (s, 1H, -
ArH), 8.29 (d, J =8.8 Hz, 1H, ArH), 8.44 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 55.4, 56.2, 56.3, 60.9, 102.9, 108.7, 110.1, 118.2, 121.7, 124.2, 124.5, 124.8, 
129.6, 131.5, 138.8, 144.3, 145.8, 145.9, 153.6 ppm. 
ST-155: 1H NMR (400 MHz, DMSO-d6): δ 3.86 (s, 6H, -OCH3), 6.14 (s, 2H, -CH2), 
6.56 (t, J =4 Hz, 1H, ArH), 6.85 (d, J =2 Hz, 1H, ArH), 7.11 (d, J =7.6 Hz, 1H, ArH), 
7.46 (d, J =7.6 Hz, 1H, ArH), 7.59 (d, J =8 Hz, 1H, ArH), 7.96 (s, 1H, -ArH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 55.9, 101.0, 102.3, 104.2, 107.7, 108.1, 109.2, 118.6, 
126.4, 128.1, 136.3, 143.3, 148.2, 149.9, 161.3 ppm. 
ST-512: 1H NMR (400 MHz, DMSO-d6): δ 3.58 (s, 3H, -OCH3), 3.61 (s, 3H, -OCH3), 
6.52 (d, J =8.0 Hz, 2H, ArH), 6.87 (d, J =8.4 Hz, 2H, ArH), 6.95 (s, 2H, -ArH), 7.12 (s, 
1H, -ArH), 7.36(s, 1H, -ArH), 9.15 (s, 1H, -OH) ppm. 13C NMR (100 MHz, DMSO-d6): 
57.9, 58.2, 101.5, 104.8, 115.4, 118.8, 125.0, 127.5, 129.8, 139.5, 145.2, 151.1, 151.5 
ppm. 
ST-514: 1H NMR (400 MHz, DMSO-d6): δ 3.73 (s, 3H, -OCH3), 3.82 (s, 6H, -OCH3), 
6.89 (d, J =8.8 Hz, 2H, ArH), 7.29 (s, 2H, -ArH), 7.57 (d, J =8.4 Hz, 2H, ArH), 7.75(s, 
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1H, -ArH), 9.94 (s, 1H, -OH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.3, 60.6, 106.9, 
109.4, 116.3, 118.8, 125.0, 127.5, 129.8, 139.5, 140.1, 153.2, 158.9 ppm. 
ST-516: 1H NMR (400 MHz, DMSO-d6): δ 7.55 (d, J =14.8 Hz, 2H, ArH), 7.61-7.65 (m, 
2H, ArH), 7.85 (d, J =7.2 Hz, 2H, ArH), 7.91 (t, J =8.6 Hz, 1H, ArH), 8.07 (d, J =8.4 Hz, 
2H, ArH), 8.11 (d, J =8.4 Hz, 2H, ArH), 8.21 (s, 1H, -ArH), 9.94 (s, 1H, -OH) ppm. 13C 
NMR (100 MHz, DMSO-d6): 111.3, 115.5, 121.4, 126.2, 126.3, 127.4, 128.1, 128.2, 
128.9, 129.6, 129.7, 130.8, 131.8, 133.1, 134.4, 134.3, 141.5, 145.8 ppm. 
ST-520: 1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 3H, -OCH3), 6.89 (d, J =8.4 Hz, 2H, 
ArH), 6.89 (d, J =8.4 Hz, 2H, ArH), 6.89 (d, J =8.0 Hz, 2H, ArH), 7.29 (s, 2H, -ArH), 
7.57 (d, J =8.0 Hz, 2H, ArH), 9.94 (s, 1H, -OH) ppm. 13C NMR (100 MHz, DMSO-d6): 
55.8, 107.7, 114.8, 116.3, 119.0, 125.3, 127.0, 127.3, 131.1, 139.8, 158.6, 161.0 ppm. 
ST-517: 1H NMR (400 MHz, DMSO-d6): δ 6.12 (s, 2H, -ArH), 6.87 (d, J =8.4 Hz, 2H, 
ArH), 7.07 (d, J =8.4 Hz, 1H, ArH), 7.38 (d, J =10 Hz, 1H, ArH), 7.52-7.54 (m, 3H, 
ArH), 7.71 (s, 1H, -ArH), 9.88 (s, 1H, -OH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.3, 
60.6, 106.9, 109.4, 116.3, 118.8, 125.0, 127.5, 129.8, 139.5, 140.1, 153.2, 158.9 ppm. 
ST-315: 1H NMR (400 MHz, DMSO-d6): δ 3.68 (s, 3H, -OCH3), 3.83 (s, 6H, -OCH3), 
6.97 (s, 2H, -ArH), 7.28-7.43 (m, 3H, ArH), 7.76 (d, J =8 Hz, 2H, ArH), 7.83 (d, J =7.2 
Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.3, 60.5, 104.9, 110.4, 114.5, 
119.5, 124.8, 125.1, 126.5, 127.3, 133.0, 153.5 ppm. 
ST-301: 1H NMR (400 MHz, DMSO-d6): δ 7.28 (d, J =16.4 Hz, 1H, ArH), 7.41 (d, J 
=16.4 Hz, 1H, ArH), 7.46 (d, J =8.4 Hz, 2H, ArH), 7.57-7.64 (m, 4H, ArH), 7.89 (d, J =2 
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Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 127.1, 127.2, 128.5, 128.8, 129.2, 
129.9, 130.2, 131.2, 131.9, 132.9, 135.9, 138.2 ppm. 
ST-321: 1H NMR (400 MHz, DMSO-d6): δ 4.00 (s, 3H, -OCH3), 7.04 (d, J =8.4 Hz, 1H, 
ArH), 7.17 (d, J =16.0 Hz, 1H, ArH), 7.54-7.61 (m, 4H, ArH), 7.71 (d, J =8.4 Hz, 2H, 
ArH), 7.84 (d, J =8.0 Hz, 1H, ArH), 8.04 (d, J =16 Hz, 1H, ArH), 8.22 (d, J =8.4 Hz, 1H, 
ArH), 8.38 (d, J =8.0 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.1, 105.0, 
120.6, 122.3, 124.2, 124.3, 125.2, 125.8, 126.2, 126.7, 127.2, 128.3, 129.0, 131.9, 132.0, 
137.3, 155.3 ppm. 
ST-302: 1H NMR (400 MHz, DMSO-d6): δ 7.52 (d, J =8.4 Hz, 2H, ArH), 7.65 (d, J =8.8 
Hz, 2H, ArH), 7.85 (d, J =2.8 Hz, 2H, ArH), 7.95 (s, 1H, ArH), 8.25 (d, J =5.6 Hz, 1H, 
ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 124.5, 127.6, 128.0, 128.9, 129.0, 130.9, 
131.1, 131.3, 132.0, 137.6, 143.8, 146.9 ppm. 
ST-312: 1H NMR (400 MHz, DMSO-d6): δ 6.03 (s, 2H, -ArH), 6.91 (s, 1H, -ArH), 7.01-
7.10 (m, 2H, ArH), 7.22 (d, J =8 Hz, 1H, ArH), 7.27 (s, 1H, -ArH), 7.47-7.54 (m, 4H, 
ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 101.5, 105.7, 108.8, 120.5, 122.3, 125.7, 
128.5, 129.5, 131.7, 131.9, 137.0, 147.6, 148.3 ppm. 
ST-313: 1H NMR (400 MHz, DMSO-d6): δ 7.44 (d, J =1.6 Hz, 2H, ArH), 7.59-7.65 (m, 
2H, ArH), 7.77 (d, J =8.4 Hz, 2H, ArH), 7.84 (d, J =8.4 Hz, 2H, ArH), 7.91 (d, J =1.6 
Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 110.4, 119.3, 127.4, 127.7, 128.8, 
129.5, 129.9, 130.8, 131.3, 132.0, 133.0, 137.7, 141.6 ppm. 
ST-309: 1H NMR (400 MHz, DMSO-d6): δ 3.66 (s, 3H, -OCH3), 3.83 (s, 6H, -OCH3), 
6.11 (s, 2H, -ArH), 6.83-6.88 (m, 4H, ArH), 7.04 (dd, J =1.2 Hz, J =1.8 Hz, 1H, ArH), 
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7.14 (d, J =16.4 Hz, 1H, ArH), 7.28 (d, J =16.4 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 51.6, 56.3, 60.5, 101.3, 130.2, 107.7, 120.1, 122.2, 122.8, 131.7, 153.5 ppm. 
ST-316: 1H NMR (400 MHz, DMSO-d6): δ 3.67 (s, 3H, -OCH3), 3.83 (s, 6H, -OCH3), 
6.93 (s, 2H, -ArH), 7.21 (s, 2H, -ArH), 7.55 (dd, J =8.8 Hz, J =13.6 Hz, 4H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 56.3, 60.5, 104.4, 120.7, 126.9, 128.6, 129.7, 
132.0, 132.9, 136.9, 137.9, 153.5 ppm. 
ST-323: 1H NMR (400 MHz, DMSO-d6): δ 7.30 (d, J =16.4 Hz, 1H, ArH), 7.52-7.60 (m, 
4H, ArH), 7.75 (d, J =8.4 Hz, 2H, ArH), 7.89 (dd, J =3.6 Hz, J =8.4 Hz, 2H, ArH), 8.96 
(d, J =9.2 Hz, 1H, ArH), 8.14 (d, J =16 Hz, 1H, ArH), 8.43 (d, J =8.0 Hz, 1H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 121.1, 123.6, 124.2, 126.2, 1263, 126.4, 126.7, 
128.5, 128.9, 129.3, 130.5, 131.2, 132.0, 133.8, 134.4, 137.0 ppm. 
ST-314: 1H NMR (400 MHz, DMSO-d6): δ 7.25-7.38 (m, 2H, ArH), 7.53-7.63 (m, 6H, 
ArH), 7.88 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 121.5, 127.1, 127.2, 
128.5, 129.0, 129.9, 130.2, 131.2, 131.9, 132.1, 136.2, 138.2 ppm. 
ST-199: 1H NMR (400 MHz, DMSO-d6): δ 2.32 (s, 3H, -CH3), 3.67 (s, 3H, -OCH3), 
3.83 (s, 6H, -OCH3), 6.93 (s, 2H, -ArH), 7.08 (d, J =7.6 Hz, 1H, ArH), 7.17 (s, 2H, -
ArH), 7.25 (t, J =15.2 Hz, 1H, ArH), 7.37 (d, J =7.6 Hz, 1H, ArH), 7.41 (s, 1H, -ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 21.4, 56.2, 60.5, 104.2, 124.0, 127.2, 128.2, 
128.6, 128.8, 129.0, 133.2, 137.4, 138.1, 153.4 ppm. 
ST-160: 1H NMR (400 MHz, DMSO-d6): δ 3.70 (s, 3H, -OCH3), 3.86 (s, 6H, -OCH3), 
6.14 (s, 2H, -CH2), 6.97 (s, 2H, -ArH), 7.11 (d, J =8 Hz, 1H, ArH), 7.46 (d, J =8 Hz, 1H, 
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ArH), 7.57 (s, 1H, -ArH), 7.91 (s, 1H, -ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 
56.5, 60.6, 102.3, 103.6, 107.9, 109.2, 126.1, 142.5, 148.2, 149.7, 153.6 ppm. 
ST-488: 1H NMR (400 MHz, DMSO-d6): δ 3.68 (s, 3H, -OCH3), 3.84 (s, 6H, -OCH3), 
6.93 (s, 2H, -CH2), 7.78 (s, 1H, -ArH), 7.85 (d, J =4 Hz, 2H, ArH) ppm. 13C NMR (100 
MHz, DMSO-d6): 56.3, 56.5, 60.4, 60.6, 102.9, 104.6, 119.0, 122.7, 122.9, 130.3, 135.4, 
135.6, 138.0, 138.2, 153.6 ppm. 
ST-527: 1H NMR (400 MHz, DMSO-d6): δ 3.81 (s, 3H, -OCH3), 3.85 (s, 3H, -OCH3), 
7.07 (d, J =4 Hz, 1H, ArH), 7.25 (d, J =8.8 Hz, 1H, ArH), 7.34 (d, J =16.2 Hz, 1H, ArH), 
7.82 (d, J =8.0 Hz, 1H, ArH), 7.92 (d, J =4.0 Hz, 1H, ArH), 7.96 (s, 1H, -CH2), 8.11 (d, J 
=4 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.0, 56.1, 108.9, 112.2, 112.5, 
117.9, 119.8, 126.1, 128.8, 131.2, 131.5, 132.0, 132.7, 135.0, 137.9, 149.6, 150.7 ppm. 
ST-526: 1H NMR (400 MHz, DMSO-d6): δ 7.59 (d, J = 8.8 Hz, 1H, ArH), 7.74-7.79 (m, 
3H, ArH), 7.87 (d, J =16.2 Hz, 2H, ArH), 7.97 (s, 1H, -CH2) ppm. 13C NMR (100 MHz, 
DMSO-d6): 108.0, 1169, 117.1, 117.7, 121.5, 125.0, 125.6, 126.4, 126.5, 129.2, 131.7, 
135.1, 135.2, 136.0, 138.7, 156.3 ppm. 
 
2.5 Synthesis of (E)-2,3-diaryl substituted acrylonitriles as anticancer agents. 
Two (E)-2,3-diaryl substituted acrylonitriles (Scheme 2.7) were synthesized to compare 
their anti-cancer activities to the isomeric (Z)-2,3-diaryl substituted acrylonitriles. 
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Scheme 2.7 Synthesis of (E)-substituted diarylacrylonitrile analogs. 
The (E)-substituted diarylacrylonitrile analogs ST-510, and ST-507(A) were obtained by 
refluxing their Z-isomer counterparts ST-145, and ST-507 in methanol under ultraviolet 
light for 24 hrs. The reaction was monitored by GC-MS. Once the reaction was complete, 
it was cooled to room temperature and the precipitate that formed was filtered off to yield 
the desired (E)-substituted diarylacrylonitrile analogs ST-510, and ST-507(A) (Scheme 
2.7). 
ST-510: yellow solid; 1H NMR (400 MHz, DMSO-d6): δ 3.71 (s, 9H, -OCH3), 3.75 (s, 
3H, -OCH3), 6.67 (s, 2H, -ArH), 6.72 (s, 1H, -ArH),    6.76 (d, J =8.4 Hz, 1H, ArH), 6.86 
(d, J =8.4 Hz, 1H, ArH), 7.42 (S, 1H, ArH), 9.15 (S, 1H, -OH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 55.86, 56.07, 56.35, 56.57, 60.53, 60.75, 106.20, 106.38, 110.00, 112.06, 
116.65, 121.06, 123.51, 126.45, 128.59, 138.55, 144.67, 144.94, 146.46, 150.16, 153.92 
ppm. 
ST-507(A): brown solid; 1H NMR (400 MHz, DMSO-d6): δ 3.92 (s, 3H, -OCH3), 3.96(s, 
6H, -OCH3), 7.04 (T, J =13.2 Hz, 2H, ArH), 7.12 (s, 1H, ArH), 7.22 (d, J =2, 8.4Hz, 1H, 
ArH), 7.31 (S, 1H, ArH), 7.35 (d, J =10.4 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 55.95, 56.07, 108.69, 108.74, 109.18, 110.59, 110.61, 111.26, 115.06, 
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115.19, 118.44, 118.75, 122.02, 122.12, 127.47, 127.66, 140.15, 140.24, 145.66, 148.25, 
149.23, 149.76 ppm. 
2.6 Synthesis of (E)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-
trimethoxyphenyl)acrylic acid for evaluation of anticancer activity and for UDP-
glucuronosyltransferase studies. 
(E)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)acrylic acid was 
designed to investigate its ability to act as a substrate for UDP-glucuronosyltransferases 
and to evaluate the anticancer activity of the compound.  
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Scheme 2.8 Synthesis of (E)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-
trimethoxyphenyl)acrylic acid (ST-12(a)). (a) TEA, Ac2O, 140 °C, 40% yield. 
3-Hydroxy-4- methoxybenzaldehyde (9) (1.0 mmol), 2-(3,4,5-trimethoxyphenyl)-acetic 
acid (10) (2.0 mmol) and triethylamine (3.2 mmol) were added to 5 mL of acetic 
anhydride. The resulting reaction mixture was refluxed at 140 °C for 4 h, with periodic 
monitoring by TLC. When the reaction was complete, 10 mL of ice-water was added and 
the mixture extracted with 10 ml of ethyl acetate. The organic phase was concentrated on 
a rotary evaporator and the desired product purified by silica gel flash column 
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chromatography using methanol/DCM as mobile phase to afford ST-12(a) in 35% yield 
(Scheme 2.8). 
ST-12(a): 1H NMR (CDCl3-d6, ppm): δ 3.43 (d, 12H,−OCH3, J = 15.2 Hz), 6.69 (d, 2H, 
−ArH, J = 2.8 Hz), 6.54 (s, 1H, −ArH), 6.61 (s, 1H, −ArH), 6.80 (s, 1H, −ArH), 8.93 (s, 
1H, −ArH), 12.41 (s, 1H, −COOH) ppm. 13C NMR (CDCl3,): δ 55.9, 56.4, 60.6, 107.2, 
110.0, 112.0, 118.0, 123.3, 127.4, 131.0, 132.5, 137.4, 139.5, 146.2, 149.3, 153.5, 169.0 
ppm. 
 
2.7 Synthesis of (Z)-5-(2-(2H-tetrazol-5-yl)-2-(3,4,5-trimethoxyphenyl)vinyl)-2-
methoxyphenol (ST-145(a)) as second generation trans-stilbenes 
Cushman and co-workers designed and synthesized a series of novel imidazole-
containing resveratrol analogues and evaluated their inhibitory activities as aromatase and 
quinone reductase inhibitors. Among the synthesized compound XC (Figure 2.7) 
displayed potent aromatase inhibitory activity (IC50 = 36 nM) and showed promising 
anticancer activity against various human tumor cell lines (Sun, Hoshino et al. 2010). We 
planned to introduce a tetrazole ring resembling the imidazole pharmacophore present on 
XC as a structural modification of our lead compound (ST-145) to improve the 
compounds water solubility and anti-cancer activity. The pharmacological assay data for 
ST-145(a) is discussed in Chapter 3. 
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Figure 2.7 Structures of the potent aromatase inhibitor XC, ST-145 and ST-145(a). 
(Z)-5-(2-(2H-tetrazol-5-yl)-2-(3,4,5-trimethoxyphenyl)vinyl)-2-methoxyphenol (ST-
145(a)) was synthesized as a second generation analogue and a structural analogue of the 
lead molecule (Z)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-
trimethoxyphenyl)acrylonitrile (ST-145). Initially we tried to synthesize ST-145(a) by 
reacting (Z)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)acrylonitrile 
with NH4Cl/NaN3 in anhydrous DMF condition, but only traces of the final tetrazole 
product were formed. Subsequently, we used tributyltin chloride/NaN3 in DMF to afford 
(Z)-5-(2-(2H-tetrazol-5-yl)-2-(3,4,5-trimethoxyphenyl)vinyl)-2-methoxyphenol (ST-
145(a)) in 58 % yield. 
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                                               Scheme 2.9 Synthesis of ST-145(a). 
(a) A mixture of (Z)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-
trimethoxyphenyl)acrylonitrile (100mg; 1mmol), sodium azide (50mg; 5mmol) and 
ammonium chloride (42mg; 5mmol) was refluxed in 4ml of anhydrous DMF for 11 hrs. 
After the reaction was complete, 12ml of water was added and the resulting mixture was 
stirred for 10 min. The resulting aqueous solution was washed with five volumes of ethyl 
acetate three times, and the organic layers were combined and concentrated on a rotary 
evaporator.  The residue was purified by DCM/methanol flash chromatography to yield 
(Z)-5-(2-(2H-tetrazol-5-yl)-2-(3,4,5-trimethoxyphenyl)vinyl)-2-methoxyphenol as a pale 
yellow solid in 5% yield. NOE experiments were carried out to confirm the structure of 
the Z-isomer product (Figures 8.7, 8.8 and 8.9).  
(b) Tributyltin chloride (9.76 g, 0.03 mole) and sodium azide (1.95 g, 0.03) were stirred 
for 30 min at 15-30° C. N,N-dimethylformamide (1.46 g, 0.02 mole) was added and the 
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mixture stirred for 30 min. Thereafter, (Z)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-
trimethoxyphenyl)acrylo nitrile (3.21 g; 0.01 mol) was added followed by o-xylene (5 
ml). The reaction mass was heated to 130-135° C and stirred for until completion of the 
reaction (TLC monitoring). The reaction mixture was then cooled to 20° C, and o-xylene 
(10 ml) and methylene chloride (10 ml) were added followed by water (10 ml). 
Hydrochloric acid (2.0 g, 35% w/w) was then slowly added at 20-25° C over 30 min and 
the slurry obtained was stirred for 60 min. The resulting solid was filtered off, washed 
with methylene chloride (5 ml) and dried to afford the desired tetrazole product as a pale 
yellow powder (58% yield). 
ST-145 (a): 1H NMR (400 MHz, DMSO-d6): δ 3.89 (s, 3H, -OCH3), 3.93 (s, 6H, -
OCH3), 3.97 (s, 3H, -OCH3),   6.85 (s, 2H, ArH), 6.92-6.94 (d, J =8.4 Hz, 1H, ArH), 
7.34 (s, 1H, ArH),  7.48-7.50(d, J =10.8 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6): 56.01, 56.28, 60.99, 103.10, 103.18, 109.26, 110.62, 115.08, 118.36, 122.34, 
127.20, 130.49, 138.76, 141.48, 145.61, 148.44, 153.52 ppm. 
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Chapter 3 
Anticancer activities of synthesized resveratrol analogs 
3.1 NCI-60 Human Tumor Cell Line Screen 
The biological evaluation of potential anticancer agents at the NCI is a two-stage process, 
starting with the screening of the submitted compounds against a panel of 60 human 
tumor cell lines at a single dose of 10 µM. The results from the single dose is reported as 
a mean graph and is analyzed by the algorithm software, COMPARE. The software is 
used for comparing the anticancer activity of various molecules at a same time. Using 
this software, compounds which showed promising growth inhibitory activity at 10 µM 
are then evaluated against the 60 cell panel at five concentration levels, viz. 10-4 M, 10-5 
M, 10-6 M, 10-7 M and 10-8 M. 
3.2 Methodology used for the in vitro anticancer screen at the NCI 
RPMI 1640 medium with 5% fetal bovine serum and 2 mM L-glutamine is used for 
growing the NCI-60 human tumor cells. Initially the tumor cells are inoculated into 96-
well microtiter plates in 100 microliters at plating densities starting from 5,000 to 40,000 
cells/well. The range is dependent on the doubling time of individual tumor cell lines. 
The plates are then incubated at 37° C for 24 hours prior to addition of the submitted 
compounds (Shoemaker 2006). 
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After 24 hrs, two microtiter plates of each tumor cell line are fixed in situ with TCA. The 
optical density reading at this point represent the cell population for each tumor cell line 
at the time of compound addition (ODtzero). The experimental compounds are dissolved 
in DMSO at 400-fold concentration to the desired final maximum test concentration, and 
frozen. Then, an aliquot part of the frozen concentrate is thawed and diluted to twice the 
chosen maximum test concentration with medium containing 50 µg/ml gentamicin. Four 
more 10-fold serial dilutions are prepared to afford a total of five drug concentrations. A 
control sample with just DMSO is also prepared. Aliquots of 100 microliters of these 
different experimental drug dilutions controls are added to the appropriate microtiter 
wells containing 100 µl of medium, resulting in the required final drug concentrations, 
viz. 10-4 M, 10-5 M, 10-6 M, 10-7 M and 10-8 M and 0 M (control). 
Once the compounds are added, the microtiter plates are incubated for 48 hrs at 37°C and 
100 % relative humidity. Cold TCA is used to terminate the assay for adherent cells. 
Cells are fixed by the addition of 50 µl of cold 50 % (w/v) TCA and further incubated for 
1 hr at 4°C. The supernatant is thrown away, and the microtiter plates are splashed five 
times with water and air dried. Sulforhodamine B (SRB) solution (100 microliters) at 0.4 
% (w/v) in 1 % CH3COOH is added to each well, and plates are incubated for another 10 
minutes at room temperature. After SRB staining, free SRB is removed by washing five 
times with 1 % acetic acid. Bound SRB stain is successively dissolved with 10 mM 
trizma base, and the optical density is measured at a wavelength of 515 nm. The growth 
inhibitory or cytotoxicity effect of the test compounds in the above cellular assay is 
measured by determining percentage cell growth (PG) inhibition. Optical density (OD) 
measurements of SRB-derived color just before exposing the cells to the test compound 
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(ODtzero) and after 48hrs exposure to the test compound (ODtest) or the control vehicle 
(ODctrl) are recorded. 
Growth percentage is calculated utilizing one of the two formulas below (Madadi, 
Penthala et al. 2014).  
A negative growth percentage implies cytotoxicity. 
If (OD test - ODtzero)≥0, then 
PG = 100-(ODtest -ODtzero)/ (ODctrl- ODtzero)    
and percentage growth is shown as positive. 
 
If (ODtest - ODtzero) < 0, then 
PG = 100 - (ODtest -ODtzero)/ODtzero and 
percentage growth is shown as negative, which implies cell death. 
 
Growth inhibitory or cytotoxicity effects of the test compounds are represented with three 
dose response parameters. They are:  
1. GI50: 50% growth inhibition, indicating concentration of drug resulting in a 50% 
reduction in net protein increase compared with control cells. 
2. TGI: 100% growth inhibition, indicating concentration of drug resulting in a 100% 
reduction in net protein increase compared with control cells. 
3. LC50: lethal concentration, indicating concentration of drug lethal to 50% of cells. 
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3.3 Anticancer activity of simple stilbenes as resveratrol analogues  
A total of 74 stilbenes analogues were synthesized (Table 2.1) and submitted to the NCI 
for screening against the panel of 60 human tumor cell lines, 22 analogs were selected for 
single dose screening at 10µM concentration. The single dose results with 10µM 
concentration are presented in the appendix section (Table 8.1- Table 8.8). From the 22 
compounds selected for single dose screening, one compound (ST-198) showed 
promising anticancer activity and was selected for full five dose study. Of interest, 
Gosslau et al. also reported that ST-198 potently inhibits the proliferation of cancer cells, 
with no inhibitory effect on normal cells (Gosslau, Pabbaraja et al. 2008). These results 
imply that for the stilbene to be active in the anticancer screens the trimethoxy 
substitution pattern on ring A and the p-methoxy group on ring B are essential structural 
elements. The GI50 and TGI values of compound ST-198 against the panel of 60 human 
cancer cell lines are presented in Table 3.1. Interestingly, the introduction a cyano group 
on the stilbene double bond next to ring A (ST-148) dramatically improved the mean 
GI50 value against the panel of NCI 60 tumor cells from μM range to nM range and the 
data is presented in Table 3.4. 
 
H3CO
H3CO
H3CO
OCH3
ST-198
H3CO
H3CO
H3CO
OCH3
ST-148
CN
 
                                 
Figure 3.1 Structures of ST-198 and ST-148. 
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Table 3.1 Growth inhibition (GI50/µM) and Total Growth Inhibition (TGI/µM) data for 
compound ST-198 against human cancer cells. 
 
Table 3.1 (continued) 
Panel/cell line ST-198 
GI50 
( µM ) 
TGI 
(µM) 
Leukemia 
CCRF-CEM 
2.89 >100 
HL-60(TB) 3.14 39.1 
K-562 3.22 >100 
MOLT-4 6.42 >100 
RPMI-8226 3.93 >100 
SR 3.04 >100 
Non-Small  Cell  Lung  Cancer  
A549/ATCC 
3.70 >100 
HOP-62 3.14 25.3 
HOP-92 7.23 >100 
NCI-H23 4.44 >100 
NCI-H522 3.37 >100 
Colon Cancer  
COLO 205 
2.07 5.01 
HCC-2998 3.59 >100 
HCT-116 3.23 >100 
HCT-15 2.82 >100 
HT29 2.32 6.79 
KM12 3.63 >100 
SW-620 3.42 >100 
CNS Cancer 
SF-268 
7.59 >100 
SNB-75 1.88 5.98 
U251 3.07 16.8 
Melanoma 
LOX IMVI 
4.89 >100 
M14 2.81 >100 
MDA-MB-435 1.04 4.49 
SK-MEL-2 3.95 22.7 
SK-MEL-28 3.86 >100 
SK-MEL-5 2.50 12.3 
UACC-62 2.37 >100 
Ovarian Cancer  
IGROV1 
5.29 >100 
OVCAR-3 3.45 14.4 
OVCAR-4 4.00 >100 
NCI/ADR-RES 3.01 31.9 
SK-OV-3 3.34 59.7 
Renal Cancer 5.42 64.8 
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Table 3.1 (continued) 
786-0 
A498 0.74 4.56 
ACHN 4.51 >100 
CAKI-1 3.00 >100 
UO-31 3.69 >100 
Prostate Cancer  
PC-3 
3.22 >100 
DU-145 4.23 >100 
Breast Cancer 
 MCF7 
1.66 >100 
MDA-MB-231/ATCC 3.74 35.6 
HS 578T 3.09 >100 
 
 
3.4 Anticancer evaluation of (E)-3,5,4’-trimethoxy resveratrol analogues with 
substitutions at the C2 position on the stilbene. 
 
Initially, analogs RES-09, RES-10, RES-14, RES-27, RES-13, RES-16, RES-23 and 
RES-18 were evaluated for their anti-proliferative activity against MCF-7 and MDA-231 
breast cancer cell lines, and A549 and H460 lung cancer cell lines in the laboratory of Dr. 
Chendil Damadaran at the University of Kentucky, College of Medicine. 
 MCF-7, MDA-231, A-549 and H-460 cancer cells lines were purchased from the 
American Type Culture Collection (ATCC) (Manassas, VA) and were utilized to test the 
antitumor activity of the above C2-substituted resveratrol analogs. Breast cancer cell 
lines, MCF-7 and MDA-231 were grown in DMEM medium supplemented with 10% 
fetal bovine serum (FBS) and 1% L-glutamine, whereas lung cancer cell lines A549 and 
H460 were maintained and propagated in RPMI 1640 medium containing 2 µM L-
glutamine, 4.5 g/L glucose, 10 µM HEPES, 1.0 µM sodium pyruvate and 10% FBS. All 
cell cultures were maintained at 37oC in a 5% CO2/95% air-humidified atmosphere. Anti-
cancer activity of the resveratrol derived analogs RES-09, RES-10, RES-14, RES-27, 
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RES-13, RES-16, RES-23 and RES-18 were assessed in cell viability assays 
(trypan blue dye exclusion) on both breast (MCF-7 and MDA-231) and lung (A-549 and 
H-460) cancer cells at 24 hours post-treatment at 5 concentrations of drug (1, 5, 10, 20 
and 40 µM) and with vehicle (DMSO) alone. All assays were performed in triplicate. 
Results were expressed as percentage growth inhibition compared to control values. IC50 
values for growth inhibition were derived from a nonlinear regression model based on 
sigmoidal dose-response curves and computed using GraphPad Prism 5 (Graphpad) 
(Koduru, Sowmyalakshmi et al. 2009). 
Table 3.2.  Tryphan blue assay results; IC50 values (µM) for resveratrol analogs (RES-
09, RES-10, RES-14, RES-27, RES-13, RES-16, RES-23 and RES-18) against lung 
and breast cancer cell lines  
Entry 
Lung cancer cell lines Breast cancer cell lines 
A-549 H-460 MCF-7 MDA-231 
RES-09 10.6 13.3 11.8 5.57 
RES-10 29.2 25.2 >40 7.59 
RES-14 33.4 37.0 7.93 4.24 
RES-27 6.19 1.20 14.8 0.99 
RES-13 3.05 7.40 2.40 10.3 
RES-16 7.52 19.3 3.96 10.1 
RES-23 9.20 28.0 1.99 4.09 
RES-18 7.34 24.0 1.28 12.3 
 
 
We initially evaluated the abilities of the resveratrol analogues to inhibit the growth of 
the two human lung cancer cell lines A-549 and H-460 (Table 3.2). All eight compounds 
exhibited IC50 values < 37 µM in both cancer cell lines, and generally showed less 
growth inhibition against A549 lung cancer cells than H460 lung cancer cells. The 
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analogs were also tested for their anti-proliferative activity against estrogen positive 
MCF-7 and estrogen negative MDA-231 breast cancer cell lines. All the compounds 
showed growth inhibition against MCF-7 cell lines with IC50 values ranging from 0.99 
µM to >40 µM. The pseudothiohydantoin analog (RES-16, IC50 = 2.61 µM) and the 
thiohydantoin analog (RES-13, IC50 = 3.05 µM) were identified as the most potent 
cytotoxic agents against A-549 lung cancer cells, whereas the creatinine analog (RES-27, 
IC50 = 1.2 µM) and thiohydantoin analog (RES-13, IC50 = 7.4 µM) were identified as the 
most potent cytotoxic agents against H460 lung cancer cells. The isobarbiturate analog 
(RES-17, IC50 = 1.28 µM) and the isorhodanine analog (RES-18, IC50 = 1.99 µM) were 
identified as potent cytotoxic agents against MCF-7 cells. The thiohydantoin analog 
(RES-13, IC50 = 2.4 µM) and the pseudothiohydantoin analog (RES-16, IC50 = 3.86 µM) 
also exhibited promising cytotoxicity against MCF-7 cells. The creatinine analog (RES-
27, IC50 = 0.99 µM) and the isorhodanine analog (RES-18, IC50 = 4.09 µM) were 
identified as the most potent cytotoxic agents against MDA-231 cells.  
From the library of resveratrol analogs synthesized, the following compounds: (Z)-2-
amino-5-(2, 4-dimethoxy-6-(4-methoxystyryl)benzylidene) 1-methyl-1H-imidazol-
4(5H)-one (RES-27), (Z)-2-amino-5-(2,4-dimethoxy-6-(4-methoxystyryl) 
benzylidene)thiazol-4(5H)-one (RES-16), (Z)-6-(2,4-dimethoxy-6-(4-
methoxystyryl)benzylidene) dihydropyrimidine-2,4,5(3H)-trione (RES-17) and (Z)-5-
(2,4-dimethoxy-6-(4-methoxystyryl) benzylidene)-4-thioxothiazolidin-2-one (RES-18) 
were identified as potent anti-proliferative agents against both lung and breast cancer cell 
lines.  
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Encouraged by the above results, a total of 31 resveratrol analogues with substitutions at 
the C2 position of the stilbene skeleton were submitted to NCI for evaluation in their 
cytotoxicity screening assays against 60 human tumor cell lines. The analogues RES-11, 
RES-17, RES-59, ST-100 and ST-127showed good activity in the 10 µM single dose 
screen, and were selected for five dose response studies for their in vitro cytotoxic effects 
on growth parameters against the 60 tumor cell line panel. Dose response curves were 
created by plotting cytotoxic effect against the log10 of the concentration for each cell 
line. The compound’s cytotoxic effects were determined as their GI50, TGI and LC50 
values, which are presented in Table 3.3. 
 Among the compounds selected for five dose testing, acrylonitrile analogs ST-
100 and ST-127 were found to be very effective against five particular human cancer cell 
lines; i.e. SR, NCI-H522, SF-539, MDA-MB-435 and RXF 393, with GI50 values that 
were less than 300 nM. Lung cancer cell line NCI-H522 appeared to be the most sensitive 
to the growth inhibition effects of ST-100 and ST-127, exhibiting GI50 values of 240 nM 
and 250 nM, respectively. Compounds ST-100 and ST-127 also exhibited impressive 
growth inhibition against melanoma cancer cell line MDA-MB-435 with GI50 values of 
240 nM and 280 nM, respectively. Importantly, compound ST-100 showed promising 
growth inhibitory activity affording GI50 values < 1 µM for more than 50% of the human 
tumor cell lines in the panel. Compound ST-127 was also effective against CNS cancer 
cell lines SF-295 (GI50 = 360 nM) and SF-539 (GI50 = 270 nM), renal cancer cell lines 
786-0 (GI50 = 380 nM), CAKI-1 (GI50 = 500 nM), RXF 393 (GI50 = 310 nM), and breast 
cancer cell line MCF-7 (GI50 = 390 nM). Compound ST-127 was also found to have an 
effective GI50 value of 280 nM against leukemia cancer cell line SR. 
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Table 3.3: Growth inhibition (GI50/µM) and cytotoxicity (LC50/µM) data for compounds 
RES-11, RES-17, RES-59, ST-100 and ST-127 against human cancer cells. 
Table 3.3 (continued) 
Panel/cell line 
RES-11 RES-17 RES-59 ST-100 ST-127 
GI50 
(µM) 
LC50 
(µM) 
GI50 
(µM) 
LC50 
(µM) 
GI50 
(µM) 
LC50 
(µM) 
GI50 
(µM) 
LC50 
(µM) 
GI50 
(µM) 
LC50 
(µM) 
Leukemia 
CCRF-CEM 3.76 >100 2.86 >100 3.75 >100 0.75 >100 2.24 >100 
HL-60(TB) 334 >100 2.13 >100 3.41 >100 1.66 >100 0.58 >100 
K-562 0.58 >100 2.58 NA NA NA 0.43 >100 0.43 >100 
MOLT-4 5.71 >100 2.06 >100 5.52 >100 4.38 >100 3.30 >100 
RPMI-8226 5.47 >100 2.77 >100 3.88 >100 1.16 >100 2.85 >100 
SR 0.52 >100 3.95 >100 1.51 >100 0.91 >100 0.28 >100 
Lung  Cancer 
A549/ATCC 5.06 >100 1.92 8.11 7.25 >100 0.91 >100 3.56 >100 
HOP-62 4.35 >100 1.99 8.96 5.63 >100 0.97 >100 2.79 >100 
NCI-H226 3.67 >100 5.37 52.3 8.54 >100 7.58 >100 17.3 >100 
NCI-H322M 73.8 >100 1.97 >100 27.2 >100 4.66 >100 7.12 >100 
NCI-H460 3.62 >100 2.23 32.6 3.85 >100 1.84 >100 3.47 >100 
NCI-H522 4.40 >100 2.14 31.1 2.29 >100 0.24 >100 0.25 55.3 
Colon Cancer 
COLO 205 
5.49 >100 1.93 6.17 6.70 >100 1.24 >100 2.28 >100 
HCC-2998 4.76 >100 1.53 6.05 8.65 >100 2.49 >100 5.47 >100 
HCT-116 3.80 >100 1.75 7.25 3.94 >100 0.49 >100 1.29 >100 
HCT-15 3.93 >100 2.14 >100 3.71 >100 0.65 >100 0.76 >100 
HT29 2.89 >100 2.05 8.41 3.59 >100 0.69 >100 0.48 >100 
KM12 2.13 >100 1.68 5.91 3.87 >100 0.78 >100 0.64 >100 
SW-620 3.00 >100 1.59 5.78 4.61 >100 0.50 >100 0.71 >100 
CNS Cancer 
SF-268 6.71 >100 1.67 6.06 7.20 >100 4.71 >100 4.18 >100 
SF-295 3.79 >100 1.95 >100 2.37 87.6 0.36 >100 2.51 >100 
SF-539 3.73 >100 2.06 11.2 3.21 90.0 0.27 >100 1.55 >100 
SNB-19 6.63 >100 12.4 69.3 6.13 >100 >100 >100 8.77 >100 
SNB-75 2.05 72.7 10.7 51.8 3.47 >100 0.47 >100 2.28 >100 
U251 3.26 >100 2.18 44.9 5.22 >100 0.64 >100 2.77 >100 
Melanoma 
M14 
2.31 >100 2.16 >100 4.21 >100 1.38 >100 1.14 >100 
MDA-MB-435 0.36 >100 3.61 >100 1.33 66.5 0.24 >100 0.28 >100 
SK-MEL-28 3.06 >100 5.38 63.9 8.67 >100 0.75 >100 4.22 >100 
SK-MEL-5 2.56 >100 5.97 43.2 3.28 >100 2.28 >100 2.44 >100 
UACC-62 4.02 >100 2.89 35.6 2.80 >100 0.70 >100 NA >100 
Ovarian Cancer  
IGROV1 11.8 >100 2.77 61.3 13.8 >100 2.35 >100 5.28 >100 
OVCAR-3 2.79 >100 1.93 9.87 3.73 79.0 0.63 >100 1.38 >100 
OVCAR-4 10.7 >100 10.2 77.5 20.7 >100 0.50 >100 3.59 >100 
OVCAR-5 9.15 >100 2.10 22.2 8.64 >100 6.71 >100 8.37 >100 
OVCAR-8 4.58 >100 3.16 >100 17.2 >100 3.75 >100 3.37 >100 
NCI/ADR-RES 1.02 >100 2.40 >100 3.30 >100 0.65 >100 0.71 >100 
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Table 3.3 (continued) 
Renal Cancer 
786-0 
3.53 >100 12.7 57.8 4.06 >100 1.72 >100 3.25 >100 
A498 2.44 >100 5.08 56.0 1.66 >100 0.38 >100 1.37 >100 
ACHN 6.79 >100 2.21 18.6 6.96 >100 0.83 >100 4.25 >100 
CAKI-1 3.12 >100 4.76 94.6 3.72 >100 0.50 >100 2.20 >100 
RXF 393 2.16 >100 3.41 38.5 3.04 >100 0.31 >100 2.00 >100 
SN12C 6.33 >100 2.55 38.9 4.72 >100 3.95 >100 4.68 >100 
TK-10 13.6 >100 10.2 52.7 7.03 >100 >100 >100 1.95 >100 
Breast Cancer 
 MCF7 
1.96 >100 1.44 7.89 3.30 >100 0.39 >100 0.72 >100 
MDA-MB-
231/ATCC 10.3 >100 2.76 65.7 2.19 >100 2.78 >100 2.83 >100 
HS 578T 3.64 >100 2.55 >100 4.95 >100 0.68 >100 1.34 >100 
BT-549 2.09 >100 3.91 49.8 6.36 >100 4.58 >100 1.31 >100 
T-47D 7.28 >100 1.66 7.26 5.23 >100 0.80 >100 3.03 >100 
MDA-MB-468 2.68 >100 1.66 7.10 1.93 >100 1.72 >100 1.70 >100 
 
In conclusion, a library of novel resveratrol analogs with different substitutions on the C2 
position of the stilbene skeleton was synthesized and evaluated for their growth inhibition 
properties against a panel of 60 human cancer cell lines. The acrylonitrile analog ST-100 
was found to be the lead compound with GI50 values < 1 µM for more than 50% of the 
cells in the panel. The novel acrylonitrile resveratrol analog ST-100 represents a 
promising lead compound that may have clinical potential in treating a variety of solid 
and hematological cancers. 
3.5 Anticancer activity of (E/Z)-2,3-diaryl substituted acrylonitriles as anticancer 
agents. 
A total of 74 (E/Z)-2,3-diaryl substituted acrylonitriles were synthesized (Table DD) and 
submitted to the NCI for screening against the 60 human tumor cell panel, and 41 analogs 
were selected for single dose screening at 10µM. The single dose results are presented in 
the appendix (Table 8.9- Table 8.14). From the 41 compounds selected for single dose 
screening 18 compounds showed promising anticancer activity and were selected for full 
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five dose studies. The GI50 and TGI values of these 18 compounds against the panel of 
60 human cancer cell lines are presented in Tables 3.4 to 3.8  
Table 3.4: Growth Inhibition (GI50/µM) and Total Growth Inhibition (TGI/µM) data for 
compounds ST-198, ST-148, ST-147 and ST-124 against human cancer cells. 
Table 3.4 (continued) 
Panel/cell line ST-198 ST-148 ST-147 ST-124 
GI50 
( µM ) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
GI50 
(µM) 
TGI 
(µM) 
GI50 
( nM ) 
TGI 
(µM) 
Leukemia 
CCRF-CEM 
2.89 >100 36.7 58.7 51.2 >100 
324 11.1 
HL-60(TB) 3.14 39.1 22.0 6.32 68.6 >100 289 0.89 
K-562 3.22 >100 <10 >100 3.14 >100 317 >100 
MOLT-4 6.42 >100 36.2 33.5 28.2 >100 438 >100 
RPMI-8226 3.93 >100 3.00 17.4 6.64 >100 339 10.5 
SR 3.04 >100 <10 >100 4.14 >100 294 18.5 
Non-Small  Cell  Lung  
Cancer  
A549/ATCC 
3.70 >100 15.1 >100 6.35 >100 
388 >100 
HOP-62 3.14 25.3 30.1 >100 7.63 >100 516 >100 
HOP-92 7.23 >100 23.9 15.7 3.57 69.5 NA NA 
NCI-H23 4.44 >100 57.8 >100 43.0 >100 537 >100 
NCI-H522 3.37 >100 <10 0.02 20.5 >100 94.3 0.61 
Colon Cancer  
COLO 205 
2.07 5.01 13.1 0.03 5.16 42.7 270 0.63 
HCC-2998 3.59 >100 43.5 >100 97.0 >100 349 16.7 
HCT-116 3.23 >100 <10 >100 6.05 >100 333 >100 
HCT-15 2.82 >100 <10 >100 4.47 >100 336 >100 
HT29 2.32 6.79 <10 16.2 4.24 >100 289 1.03 
KM12 3.63 >100 <10 13.6 4.97 >100 388 12.8 
SW-620 3.42 >100 10.6 >100 5.17 >100 424 >100 
CNS Cancer 
SF-268 
7.59 >100 40.7 >100 25.3 >100 
848 >100 
SF-295 2.18 8.20 <10 30.3 5.33 >100 222 0.95 
SF-539 2.18 5.70 <10 0.03 6.60 57.4 223 0.51 
SNB-19 4.85 >100 59.7 >100 5.46 >100 988 >100 
SNB-75 1.88 5.98 <10 >100 2.67 >100 295 59.2 
U251 3.07 16.8 29.3 60.2 7.82 >100 343 30.6 
Melanoma 
LOX IMVI 
4.89 >100 14.1 >100 5.31 >100 580 >100 
M14 2.81 >100 19.3 >100 4.45 94.1 288 >100 
MDA-MB-435 1.04 4.49 <10 NA 1.63 7.58 173 0.48 
SK-MEL-2 3.95 22.7 85.1 >100 5.44 79.7 887 >100 
SK-MEL-28 3.86 >100 NA >100 14.0 >100 498 >100 
SK-MEL-5 2.50 12.3 12.7 0.06 4.70 68.1 278 1.36 
UACC-62 2.37 >100 <10 >100 2.42 61.7 404 >100 
Ovarian Cancer  
IGROV1 5.29 >100 26.3 >100 14.6 >100 
532 >100 
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Table 3.4 (continued) 
OVCAR-3 3.45 14.4 <10 NA 6.69 >100 300 0.73 
OVCAR-4 4.00 >100 14.6 >100 7.48 >100 734 >100 
NCI/ADR-RES 3.01 31.9 <10 86.8 3.25 38.3 274 >100 
SK-OV-3 3.34 59.7 <10 58.3 14.4 >100 370 NA 
Renal Cancer 
786-0 
5.42 64.8 21.6 >100 13.0 >100 425 13.8 
A498 0.74 4.56 <10 0.02 1.29 43.3 252 2.08 
ACHN 4.51 >100 10.6 >100 9.78 >100 532 >100 
CAKI-1 3.00 >100 NA NA 6.19 >100 544 20.9 
UO-31 3.69 >100 <10 28.3 1.92 17.9 490 >100 
Prostate Cancer  
PC-3 
3.22 >100 10.1 >100 4.71 >100 363 >100 
DU-145 4.23 >100 23.7 >100 71.2 >100 501 16.5 
Breast Cancer 
 MCF7 
1.66 >100 <10 >100 4.35 >100 310 >100 
MDA-MB-231/ATCC 3.74 35.6 28.3 >100 4.83 64.3 434 6.95 
HS 578T 3.09 >100 <10 >100 16.7 >100 317 >100 
MDA-MB-468 2.22 >100 21.1 20.5 3.44 57.0 294 2.45 
 
Table 3.5: Growth Inhibition (GI50/µM) and Total Growth Inhibition (TGI/µM) data for 
compounds ST-507, ST-507(a), ST-145 and ST-510 against human cancer cells. 
Table 3.5 (continued) 
Panel/cell line 
ST-507 ST-507(a) ST-145 ST-510 
GI50 
( nM ) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
Leukemia 
CCRF-CEM 
34.3 >100 38.9 46.5 <10 23.8 <10 >100 
HL-60(TB) 29.9 NA 30.4 NA <10 <0.01 <10 >100 
K-562 22.6 >100 31.5 >100 <10 >100 <10 >100 
MOLT-4 51.1 >100 73.8 22.7 <10 14.0 <10 >100 
RPMI-8226 42.0 54.5 44.6 25.6 <10 2.21 <10 >100 
SR 21.9 >100 26.6 49.6 <10 45.9 <10 >100 
Non-Small  Cell  Lung  
Cancer 
A549/ATCC 
218 >100 259 >100 <10 29.0 <10 >100 
HOP-62 34.6 >100 33.3 93.1 <10 29.1 NA NA 
HOP-92 16900 >100 8650 85.1 <10 1.37 <10 NA 
NCI-H23 76.3 >100 79.7 36.6 <10 17.9 <10 >100 
NCI-H522 <10 0.05 12.9 0.07 <10 <0.01 <10 <0.01 
Colon Cancer 
COLO 205 12400 47.1 12600 44.7 2990 24.9 301 11.1 
HCC-2998 181 >100 172 34.5 26.1 12.1 <10 >100 
HCT-116 36.4 >100 33.7 40.0 <10 10.3 <10 0.01 
HCT-15 36.6 >100 32.9 12.5 <10 16.6 <10 >100 
HT29 5780 >100 6230 >100 3180 46.9 320 4.61 
KM12 22.9 >100 38.2 16.3 <10 19.5 <10 >100 
SW-620 35.2 >100 38.6 78.7 <10 >100 <10 >100 
CNS Cancer 66.3 >100 77.0 65.0 <10 60.4 <10 >100 
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SF-268 
SF-295 966 >100 5870 22.8 49.6 13.7 13.1 >100 
SF-539 21.7 NA 23.1 NA <10 <0.01 <10 <0.01 
SNB-19 50.5 >100 43.7 >100 <10 >100 <10 >100 
SNB-75 21.6 NA 16.8 NA <10 41.1 <10 >100 
U251 43.9 >100 47.3 >100 11.2 25.8 <10 >100 
Melanoma 
LOX IMVI 58.2 >100 69.5 22.6 <10 19.5 <10 >100 
M14 27.5 >100 22.8 NA <10 14.8 <10 NA 
MDA-MB-435 <10 <0.01 <10 0.02 <10 <0.01 <10 <0.01 
SK-MEL-2 NA >100 NA 49.8 <10 39.8 <10 >100 
SK-MEL-28 11100 >100 12700 68.6 1010 24.5 <10 >100 
SK-MEL-5 43.5 2.1 45.4 1.76 <10 0.02 <10 <0.01 
UACC-62 20.9 >100 NA 35.8 <10 21.4 <10 >100 
Ovarian Cancer 
IGROV1 
61.3 >100 71.0 >100 <10 >100 <10 <0.01 
OVCAR-3 17.3 NA 20.8 NA <10 43.7 <10 >100 
OVCAR-4 15600 >100 10700 56.5 <10 22.6 <10 >100 
NCI/ADR-RES 16.2 >100 22.3 0.12 <10 NA <10 >100 
SK-OV-3 48.7 >100 53.7 54.6 16.9 43.5 <10 >100 
Renal Cancer 
786-0 
3660 >100 2430 >100 <10 34.3 14.8 0.85 
A498 20.0 NA 25.0 NA <10 <0.01 <10 >100 
ACHN 84.4 >100 85.6 48.8 <10 43.3 <10 >100 
CAKI-1 >100 >100 423 >100 34.2 33.9 <10 >100 
UO-31 57.2 >100 88.9 26.9 <10 19.3 <10 >100 
Prostate Cancer 
PC-3 
41.2 >100 39.3 50.1 <10 17.0 <10 >100 
DU-145 36.5 >100 37.4 58.7 <10 39.6 <10 >100 
Breast Cancer 
MCF7 
35.3 >100 35.4 24.0 <10 12.1 <10 >100 
MDA-MB-231/ATCC 44.9 >100 45.6 >100 <10 90.8 <10 >100 
HS 578T 25.7 >100 27.7 NA <10 92.2 <10 >100 
MDA-MB-468 43.4 >100 44.6 30.2 <10 <0.01 <10 >100 
 
Table 3.6: Growth Inhibition (GI50/µM) and Total Growth Inhibition (TGI/µM) data for 
compounds ST-179, ST-163, ST-178 and ST-180 against human cancer cells. 
Table 3.6 (continued) 
Panel/cell line 
ST-179 ST-163 ST-178 ST-180 
GI50 
( µM ) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
GI50 
(µM) 
TGI 
(µM) 
GI50 
( nM ) 
TGI 
(µM) 
Leukemia 
CCRF-CEM 
1.91 25.9 250 >100 3.65 >100 46.9 >100 
HL-60(TB) 1.57 17.7 247 >100 3.50 55.2 25.7 >100 
K-562 0.53 30.9 41.3 >100 0.79 70.7 36.4 >100 
MOLT-4 3.71 >100 450 >100 4.99 >100 67.4 >100 
RPMI-8226 3.85 >100 494 >100 4.49 >100 192 >100 
SR 5.44 12.6 54.7 >100 1.60 21.2 35.5 >100 
Non-Small  Cell  2.65 >100 277 >100 500 >100 99.6 >100 
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Table 3.6 (continued) 
Lung  Cancer 
A549/ATCC 
HOP-62 2.14 14.5 308 62.8 3.77 >100 76.9 >100 
HOP-92 12.0 63.2 >1000 >100 4.55 53.0 >1000 >100 
NCI-H23 5.09 91.8 NA >100 6.45 >100 325 >100 
NCI-H522 2.37 7.78 43.0 0.51 2.89 9.73 15.6 0.057 
Colon Cancer 
COLO 205 1.61 4.81 140 1.06 2.58 7.45 36.1 0.200 
HCC-2998 5.42 >100 >1000 >100 11.0 >100 275 >100 
HCT-116 2.41 >100 229 >100 3.72 >100 45.2 >100 
HCT-15 0.75 >100 74.4 >100 1.77 >100 47.3 >100 
HT29 1.60 >100 61.3 >100 3.02 22.6 33.0 13.1 
KM12 2.39 >100 73.8 >100 3.77 >100 51.6 >100 
SW-620 0.72 >100 122 >100 3.72 >100 50.1 >100 
CNS Cancer 
SF-268 9.34 >100 730 >100 8.99 >100 >1000 >100 
SF-295 1.91 10.5 202 13.1 2.96 >100 38.1 20.0 
SF-539 1.58 6.97 249 1.42 2.71 11.0 45.1 >100 
SNB-19 4.24 95.0 751 >100 6.29 >100 237 >100 
SNB-75 1.14 4.88 NA >100 2.45 9.44 27.5 18.2 
U251 2.71 16.4 438 >100 3.85 >100 67.0 38.6 
Melanoma 
LOX IMVI 3.96 >100 571 >100 4.22 >100 56.7 40.2 
M14 1.68 >100 123 >100 3.13 >100 49.5 >100 
MDA-MB-435 0.31 >100 27.5 0.095 0.43 6.20 25.4 0.104 
SK-MEL-2 2.90 17.8 209 50.8 3.18 >100 43.5 >100 
SK-MEL-28 4.52 >100 457 >100 5.84 >100 247 >100 
SK-MEL-5 1.52 18.9 212 >100 3.20 2.04 57.3 2.67 
UACC-62 1.51 41.1 594 >100 2.63 >100 56.3 >100 
Ovarian Cancer 
IGROV1 
4.07 >100 >1000 >100 5.95 >100 90.3 >100 
OVCAR-3 3.04 NA 271 >100 4.18 28.4 37.9 >100 
OVCAR-4 3.79 >100 NA >100 8.25 >100 >1000 >100 
NCI/ADR-RES 1.65 >100 79.2 >100 2.52 >100 42.4 >100 
SK-OV-3 2.35 >100 404 >100 3.58 >100 56.2 >100 
Renal Cancer 
786-0 
4.38 29.1 >1000 >100 5.62 50.6 887 >100 
A498 0.41 5.38 201 6.17 1.17 7.08 31.6 2.50 
ACHN 4.24 >100 525 >100 4.52 >100 63.2 >100 
CAKI-1 2.06 >100 NA >100 4.18 >100 48.9 >100 
UO-31 6.24 >100 579 >100 6.48 >100 83.2 >100 
Prostate Cancer 
PC-3 
3.04 >100 321 >100 5.52 >100 55.6 >100 
DU-145 3.49 >100 587 >100 6.94 >100 216 >100 
Breast Cancer 
MCF7 
0.61 >100 81.0 >100 1.99 >100 87.9 >100 
MDA-MB-
231/ATCC 2.43 >100 >1000 >100 5.11 >100 180 >100 
HS 578T 2.63 80.5 466 >100 3.54 81.6 82.8 >100 
MDA-MB-468 0.51 11.9 281 >100 2.11 62.6 383 45.7 
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Table 3.7: Growth Inhibition (GI50/µM) and Total Growth Inhibition (TGI/µM) data for 
compounds ST-257, ST-260, ST-261 and ST-253 against human cancer cells. 
Table 3.7 (continued) 
Panel/cell line 
ST-257 ST-260 ST-261 ST-253 
GI50 
( µM ) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
GI50 
( nM ) 
TGI 
(µM) 
GI50 
( nM ) 
TGI 
(µM) 
Leukemia 
CCRF-CEM 3.76 >100 297 >100 52.2 >100 209 >100 
HL-60(TB) 2.07 17.9 60.3 NA 30.9 NA 40.4 25.4 
K-562 NA >100 NA NA NA NA NA NA 
MOLT-4 8.85 >100 1010 >100 60.5 >100 622 >100 
RPMI-8226 4.81 >100 34.2 76.2 53.4 >100 57.0 20.8 
SR 0.93 31.5 67.9 21.1 31.7 >100 64.1 >100 
Non-Small  Cell  
Lung  Cancer 
A549/ATCC 
4.12 >100 146 >100 35.8 27.6 60.2 >100 
HOP-62 2.98 >100 94.9 >100 44.2 17.4 51.5 >100 
HOP-92 9.64 >100 1410 72.0 37.9 23.9 119 42.1 
NCI-H23 6.61 >100 598 >100 48.1 16.5 158 >100 
NCI-H522 2.80 >100 67.6 >100 2.73 87.9 51.1 >100 
Colon Cancer 
COLO 205 
2.77 12.3 131 0.42 22.2 0.04/0.08 121 0.38 
HCC-2998 8.85 >100 331 >100 38.9 53.5 140 >100 
HCT-116 2.71 >100 45.2 13.0 30.1 1.13 34.3 13.5 
HCT-15 0.73 >100 57.4 >100 30.6 >100 39.2 >100 
HT29 NA >100 NA NA NA NA NA >100 
KM12 1.59 >100 80.3 >100 39.7 >100 54.4 >100 
SW-620 1.04 >100 54.3 >100 37.8 >100 44.2 >100 
CNS Cancer 
SF-268 5.38 >100 651 >100 51.4 43.2 113 >100 
SF-295 2.49 21.8 41.1 13.1 28.4 13.1 28.6 33.5 
SF-539 2.56 >100 48.8 0.47 25.0 0.09/2.47 25.2 0.07 
SNB-19 4.08 >100 414 >100 60.6 62.0 199 >100 
SNB-75 2.16 >100 91.3 >100 44.4 16.3 34.2 >100 
U251 3.97 44.3 218 >100 36.4 10.3 49.8 60.7 
Melanoma 
LOX IMVI 4.92 >100 145 >100 31.1 >100 64.4 >100 
M14 1.63 >100 48.1 NA 25.6 NA 34.7 NA 
MDA-MB-435 0.26 1.21 25.9 0.092 20.9 0.06 21.4 NA 
SK-MEL-2 1.84 >100 558 >100 NA NA NA >100 
SK-MEL-28 4.59 >100 155 >100 49.1 >100 62.5 >100 
SK-MEL-5 0.84 33.9 66.4 11.9 23.2 0.06 33.1 0.18 
UACC-62 1.04 >100 35.1 >100 38.7 >100 35.3 >100 
Ovarian Cancer 
IGROV1 9.40 >100 660 >100 76.2 >100 633 >100 
OVCAR-3 2.16 10.1 51.8 29.4 36.4 4.55 36.2 >100 
OVCAR-4 11.2 >100 927 >100 77.8 >100 266 >100 
NCI/ADR-RES 1.52 >100 56.2 >100 31.0 >100 32.7 >100 
SK-OV-3 3.24 58.1 113 15.5 30.9 0.09 43.1 >100 
Renal Cancer 3.88 >100 62.4 >100 34.6 >100 38.4 16.8 
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Table 3.7 (continued) 
786-0 
A498 1.35 9.26 49.8 90.0 32.8 2.50 26.3 13.8 
ACHN 7.61 >100 306 >100 46.2 >100 79.8 >100 
CAKI-1 2.92 >100 91.1 >100 50.9 >100 50.1 >100 
UO-31 501 >100 761 >100 2040 >100 NA >100 
Prostate Cancer 
PC-3 4.57 >100 160 >100 41.0 >100 56.3 >100 
DU-145 4.69 >100 381 >100 38.8 21.2 135 >100 
Breast Cancer 
MCF7 0.86 >100 157 >100 32.0 >100 40.2 56.5 
MDA-MB-
231/ATCC 
4.69 >100 376 52.7 26.8 0.07 170 >100 
HS 578T 5.56 >100 154 >100 38.6 >100 71.2 >100 
MDA-MB-468 1.11 >100 94.0 5.64 27.4 0.28 34.0 0.77 
 
Table 3.8: Growth Inhibition (GI50/µM) and Total Growth Inhibition (TGI/µM) data for 
compounds ST-252 and ST-173 against human cancer cells. 
Table 3.8 (continued) 
Panel/cell line 
ST-252 ST-173 
GI50 
( µM ) 
TGI 
(µM) 
GI50 
( µM ) 
TGI 
(µM) 
Leukemia 
CCRF-CEM >100 >100 1.56 24.8 
HL-60(TB) >100 >100 1.49 >100 
K-562 NA >100 0.39 >100 
MOLT-4 >100 >100 2.81 >100 
RPMI-8226 >100 >100 3.23 >100 
SR 2.76 >100 0.53 47.0 
Non-Small  Cell  Lung  
Cancer 
A549/ATCC 
21.7 >100 2.65 
 
>100 
HOP-62 >100 >100 3.30 >100 
HOP-92 >100 >100 7.42 >100 
NCI-H23 >100 >100 6.33 >100 
NCI-H522 >100 >100 2.58 8.98 
Colon Cancer 
COLO 205 >100 >100 1.59 3.77 
HCC-2998 7.78 >100 11.9 >100 
HCT-116 6.33 >100 2.68 >100 
HCT-15 2.10 >100 0.87 >100 
HT29 NA >100 0.71 >100 
127 
 
Table 3.8 (continued) 
KM12 4.26 >100 2.25 >100 
SW-620 3.93 >100 1.23 >100 
CNS Cancer 
SF-268 >100 >100 9.36 
>100 
SF-295 10.6 >100 1.75 >100 
SF-539 73.1 >100 1.61 4.31 
SNB-19 >100 >100 6.95 >100 
SNB-75 21.9 >100 NA >100 
U251 >100 >100 3.59 >100 
Melanoma 
LOX IMVI NA >100 5.33 
>100 
M14 3.87 >100 1.32 >100 
MDA-MB-435 0.51 4.50 0.30 >100 
SK-MEL-2 36.8 >100 0.72 >100 
SK-MEL-28 >100 >100 4.47 >100 
SK-MEL-5 3.54 >100 2.58 >100 
UACC-62 8.68 >100 2.32 >100 
Ovarian Cancer 
IGROV1 >100 >100 8.80 
>100 
OVCAR-3 37.1 >100 3.10 >100 
OVCAR-4 24.9 >100 1.65 5.73 
NCI/ADR-RES 4.45 >100 2.41 >100 
SK-OV-3 >100 >100 2.75 >100 
Renal Cancer 
786-0 35.8 >100 4.93 
>100 
A498 >100 >100 1.33 8.62 
ACHN >100 >100 4.92 >100 
CAKI-1 >100 >100 NA >100 
UO-31 >100 >100 6.66 >100 
Prostate Cancer 
PC-3 >100 >100 3.03 
>100 
DU-145 >100 >100 3.62 >100 
Breast Cancer 
MCF7 3.01 >100 0.85 
>100 
MDA-MB-231/ATCC 69.3 >100 3.36 >100 
HS 578T >100 >100 3.62 >100 
MDA-MB-468 4.29 >100 0.69 >100 
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From the 74 (E/Z)-2,3-diaryl substituted acrylonitriles that were synthesized, analogues 
ST-145 and ST-510 were found to be the lead compounds from the five-dose studies 
against the panel of 60 human cancer cell lines. These compounds were remarkable in 
that they afforded GI50 values that were less than 10 nM against almost all human cancer 
cells in the NCI panel. Although, the GI50 values of the two isomers ST-145 and ST-510 
are comparable, the Z isomer, ST-145, had the best TGI (Total Growth Inhibition) profile 
against HL-60(TB), NCI-H522, SF-539, MDA-MB-435, A-498, MDA-MB-468 tumor 
cell lines with values less than 10 nM. 
3.6 In vitro toxicity and tubulin affinity study of ST-145, ST-510, ST-507 and ST-
507(a) against acute myeloid leukemia (AML) cell line MV-411 
 
Compounds ST-507, ST-507(a), ST-145 and ST-510 were found to be very effective 
against the human leukemia sub-panel of cells, and especially the two analogs ST-145 
and ST-510, which had GI50 values of less than 10 nM across all the leukemic cells in the 
subpanel. At this point, we decided to test the lead compounds ST-507, ST-507(a), ST-
145 and ST-510 against acute myeloid leukemia MV-411 cells. The biological assays 
related to MV-411 cell lines were conducted by Dr. Monica Guzman’s research group. 
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Figure 3.2.  Lead compounds ST-507, ST-507(a), ST-145 and ST-510 exhibit potent 
anti-leukemia activity.  MV-411 cells were treated with the indicated compounds for 24 
and 48 h. Cell viability was determined by Annexin V staining.  Percent viability was 
calculated as the percent of annexin v-/7-AAD-cells relative to control.  
 
MV-411 cells (AML cell line) were treated with increasing concentrations of the lead 
compounds ST-507, ST-507(a), ST-145 and ST-510 for 24 and 48 hours.  Figure 3.2 
shows the dose-response curves for each of the compounds at both time courses.  We 
found that ST-510 was the most potent anti-leukemia compound in the series, causing 
more than 80 percent cell death over both 24h and 48h drug treatments at concentrations 
below 5 nM (Figure 3.2 top left panel). Compound ST-145 afforded an LD50 of ~30nM 
over 48 hours of drug treatment (Figure 3.2).  Compounds ST-507 and ST-507(a) 
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presented LD50 values of ~238nM and ~280nM, respectively, at 48h (Figure 3.2).  These 
data suggest that further investigation into the value of the above analogues as possible 
treatment for AML and associated leukemias is warranted, and may provide novel 
therapeutic avenues for treating this hematological malignancy. 
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Figure 3.3: Structures of the lead cyano stilbenes ST-507, ST-507(a), ST-145 and ST-
510 tested against MV-411 (AML) cells. 
 
We wanted to test our hypothesis that the mode of action of the cyano stilbene analogues 
as anticancer agents was through disruption of microtubule dynamics, resulting in the 
inhibition of mitosis. We investigated whether our lead compounds ST-507, ST-507(a), 
ST-145 and ST-510 could interfere with microtubule polymerization by 
immunofluorescence using antibody against tyrosinated tubulin (a marker for dynamic 
microtubules) (Gundersen, Kalnoski et al. 1984, Baas and Black 1990). Through this 
study we also wanted to compare depolymerization activity in the presence of the E/Z 
cyano stilbenes.  
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MV4-11 cells were treated with the indicated doses (25, 50 and 100 nM) of ST-507, ST-
507(a), ST-145 and ST-510 for 2 hrs. Intracellular staining was performed using 
antibody against tyrosinated α-tubulin. Cells were stained with DAPI before mounting to 
the slides to show the cell nucleus. Cells were lysed in microtubule stabilizing buffer. The 
polymerized α-tubulin in the pellets (P) and unpolymerized α-tubulin in the supernatants 
(S) were detected by Western blotting using antibody against tyrosinated α-tubulin.  
 
Figure 3.4: Microtubule depolymerization assay with the lead compounds ST-507, ST-
507(a), ST-145 and ST-510. 
 
Consistent with the superior anti-leukemia activity observed for ST-510 over ST-145 in 
MV4-11 cells, ST-510 demonstrated a more potent inhibition of MT polymerization 
when compared to ST-145 (Figure 3.5).  Thus, our data strongly demonstrates that all 
four E/Z diarylacrylonitriles bind to tubulin directly to inhibit its polymerization. 
In conclusion a library of E/Z diarylacrylonitriles analogs resembling resveratrol were 
synthesized and evaluated for their anticancer activity in an NCI panel of 60 human 
tumor cell lines and the lead compounds from the study (i.e. ST-507, ST-507(a), ST-145 
and ST-510) were tested against MV-411 (Acute Myeloid Leukemia) cells. Analogs ST-
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145 and ST-510 were found to have potent anticancer properties that are likely mediated 
through interference with tubulin polymerization. This data suggests that further 
investigation into the clinical potential of these analogues for treatment of AML could 
provide novel therapeutics for treatment of this hematological malignancy. 
3.7 Anticancer activity of (Z)-5-(2-(2H-tetrazol-5-yl)-2-(3,4,5-
trimethoxyphenyl)vinyl)-2-methoxyphenol (ST-145(a)) as a second generation 
trans stilbene analogue 
 
From the library of synthesized resveratrol analogs, ST-145 was found to a lead 
anticancer agent. However, we wanted to synthesize second generation drug-like 
molecule with improved water solubility while preserving the potency of ST-145. ST-
145(a) is a tetrazole substituted stilbene and was prepared as a second generation 
anticancer molecule in the resveratrol series. The GI50 TGI and LD50 values of the ST-
145(a) against the panel of NCI 60 human cancer cell line panel are presented in Table 
3.9.   
Table 3.9: Growth Inhibition (GI50/µM), Total Growth Inhibition (TGI/µM) and 
Cytotoxicity (LC50/µM) data for compound ST-145(a) against human cancer cells. 
Table 3.9 (continued) 
Panel/cell line ST-145(a) 
GI50 
(nM) 
TGI 
(µM) 
LC50 
(µM) 
Leukemia 
CCRF-CEM <10 20.10 
>100 
HL-60(TB) <10 NA >100 
K-562 <10 >100 >100 
MOLT-4 <10 19.80 >100 
RPMI-8226 <10 8.06 >100 
SR <10 25.50 >100 
Non-Small  Cell  Lung  Cancer  
A549/ATCC <10 21.7 
>100 
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Table 3.9 (continued) 
HOP-62 <10 28.1 >100 
HOP-92 <10 6.66 >100 
NCI-H23 <10 48.5 >100 
NCI-H522 <10 <0.01 >100 
Colon Cancer  
COLO 205 970 11.1 
44.0 
HCC-2998 <10 32.1 >100 
HCT-116 <10 20.1 >100 
HCT-15 <10 27.0 >100 
HT29 2200 59.8 >100 
KM12 <10 11.9 54.4 
SW-620 <10 57.7 >100 
CNS Cancer 
SF-268 <10 40.3 
>100 
SF-295 528 18.6 61.9 
SF-539 <10 <0.01 >100 
SNB-19 <10 >100 >100 
SNB-75 <10 23.7 96.3 
U251 <10 NA >100 
Melanoma 
LOX IMVI <10 25.4 
>100 
M14 <10 16.3 44.6 
MDA-MB-435 <10 <0.01 95.4 
SK-MEL-2 <10 23.3 63.9 
SK-MEL-28 <10 28.5 78.7 
SK-MEL-5 <10 <0.01 5.69 
UACC-62 <10 18.4 47.0 
Ovarian Cancer  
IGROV1 <10 25.7 
>100 
OVCAR-3 <10 NA >100 
OVCAR-4 <10 76.7 >100 
NCI/ADR-RES <10 >100 >100 
SK-OV-3 <10 19.7 >100 
Renal Cancer 
786-0 <10 51.4 
>100 
A498 <10 <0.01 97.5 
ACHN <10 42.3 >100 
RXF 393 <10 25.8 >100 
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Table 3.9 (continued) 
UO-31 <10 16.4 >100 
Prostate Cancer  
PC-3 <10 16.0 
>100 
DU-145 <10 15.3 74.1 
Breast Cancer 
 MCF7 <10 14.2 
80.4 
MDA-MB-231/ATCC <10 59.6 >100 
HS 578T <10 47.7 >100 
MDA-MB-468 <10 12.7 >100 
 
ST-145(a) was selected for full dose response studies had very effective GI50 and TGI 
(Total Growth Inhibition) values against various human tumor cell lines. The majority of 
the LD50 values were >100μM against most of the human cancer cell lines, implying the 
compound is a potent anti-proliferative agent.  ST-145(a) had impressive GI50 values of 
<10nM against almost all the cell lines in the panel except for colon cancer cell lines 
HT29 and COLO 205. The compound also showed potent TGI values of <10nM against 
non-small cell lung cancer cell line NCI-H522, CNS cancer cell line SF-539, Melanoma 
cell line MDA-MB-435 and renal cancer cell line A498.  
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3.8 In vitro toxicity study of ST-145(a) against Acute Myeloid Leukemia cell line 
MV-411 
 
 
Figure 3.5.  Lead compound ST-145(a) exhibited potent anti-leukemia activity against 
MV-411 cells. 
MV-411 cells (AML cell line) were treated with increasing concentrations of the lead 
compound ST-145(a) for 48 hours. Cell viability was determined by Annexin V staining.  
Percent viability was calculated as the percent of annexin v-/7-AAD- cells relative to 
control. Compound ST-145(a) exhibited an LD50 <40nM after 48 hours of drug treatment 
(Figure 3.5), and is worthy of further preclinical investigation as a possible treatment for 
AML. ST-145(a) may also have clinical potential in treating a variety of human cancers. 
3.9 Conclusion 
 In conclusion, a large library of resveratrol analogs have been synthesized and evaluated 
for anticancer activity in the NCI panel of 60 human tumor cell lines. Figure 3.6 
illustrates the triage flow chart with the number of compounds submitted to the NCI 
(180) versus the number of compounds selected for 10µM single dose screening (85). 
LD
50
 ~40 nM 
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Out of 85 compounds screened, 25 showed promising growth inhibitory activity against 
human tumor cell lines and were selected for full dose-response study. The lead 
compounds emerging from these five-dose study were also tested for their tubulin 
binding activity and their cytotoxicity against MV-411 (Acute Myeloid Leukemia) cells 
was determined.  
 
 
 
Figure 3.6: Triage flow chart of resveratrol analogues that were submitted for anticancer 
screening in the NCI panel of 60 human cancer cell lines. 
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Figure 3.7: Structures of the lead resveratrol analogs ST-145(a), ST-145 and ST-510. 
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Three lead compounds, ST-145(a), ST-145 and ST-510 (Figure 3.7) that may have 
clinical potential in treating a variety of human cancers have been discovered that have 
potent anticancer properties. The mechanism of action of these compounds are likely 
mediated through their interference with tubulin polymerization. Further investigation of 
this important class of compounds may provide novel therapeutic agents with clinical 
potential. 
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Chapter 4 
 
Preparation of novel 4,5 disubstituted-2H-1,2,3-triazoles as combretastatin A4 
analogues 
4.1 Introduction 
Although, significant research has been carried out to date to treat cancer, there is still a 
lack of effective chemotherapeutic treatment to cure it completely with minimal side 
effects. Also, considerable effort has been put into identifying molecules with anti-cancer 
properties from both natural and synthetic sources. More than 60% of the anticancer 
drugs currently available are from natural sources (Gordaliza 2007). The search for 
potent semi-synthetically derived anticancer agents from parent natural products 
continues to be an important part of the drug discovery process. 
Antimitotic agents are a major class of cytotoxic drugs for the treatment of cancer, and 
drugs that target microtubule/tubulin dynamics are widely used in cancer chemotherapy 
(Jordan 2002). There are three major binding sites for tubulin. They are the vinca, taxane 
and colchicine domains. The vinca alkaloids such as vincristine and vinblastine, bind to 
the vinca domain and inhibit the assembly of microtubule structures and arrest mitosis 
(Hadfield, Ducki et al. 2003). Paclitaxel acts at the taxane domain and stabilizes 
microtubules interfering with the normal breakdown of microtubules during mitosis 
(Jordan and Wilson 2004). Our area of interest was the colchicine binding site. 
Colchicine binds to tubulin and inhibits microtubule polymerization. Anti-mitotic agents 
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such as combretastatin A-4 (CA-4) and related compounds have the capability of binding 
at the colchicine domain of tubulin. These natural products are structurally related to 
resveratrol and have received much attention lately, since the water-soluble phosphate 
salt of CA-4 is currently in phase III clinical trials for treatment of anaplastic thyroid 
cancer. The phosphate salt of of CA-4 is also in phase II clinical trials as a treatment for 
polypoidal choroidal vasculopathy and neovascular age-related macular degeneration 
(Young and Chaplin 2004, Cooney, Ortiz et al. 2005). 
Combretastatin A4 (CA-4) is a cis-stilbene compound originating from the South African 
willow tree, combretum caffrum. CA-4 functions as a microtubule targeting agent, 
interfering with microtubule dynamics and perturbing the mitotic cycle (Tron, Pirali et al. 
2006). When compared to colchicine, the vascular disrupting effects of CA-4 are well 
below the maximum tolerable dose with fewer side effects in vivo (Tozer, Kanthou et al. 
2002). However, CA-4 suffers from chemical stability issues because of facile cis-trans 
isomerism in solution. CA-4 is a cis-configured stilbene which is readily converted to the 
thermodynamically more stable, but less potent trans-isomer (Hsieh, Liou et al. 2005). 
Extensive studies have been conducted in attempts to stabilize the cis-configuration of 
CA-4 by replacing the ethylene bridge in the molecule with heterocyclic ring systems 
such as β-lactam, azetidone, thiazole, tetrazole, imidazole, pyrazole, oxazolone, triazole, 
furanone moieties (Shirai, Takayama et al. 1998, Tron, Pagliai et al. 2005, Carr, Greene 
et al. 2010, Beale, Bond et al. 2012, Banimustafa, Kheirollahi et al. 2013, Demchuk, 
Samet et al. 2014).  
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Figure 4.1: Structures of Combretastatin A4 (CA-4) (A), Colchicine (B), and 
heterocyclic anti-tubulin compounds (C-I). 
 
In the work described herein, we report on the synthesis of novel and potent cis-
constrained 4,5-disubstituted 2H-1,2,3-triazole combretastatin A-4 analogs which 
incorporates a unique heterocyclic moiety between the two aromatic rings to afford a 
chemically stable, cis-configured CA-4 scaffold. Evaluation of the anti-cancer properties 
of a sub-lbrary of these novel CA-4 analogues against the NCI panel of 60 human tumor 
cell lines has been performed, as well as with the determination of activity of these 
compounds in the tubulin polymerization assay. 
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4.2 Methodology, Development, and Design of 4,5 disubstitutes-2H-1,2,3-triazoles 
1,2,3-Triazoles are an important class of heterocycles which have a wide range of 
applications in agricultural, industrial and pharmaceutical arenas .  This ring system is 
present in a number of drugs with various biological properties, such as anti-cancer, anti-
fungal, anti-viral, anti-consulvant (Pålhagen, Canger et al. 2001), and anti-HIV 
agents (Alvarez, Velazquez et al. 1994),  Industrial applications include dyes, 
photostabilizers, photographic materials and anti-corrosives. Our laboratory is currently 
focusing on the development of anticancer agents structurally related to resveratrol and 
combretastatin A4 (CA-4) (Figure 4.1, A) (Pettit, Singh et al. 1995, Penthala, Janganati et 
al. 2014).  CA-4 suffers from chemical instability in solution, due to cis-trans isomerism 
(Nathwani, Hughes et al. 2013). We are currently involved in identifying chemically 
stable analogues of cis-cyano-CA4 and related compounds that retain their potent 
anticancer properties One approach we are exploring is the replacement of the 
acrylonitrile moiety in these active anticancer agents with a heterocyclic ring system such 
as the triazole moiety, to afford geometrically stable triazole analogs of cyano-CA4 
(Figure 4.2, C) that do not undergo cis-trans isomerism in solution. 
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Figure 4.2: Structures of CA4 and cis constraines heterocyclic CA4 analogs. 
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  The conventional route for preparing 1,2,3-triazoles is via the Huisgen 1,3-dipolar 
cycloaddition of azides with alkynes (Scheme 4.1). However, the disadvantages of this 
synthetic approach are poor regioselectivity and long reaction times. A variety of 
triazoles can also be synthesized by the click chemistry methodologies developed by 
Sharpless et al. between azides and alkynes, to yield 1,5-disubstituted 1,2,3-triazoles 
(Krasiński, Fokin et al. 2004). However, inorganic azides (e.g. NaN3) are not good 
substrates for this reaction, and these methods cannot be applied to the synthesis of 
internal alkynes. Recently, Majireck et al. and Tsai et al. have reported the synthesis of 
4,5-disubstituted 2H-1,2,3-triazoles by cycloaddition of internal alkynes with alkyl azides 
or metal azides, but the disadvantage of this approach is the low yielding synthesis of the 
alkyne reactant,  especially when an electron donating group is attached to the alkyne 
terminus (Majireck and Weinreb 2006, Tsai, Yang et al. 2009). 
R N3 R1
N
N
N
R
R1
N
N
N
R
R1
R2
R2 R2  
Scheme 4.1: 1,2,3 triazole synthesis by the Huisgen azide-alkyne 1,3 dipolar cyclization. 
 
A less explored route for the synthesis of 2H-1,2,3-triazoles is the  cycloaddition of 
azides with alkenes bearing a good leaving group. Zard et al. reported the synthesis of 
4,5-disubstituted-1H-1,2,3-triazoles from nitroalkenes, but did not report any formation 
of 4,5-disubstituted 2H-1,2,3-triazoles via this approach (Quiclet-Sire and Zard 2005). 
Sengupta et al. have reported the synthesis of 4,5-disubstituted 2H-1,2,3-triazoles from 
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nitroalkenes, however, the presence of a vinyl group was necessary for the reaction to 
proceed (Sengupta, Duan et al. 2008). 
 
Herein, we report a novel synthetic procedure for the synthesis of 4,5-disubstituted 2H-
1,2,3-triazoles from (Z)-2,3-diaryl-substituted acrylonitriles by treatment with 
NaN3/NH4Cl in aqueous DMF (Scheme 4.3). The advantage of this methodological 
approach is that cyano-CA4 analogs bearing a broad range of aromatic functionalities can 
be easily converted to their corresponding 2H-1,2,3-triazole derivatives in one step. 
Utilizing (Z)-3-(3,4-dichlorophenyl)-2-(3,4-dimethoxyphenyl) acrylonitrile as a model 
reactant, it was observed that using a combination of 10:1 volumes of DMF/H2O as 
solvent significantly improved the yield of 4-(3,4-dichlorophenyl)-5-(3,4-
dimethoxyphenyl)-2H-1,2,3-triazole compared to using DMF alone (Scheme 4.3). The 
reaction did not proceed in anhydrous THF. The rate of the reaction was found to be 
dependent on the molar amount of NaN3/NH4Cl used (Table 4.1). The optimum 
conditions for this reaction are: heating the reactant under reflux with 3 molar equivalents 
of NH4Cl and 3 molar equivalents of NaN3 in 10:1 volumes of DMF/H2O. X-ray 
crystallographic studies on compounds ST-464 and ST-447(a) confirmed the presence of 
a 2H-1,2,3-triazole ring system and the position of N-methylation (Figure 4.3).  
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Scheme 4.2: Proposed mechanism and optimization of the reaction conditions for the 
synthesis of 4-(3,4-dichloro)-5-(3,4-dimethoxyphenyl)-2H-1,2,3-triazole and synthesis of 
its methylated product. 
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Table 4.1: Optimization of the reaction conditions for the synthesis of 4-(3,4-dichloro)-5-
(3,4-dimethoxyphenyl)-2H-1,2,3-triazole . 
Entry Solvent Reaction Conditions Yielda (%) 
1     DMFc Reflux, 5 hrs, 3 eq NH4Cl/ 3eq NaN3 24 
2 DMF/H2Ob Reflux, 5 hrs, 3 eq NH4Cl/ 3eq NaN3 81 
3 DMF/H2Ob Reflux, 5 hrs, 1 eq NH4Cl/ 1eq NaN3 45 
4 DMF/H2Ob                        Reflux, 5 hrs,  3eq NaN3 32 
5     THFc Reflux, 5 hrs, 3 eq NH4Cl/ 3eq NaN3 0 
 
Previous reports have not elaborated on the mechanism of formation of the 2H-1,2,3-
triazole ring in stilbenes of structure 1a (Scheme 4.3) (Majireck and Weinreb 2006, Tsai, 
Yang et al. 2009). The proposed mechanism of triazole ring formation likely involves 
145 
 
initial Michael addition of azide ion at the unsubstituted sp2 olefinic carbon to afford 
compound X followed by cyclization to Y (Scheme 4.2). Acid-catalyzed elimination of 
the cyano moiety then affords ST-447. It is evident from the optimization studies that 
NH4Cl and water are essential components in the reaction (Table 4.1).  All the reactions 
were conducted with (Z)-2,3-diarylacrylonitriles.  However, we did examine the relative 
usefulness of utilizing (E)-2,3-diarylacrylonitriles in these reactions. Thus, (E)-3-(3-
hydroxy-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-acrylonitrile, the corresponding 
(E)-isomer of  1e (Table 4.2), was used as a starting material for the synthesis of 
compound ST-145(b). The yield of the resulting 2H-1,2,3-triazole ST-145(b) was 21% 
compared to 59% when the (Z)-isomer was utilized under similar reaction conditions 
(Table 4.2; Entry 5), indicating that (E)-2,3-diarylacrylonitriles are less useful than their 
(Z)-counterparts in the synthesis of 2H-1,2,3-triazoles of structure 2 (Scheme 4.3). Also 
when (E)-1,3-dimethoxy-5-(4-methoxystyryl)benzene (TMR) was used as a starting 
material the reaction did not proceed (Table 4.2). 
4.3 Chemistry  
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NaN3, NH4Cl
CN
X
R
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N
H
N
N
1 2R
 
 
Scheme 4.3: Synthesis of 4,5-disubstituted 2H-1,2,3-triazoles from (Z)-2,3-
diarylacrylonitriles. 
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General experimental procedure: A typical experimental procedure entailed refluxing a 
mixture of the (Z)-2,3-diarylacrylonitrile (1, Scheme 4.3), NaN3 and NH4Cl in a mole 
ratio of 1: 3: 3 in 10: 1 volumes of DMF/ H2O for 5-12 hrs. The reaction was monitored 
by TLC and GC-MS. When the starting material had completely disappeared, cold water 
was added and the mixture was stirred over 10-15 min, during which time the final 
product precipitated out and could be filtered off. In the absence of a precipitate, the 
product was extracted into ethyl acetate, the organic extract washed with copious 
amounts of water, and the resulting organic liquor evaporated to dryness on a 
rotovaporator. The residue obtained was purified by flash column chromatography [need 
eluting solvent details] to afford the corresponding triazole (2, Scheme 4.3). Yields of the 
synthesized triazoles are presented in Table 4.2, and ranged from 59% to 87%. 
    A variety of cyano-CA4 analogs were subjected to treatment with NaN3/DMF/H2O 
under the above optimized reaction conditions, and their corresponding 4,5-disubstituted 
2H-1,2,3-triazoles were obtained in modest to good yields (Table 2). No significant side 
products were formed in the reactions shown in Scheme 4.4.  
R1
CN
R2 CHO R2
NC
R1 R1 R2
N
H
N
N
acetonitrile aldehyde (Z)-2,3-diarylacetonitriles 4,5-disubstituted 2H-1,2,3-triazoles
1a-1p
a b
R1 = R2 = variable Aryl, heteroaryl rings  
Scheme 4.4: Synthesis of 4,5-disubstituted 2H-1,2,3-triazoles; reagents and conditions: 
(a) 5% NaOMe, MeOH, reflux. (b) NaN3, NH4Cl, DMF/H2O. 
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Table 4.2: Synthesis of 4,5-disubstituted-2H-1,2,3-triazoles from their corresponding (Z)-
2,3-diaryl substituted acrylonitriles. 
 
Table 4.2 (continued) 
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Table 4.2 (continued) 
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Table 4.2 (continued) 
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Table 4.2 (continued) 
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Table 4.2 (continued) 
1w ST-440 
24   - - 
H3CO
H3CO
OCH3
 
TMR 
No reaction 
 
 
 
4.4 Analytical Data: 
ST-464: 1H NMR (400 MHz, DMSO-d6): δ 3.77 (s, 12H, -OCH3), 3.88 (s, 6H, -
OCH2), 6.85 (s, 4H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.02, 56.11, 
56.19, 60.91, 60.99, 105.47, 125.64, 138.25, 153.27 ppm. HRMS (ESI): m/z calcd for 
C20H23N3O6 [M-H] 402.1665; found 402.1668. 
 
ST-475: 1H NMR (400 MHz, DMSO-d6): δ 3.75 (s, 6H, -OCH3), 5.29 (s, 2H, -CH2), 
5.99 (s, 2H,  ArH), 6.48 (s, 1H,  ArH), 6.72-6.73 (d, J =2.4 Hz, 2H, ArH), 6.80-6.83 
(d, J =8.8 Hz, 1H, ArH), 7.05-7.07 (d, J =6.4 Hz, 2H, ArH), 7.26 (S, 1H, ArH) 
ppm. 13C NMR (100 MHz, DMSO-d6): 55.42, 55.51, 101.05, 101.25, 106.12, 108.51, 
108.80, 122.38, 131.91, 147.81, 147.98, 160.87 ppm. HRMS (ESI): m/z calcd for 
C17H16N3O4 [M-H] 326.1141; found 326.1133.    
 
ST-471: 1H NMR (400 MHz, DMSO-d6): δ 6.00 (s, 2H, -CH2), 6.80-6.82 (d, J =8.8 
Hz, 1H, ArH), 7.03-7.05 (d, J =6.8 Hz, 2H, ArH), 7.38-7.40 (t, J =5.2 Hz, 3H, ArH), 
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7.56-7.58 (m, J =9.6 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 101.25, 
108.58, 108.70, 122.23, 128.24, 128.70, 147.85 ppm. HRMS (ESI): m/z calcd for 
C15H12N3O2 [M-H] 266.0930; found 266.0928. 
 
ST-466: 1H NMR (400 MHz, DMSO-d6): δ 3.70-3.72 (d, 9H, -OCH3), 6.80 (s, 2H,  
ArH), 7.86 (s, 2H, ArH), 8.29-8.31 (d, J =8.4 Hz, 2H, ArH) ppm. 13C NMR (100 
MHz, DMSO-d6): 56.18, 60.81, 124.58, 126.83, 127.84, 137.86, 139.57, 143.83, 
149.52, 154.62 ppm. HRMS (ESI): m/z calcd for C17H17N4O5 [M-H] 357.1199; 
found 357.1199. 
 
ST-467: 1H NMR (400 MHz, DMSO-d6): δ 3.74 (s, 6H, -OCH3), 3.84 (s, 3H, -
OCH3), 3.89 (s, 3H, -OCH3),    6.83 (s, 2H, ArH), 6.91-6.93 (d, J =8.4 Hz, 2H, ArH), 
7.51-7.53 (d, J =8.0 Hz, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6):55.27, 
55.36, 55.96, 56.05, 60.90, 60.99, 105.14, 105.18, 114.03, 125.86, 129.79, 138.07, 
153.27, 159.97 ppm. HRMS (ESI): m/z calcd for C18H20N3O4 [M-H] 342.1454; 
found 342.1448. 
 
ST-145b: 1H NMR (400 MHz, DMSO-d6): δ 3.74 (s, 6H, -OCH3), 3.90 (s, 6H, -
OCH3), 6.84-6.85 (d, J =2 Hz, 3H, ArH), 7.05-7.07 (d, J =8.4 Hz, 1H, ArH), 7.21 (s, 
1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 55.92, 55.98, 56.07, 60.91, 60.98, 
105.23, 110.63, 114.72, 120.61, 123.01, 125.74, 138.09, 145.66, 147.10, 153.23 ppm. 
HRMS (ESI): m/z calcd for C18H20N3O5 [M-H] 358.1403; found 358.1408. 
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ST-450: 1H NMR (400 MHz, DMSO-d6): δ 3.57 (s, 6H, -OCH3), δ 3.84 (s,  3H, -
OCH3), 6.80 (s, 2H, ArH), 7.34-7.39 (m, J =20 Hz, 1H, ArH), 7.61 (s, 1H, ArH), 
7.75-7.77 (d, J =7.6 Hz, 1H, ArH), 7.90-7.92(d, J =8 Hz, 1H, ArH) ppm. 13C NMR 
(100 MHz, DMSO-d6):55.72, 55.85, 60.85, 60.99, 104.57, 104.64, 122.61, 122.73, 
123.65, 123.77, 124.66, 124.74, 124.83, 124.94, 125.28, 127.21, 127.37, 137.56, 
138.12, 139.89, 153.24 ppm. HRMS (ESI): m/z calcd for C19H17N3O3S [M-H] 
367.0991; found 367.0909. 
 
ST-440: 1H NMR (400 MHz, DMSO-d6): 7.22-7.36 (m, J =54 Hz, 3H, ArH), 7.50 (s, 
1H, ArH), 7.68-7.70 (d, J =8.0 Hz, 1H, ArH), 7.85-7.87(d, J =8 Hz, 2H, ArH), 8.55-
8.56 (d, J =3.6 Hz, 1H, ArH), 8.94 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-
d6):122.69, 122.78,123.33, 123.42, 123.72, 123.77, 124.70, 124.72, 124.90, 124.94, 
125.35, 126.97, 127.08, 127.42, 135.37, 135.46, 137.31, 140.12, 141.14, 147.94, 
148.00, 148.51 ppm. 
 
ST-452: 1H NMR (400 MHz, DMSO-d6): δ 7.26(s, 1H, ArH), 7.38-7.40(d, J =8 Hz, 
2H, ArH), 749-7.54 (m, J =16.4 Hz, 2H, ArH), 7.66-7.68(d, J =6.8 Hz, 1H, ArH), 
8.63 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6):121.33, 123.62, 127.45, 
128.96, 129.75, 129.89, 132.95, 134.99, 135.77, 137.04, 149.66 ppm. HRMS (ESI): 
m/z calcd for C13H9Cl2N4 [M-H] 291.0204; found 291.0201. 
 
ST-447: 1H NMR (400 MHz, DMSO-d6): δ 3.82 (s, 3H, -OCH3), δ 3.93 (s, 3H, -
OCH3), 6.87-6.89 (d, J =8 Hz, 1H, ArH), 7.05-7.07 (d, J =12 Hz, 2H, ArH), ), 7.42 
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(s, 2H, ArH), 7.78 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6):55.87, 55.96, 
111.05, 127.31, 129.80, 129.89, 130.54, 132.60, 132.86, 149.15, 149.754 ppm. 
 
ST-441: 1H NMR (400 MHz, DMSO-d6): δ 3.81 (s, 6H, -OCH3), δ 3.90 (s, 3H, -
OCH3), 6.9 (s, 2H, ArH), 7.29-7.26 (d, J =12.8 Hz, 2H, ArH), 7.70 (s, 2H, ArH), 8.67 
(s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6): 56.22, 56.33, 61.13, 100.71, 
123.62, 124.25, 127.35, 137.22, 139.48, 149.5, 153.1, 154.8 ppm. HRMS (ESI): m/z 
calcd for C16H17N4O3 [M-H] 313.1301; found 313.1298. 
 
ST-445: 1H NMR (400 MHz, DMSO-d6): δ 7.21-7.22(d, J =4.8 Hz, 1H, ArH), 7.31-
7.33 (d, J =8.4 Hz, 1H, ArH), 7.38-7.41(m, J =14.8 Hz, 3H, ArH), 7.49-7.50 (d, J 
=1.2 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6):116.17, 116.22, 116.39, 
116.44, 121.32, 121.49, 124.56, 126.73, 126.76, 127.01, 129.50, 130.75, 130.83, 
130.92, 138.32, 141.30, 156.84, 159.31 ppm. HRMS (ESI): m/z calcd for 
C12H8ClFN3S [M-H] 280.0111; found 280.0118. 
 
ST-442: 1H NMR (400 MHz, DMSO-d6): δ 5.99 (s, 2H, -CH2), 6.82-6.84(d, J =8.4 
Hz, 1H, ArH), 7.13-7.14 (d, J =6 Hz, 2H, ArH), 7.26-7.28(d, J =8.4 Hz, 1H, ArH), 
7.69-7.71 (d, J =7.2 Hz, 2H, ArH), 8.69 (s, 1H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6):101.15, 101.25, 101.35, 108.52, 109.31, 109.34, 122.78, 123.30, 124.04, 
137.02, 14777, 148.06, 149.56 ppm. HRMS (ESI): m/z calcd for C14H11N4O2 [M-
H] 267.0882; found 267.0879. 
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ST-478: 1H NMR (400 MHz, DMSO-d6): δ 3.76 (s, 3H, -OCH3), 7.03-7.04(d, J =4.8 
Hz, 2H, ArH), 7.39-7.47 (m, J =35.2 Hz, 2H, ArH), 7.62-7.63(d, J =1.6 Hz, 1H, 
ArH), 7.71 (s, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6):55.51, 111.54, 
121.21, 122.83, 129.17, 130.48, 131.29, 133.34, 133.42, 134.96, 156.51 ppm. HRMS 
(ESI): m/z calcd for C15H12Br2N3O [M-H] 407.9347; found 407.9327. 
 
ST-489: 1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 6H, -OCH3), 3.91 (s, 3H, -
OCH3), 6.77 (s, 2H, ArH), 7.46 (s, 2H, ArH), 7.82 (s, 1H, ArH) ppm. 13C NMR (100 
MHz, DMSO-d6):56.12, 56.23, 60.96, 61.05, 105.39, 105.45, 127.44, 129.88, 129.97, 
130.53, 132.74, 132.84, 138.69, 153.53 ppm. HRMS (ESI): m/z calcd for 
C17H16Cl2N3O3 [M-H] 380.0569; found 380.0564. 
 
ST-492: 1H NMR (400 MHz, DMSO-d6): δ 3.47 (s, 6H, -OCH3), 3.81 (s, 3H, -
OCH3),  6.65 (s, 2H, ArH), 7.50-7.52(t, J =8 Hz, 1H, ArH), 7.54-7.56(d, J =4.4 Hz, 
1H, ArH), 7.76-7.77(t, J =1.6 Hz, 1H, ArH), 7.82-7.84(d, J =8 Hz, 1H, ArH), 8.27-
8.29(d, J =8.8 Hz, 1H, ArH), 9.03-9.04(d, J =4.4 Hz, 1H, ArH) ppm. 13C NMR (100 
MHz, DMSO-d6): 55.70, 55.79, 0.85, 60.95, 104.47, 104.55, 122.68, 122.76, 124.69, 
125.95, 126.66, 127.52, 129.42, 130.21, 138.21, 138.45, 148.15, 149.63, 149.69, 
153.24 ppm. HRMS (ESI): m/z calcd for C20H19N4O3 [M-H] 363.1457; found 
363.1460. 
 
ST-491: 1H NMR (400 MHz, DMSO-d6): δ 3.82 (s, 3H, -OCH3), 3.92 (s, 3H, -
OCH3),  6.87-6.89(d, J =8 Hz, 1H, ArH), 7.04-7.08(m, J =14.4 Hz, 2H, ArH), 7.42-
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7.42(d, J =0.8 Hz, 2H, ArH), 7.78 (s, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-
d6):55.85, 55.95, 60.47, 111.19, 111.24, 121.00, 127.31, 129.78, 129.87, 130.49, 
130.87, 132.41, 132.79, 149.09, 149.62, 171.36 ppm. HRMS (ESI): m/z calcd for 
C16H14Cl2N3O2 [M-H] 350.0463; found 350.0465. 
 
ST-482: Yellow solid; Yield %; 1H NMR (400 MHz, DMSO-d6): δ 3.77 (s, 6H, -
OCH3), 3.89 (s, 3H, -OCH3),  4.26-4.29 (q, J =12.4 Hz, 4H, ArH), 6.84(s, 2H, ArH), 
6.87-6.89(d, J =8 Hz, 1H, ArH), 7.04-7.05, 7.04-7.07(dd, J =2 Hz, 8 Hz, 1H, ArH), 
7.15-7.16(d, J =1.6 Hz, 1H, ArH), 7.26(s, 1H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6):55.99, 56.08, 60.90, 60.99, 64.27, 64.47, 105.24, 105.28, 117.42, 121.80, 
138.18, 143.59, 144.09, 153.26 ppm. HRMS (ESI): m/z calcd for C19H20N3O5 [M-
H] 370.1403; found 370.1398. 
 
ST-497: Yellow solid; Yield %; 1H NMR (400 MHz, DMSO-d6): δ 3.78 (s, 6H, -
OCH3), 3.91 (s, 3H, -OCH3),  7.08 (s, 2H, ArH), 7.54-7.58(t, J =14.8 Hz, 1H, ArH), 
7.70-7.74(t, J =14.8 Hz, 1H, ArH), 7.82-7.83(d, J =6.4 Hz, 2H, ArH), 8.08-8.10 (d, J 
=8.8 Hz, 1H, ArH), 8.16-8.18(d, J =8.4 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, 
DMSO-d6):56.08, 56.18, 60.92, 61.01, 106.21, 120.70, 125.57, 127.12, 127.56, 
127.73, 127.68, 129.04, 130.20, 136.83, 138.50, 147.76, 153.19 ppm. HRMS (ESI): 
m/z calcd for C20H19N4O3 [M-H] 363.1457; found 363.1456. 
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ST-494: Yellow solid; Yield %; 1H NMR (400 MHz, DMSO-d6): δ 3.73 (s, 3H, -
OCH3), 3.80 (s, 6H, -OCH3), 6.83 (s, 2H, ArH) ppm. 13C NMR (100 MHz, DMSO-
d6):56.48, 56.67, 65.20, 106.29, 116.04, 116.84, 130.15, 139.13, 153.08 ppm. 
 
ST-513: Yellow solid; Yield %; 1H NMR (400 MHz, DMSO-d6): δ 3.72 (s, 6H, -
OCH3), 5.29 (s, 1H, ArH), 6.73 (s, 2H, ArH), 6.83-6.85 (d, J =8.4 Hz, 1H, ArH), 
7.42-7.44(d, J =8.8 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, DMSO-d6):56.08, 
56.18, 60.92, 61.01, 106.21, 120.70, 125.57, 127.12, 127.56, 127.73, 127.68, 129.04, 
130.20, 136.83, 138.50, 147.76, 153.19 ppm. 
 
A  mixture of 5-(3,4-dichlorophenyl)-4-(3,4-dimethoxyphenyl)-2H-1,2,3-triazole 
(ST-447) (1 mmol), K2CO3 ( 10 mmol) and MeI ( 2 mmol) in 10 volumes of acetone 
was refluxed for 5 hrs. 2M aqueous HCl was then added to quench the reaction and 
the resulting mixture was evaporated to dryness on a rotavaporator. The resulting 
residue was dissolved in ethyl acetate, filtered, and the filtrate submitted to ethyl 
acetate/hexane flash column chromatography to yield 4-(3,4-dichlorophenyl)-5-(3,4-
dimethoxyphenyl)-2-methyl-2H-1,2,3-triazole 
(ST-447(a)): Pale yellow solid; 1H NMR (400 MHz, CDCl3-d): δ 3.83 (s, 3H, -
OCH3), 3.92 (s,  3H, -OCH3), 4.25 (s,  3H, -CH3), 6.86 (d, J =8 Hz, 1H, ArH), 7.05 
(dd, J =15.2 Hz, 2H, ArH), , 7.42 (dd, J =16.8 Hz, 2H, ArH), 7.74 (d, J =1.6 Hz, 1H, 
ArH) ppm. 13C NMR (100 MHz, CDCl3-d): 41.98, 56.08, 111.40, 121.07, 123.09, 
127.45, 129.97, 130.59, 131.376, 132.41, 132.91, 141.99, 144.87, 149.25, 149.63 
ppm. 
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Figure 4.3: X-ray Crystal structures of compounds ST-464 and ST-447(a). 
 
4.5 Biological Evaluation 
4.5.1 Anticancer activity of 2H-triazole analogs against a panel of NCI 60 human 
cancer cells  
The sulforhodamine B (SRB) assay procedure described in Chapter 3 was used to screen 
the synthesized 2H-triazole CA-4 analogues against the panel of 60 human tumor cell 
lines at the NCI (Rubinstein, Shoemaker et al. 1990). The growth inhibitory and cytotoxic 
properties of a tested compound in our present assay is measured by its percentage 
growth (PG) which is proportional to optical density (OD) of the tumor (Madadi, 
Penthala et al. 2014). Optical density (OD) measurements of SRB-derived color just 
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before exposing the cells to the test compound and after 48hrs exposure to the test 
compound or the control vehicle are recorded. All the synthesized CA-4 analogues were 
initially screened at a single dose (10-5 M) to determine growth inhibition properties. The 
NCI screening protocol requires 60% growth inhibition at 10-5 M in at least eight cell 
lines from the panel of 60 cell lines for the compounds to be selected for a complete 
dose-response study at five different concentrations, viz. 10-4 M, 10-5 M, 10-6 M, 10-7 M 
and 10-8 M. 
Out of the submitted twenty three triazole derivatives, 12 analogues: ST-124(a), ST-440, 
ST-442, ST-452, ST-467, ST-471, ST-475, ST-482, ST-492, ST-497 and ST-145(b) 
were selected for single dose screening. The growth percentage values obtained from the 
initial single dose screens are represented in Table 4.3 and Table 4.4.  
Table 4.3: Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-124(a), ST-440, ST-442, ST-447, ST-452 and ST-467 at 10µM concentration. 
Table 4.3 (continued) 
Cancer 
Cell 
Type 
ST-
124(a) 
Growth 
% 
ST-440 
Growth 
% 
ST-442 
Growth 
% 
ST-447 
Growth 
% 
ST-452 
Growth 
% 
ST-467 
Growth 
% 
Leukemi
a 
CCRF-
CEM NA 90.7 97.6 79.5 13.3 3.3 
HL-
60(TB) -12.6 108.8 117.2 80.9 67.8 -3.8 
K-562 10.8 108.2 116.8 57.9 46.6 9.3 
MOLT-4 4.0 106.3 123.2 81.4 53.6 6.2 
RPMI-
8226 23.7 92.1 98.3 73.8 55.8 7.1 
SR 5.7 99.9 108.1 79.2 32.4 10.7 
Non-
Small 
Cell 
Lung 
Cancer 
A549/AT
CC 15.2 99.3 102.7 92.5 45.4 21.1 
HOP-62 24.2 99.0 106.9 76.5 43.9 24.0 
HOP-92 NA 84.5 95.4 73.9 79.4 26.5 
NCI-
H226 46.9 94.0 101.7 96.6 71.7 81.5 
NCI-H23 22.1 96.0 98.1 71.4 55.1 29.0 
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Table 4.3 (continued) 
NCI-
H322M 26.0 92.8 98.7 89.2 22.8 40.2 
NCI-
H460 2.4 101.6 102.6 93.1 32.9 4.3 
NCI-
H522 -26.6 97.3 105.0 68.0 60.3 -13.8 
Colon 
Cancer 
COLO 
205 -57.1 105.2 102.9 96.7 64.7 -75.2 
HCC-
2998 -5.3 112.1 111.4 90.8 64.0 20.4 
HCT-116 3.7 102.2 96.0 74.0 26.6 9.5 
HCT-15 14.2 91.7 89.8 62.3 23.0 8.9 
HT29 -10.1 105.4 107.8 102.3 44.0 5.8 
KM12 3.0 103.1 104.1 74.3 59.2 5.1 
SW-620 20.5 100.5 102.2 83.8 48.0 21.8 
CNS 
Cancer 
SF-268 11.2 107.7 105.0 84.7 56.0 17.6 
SF-295 -10.4 95.4 108.9 76.5 34.1 5.9 
SF-539 -38.7 97.0 96.9 91.0 64.2 -20.3 
SNB-19 108.5 102.3 91.4 93.3 69.5 37.3 
SNB-75 18.1 80.7 73.2 58.5 67.6 25.0 
U251 -5.8 96.4 103.8 84.0 46.1 6.0 
Melanom
a 
LOX 
IMVI 20.7 NA NA NA NA 21.5 
MALME
-3M 53.6 NA NA AN NA 78.7 
M14 5.4 102.0 104.6 82.2 52.1 16.7 
MDA-
MB-435 -52.3 102.5 105.5 29.4 68.1 -23.4 
SK-
MEL-2 55.3 110.8 118.0 88.2 90.8 45.0 
SK-
MEL-28 5.8 105.0 113.8 96.2 86.7 43.9 
SK-
MEL-5 58.9 NA 
   
-46.9 
UACC-
257 36.6 100.9 101.2 107.0 94.4 72.6 
UACC-
62 13.5 92.5 96.1 67.1 38.0 32.6 
Ovarian 
Cancer 
IGROV1 -16.2 105.0 104.8 67.4 41.7 22.8 
OVCAR-
3 35.1 106.4 109.3 94.6 28.2 -9.6 
OVCAR-
4 36.0 97.2 96.8 77.9 39.5 34.0 
OVCAR-
5 5.4 103.6 102.4 92.9 88.8 17.5 
OVCAR-
8 9.2 101.5 98.7 97.7 44.6 16.3 
NCI/AD 15.9 NA NA NA NA 4.1 
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Table 4.3 (continued) 
R-RES 
SK-OV-
3 27.8 104.2 108.9 82.4 64.7 18.5 
Renal 
Cancer 
786-0 -12.0 111.0 104.2 73.6 51.3 13.8 
A498 33.2 62.9 39.4 66.5 56.3 -14.1 
ACHN 21.8 100.8 99.6 82.9 35.6 15.7 
CAKI-1 45.3 95.4 92.4 66.1 20.5 21.6 
SN12C 25.4 94.0 98.1 93.1 63.7 30.8 
TK-10 43.2 103.2 102.1 64.9 66.8 58.4 
UO-31 20.7 73.5 76.6 47.0 -1.6 24.7 
Prostate 
Cancer 
PC-3 10.2 90.5 92.4 79.9 64.1 10.8 
DU-145 -26.2 112.1 111.2 96.2 66.2 4.1 
Breast 
Cancer 
MCF7 12.5 85.3 95.6 52.7 40.5 11.9 
MDA-
MB-231 -28.4 101.1 85.1 76.7 54.5 16.5 
HS 578T 22.0 102.8 99.7 71.8 76.8 16.0 
BT-549 21.7 108.9 93.7 56.4 66.6 41.5 
T-47D 54.3 92.6 99.5 64.0 35.6 67.9 
MDA-
MB-468 47.5 96.4 98.4 55.6 61.9 NA 
 
 
 
 
 
Table 4.4: Percentage growth inhibition of NCI 60 human cancer cells by compounds ST-471, 
ST-475, ST-482, ST-492, ST-497 and ST-145(b) at 10µM concentration. 
 
Table 4.4 (continued) 
Cancer 
Cell 
Type 
ST-471 
Growth 
% 
ST-475 
Growth 
% 
ST-482 
Growth 
% 
ST-492 
Growth 
% 
ST-497 
Growth 
% 
ST-
145(b) 
Growth 
% 
Leukemi
a 
CCRF-
CEM 97.8 NA NA 58.7 11.3 NA 
HL-
60(TB) 106.0 NA NA 60.4 -7.2 NA 
K-562 98.2 NA NA 62.0 11.3 NA 
MOLT-4 92.3 NA NA 63.8 7.1 NA 
RPMI-
8226 94.0 NA NA 45.2 14.4 NA 
SR 89.9 NA NA 25.9 4.2 NA 
Non-
Small 
Cell 
Lung 
Cancer 
A549/A
TCC 98.9 NA NA 87.2 15.1 NA 
HOP-62 91.1 NA NA 60.1 12.3 NA 
HOP-92 73.2 NA NA -11.9 44.3 NA 
NCI- 101.2 NA NA 80.9 61.6 NA 
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Table 4.4 (continued) 
H226 
NCI-H23 111.5 NA NA 76.6 14.4 NA 
NCI-
H322M 106.0 NA NA 89.2 41.4 NA 
NCI-
H460 103.9 NA NA 89.4 1.2 NA 
NCI-
H522 104.2 NA NA 30.1 -41.5 NA 
Colon 
Cancer 
COLO 
205 100.7 NA NA 74.9 -66.0 NA 
HCC-
2998 111.7 NA NA 80.3 6.2 NA 
HCT-
116 95.4 NA NA 71.4 8.7 NA 
HCT-15 104.8 NA NA 70.2 6.0 NA 
HT29 102.9 NA NA 74.9 -23.1 NA 
KM12 97.2 NA NA 71.8 6.1 NA 
SW-620 102.7 NA NA 83.5 17.9 NA 
CNS 
Cancer 
SF-268 98.3 NA NA 86.1 22.8 NA 
SF-295 95.2 NA NA 64.5 1.4 NA 
SF-539 100.7 NA NA 66.0 -43.5 NA 
SNB-19 105.8 NA NA 84.7 42.8 NA 
SNB-75 83.0 NA NA 30.9 15.2 NA 
U251 99.2 NA NA 87.8 -10.5 NA 
Melano
ma 
LOX 
IMVI 105.0 NA NA 75.1 13.4 NA 
MALME
-3M 102.0 NA NA 76.0 47.7 NA 
M14 103.8 NA NA 47.4 15.1 NA 
MDA-
MB-435 101.8 NA NA 41.8 -13.7 NA 
SK-
MEL-2 116.0 NA NA 84.0 15.0 NA 
SK-
MEL-28 110.2 NA NA 72.4 16.8 NA 
SK-
MEL-5 94.9 NA NA 63.1 -38.8 NA 
UACC-
257 107.6 NA NA 76.3 38.1 NA 
UACC-
62 104.6 NA NA 47.4 28.1 NA 
Ovarian 
Cancer 
IGROV1 105.6 NA NA 91.8 17.7 NA 
OVCAR
-3 104.9 NA NA 83.9 -27.0 NA 
OVCAR
-4 98.0 NA NA 71.6 34.4 NA 
OVCAR 110.3 NA NA 76.2 10.5 NA 
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Table 4.4 (continued) 
-5 
OVCAR
-8 105.8 NA NA 85.6 8.1 NA 
NCI/AD
R-RES 110.7 NA NA 78.8 0.8 NA 
SK-OV-
3 96.4 NA NA 80.8 12.4 NA 
Renal 
Cancer 
786-0 100.4 NA NA 58.3 25.0 NA 
A498 84.3 NA NA 79.3 -17.6 NA 
ACHN 106.0 NA NA 85.2 6.6 NA 
CAKI-1 87.1 NA NA 42.1 16.0 NA 
SN12C 101.5 NA NA 98.0 39.1 NA 
TK-10 100.0 NA NA 36.5 60.1 NA 
UO-31 93.7 NA NA 35.9 21.4 NA 
Prostate 
Cancer 
PC-3 87.3 NA NA 39.0 14.5 NA 
DU-145 108.6 NA NA 99.9 4.9 NA 
Breast 
Cancer 
MCF7 106.8 NA NA 55.9 10.4 NA 
MDA-
MB-231 104.2 NA NA 81.7 22.4 NA 
HS 578T 98.1 NA NA 65.7 14.8 NA 
BT-549 81.2 NA NA NA 17.3 NA 
T-47D 90.5 NA NA 70.7 64.4 NA 
MDA-
MB-468 NA NA NA NA NA NA 
NA: Not Available 
 
 
Out of the 12 compounds selected for single dose screening, six compounds were 
selected for full five dose-response studies; below (Table 4.5) are the five dose study 
results for these six compounds.  
 
 
Table 4.5: Growth Inhibition (GI50/µM) and Total Growth Inhibition (TGI/µM) data for 
compounds ST-497, ST-124(a) and ST-467 against NCI human cancer cells. 
Table 4.5 (continued) 
Panel/cell line 
ST-497 ST-124(a) ST-467 
GI50 
(nM) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
Leukemia 
CCRF-CEM 37.3 >100 31.9 21.8 <10 46.3 
HL-60(TB) 30.0 5.74 22.7 NA <10 NA 
K-562 25.7 >100 <10 >100 <10 >100 
MOLT-4 68.2 >100 48.2 20.0 12.0 16.1 
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Table 4.5 (continued) 
RPMI-8226 36.5 87.6 36.8 21.1 <10 24.6 
SR 21.1 >100 <10 16.9 <10 >100 
Non-Small Cell  
Lung  Cancer  
A549/ATCC 
54.1 >100 37.4 >100 <10 73.4 
HOP-62 46.7 >100 25.0 >100 <10 72.4 
HOP-92 98.9 11.3 <10 2.67 <10 0.08 
NCI-H23 64.9 >100 37.7 27.9 <10 68.7 
NCI-H460 38.1 >100 34.2 >100 <10 10.9 
Colon Cancer  
COLO 205 228 1.16 149 0.64 29.2 0.12 
HCC-2998 230 >100 45.9 11.4 24.9 22.4 
HCT-116 40.2 NA <10 1.47 <10 >100 
HCT-15 37.3 >100 <10 5.13 <10 >100 
HT29 214 14.5 47.6 20.5 <10 10.8 
KM12 35.3 >100 29.8 23.8 <10 0.05 
SW-620 40.6 >100 29.5 >100 <10 >100 
CNS Cancer 
SF-268 503 >100 177 >100 <10 90.0 
SF-295 14.4 >100 10.8 0.15 <10 27.5 
SF-539 20.0 0.05 13.8 0.04 <10 <0.01 
SNB-19 52.5 >100 36.9 >100 <10 >100 
SNB-75 15.7 NA 14.2 >100 <10 NA 
U251 37.1 46.9 37.9 >100 <10 16.5 
Melanoma 
LOX IMVI 65.2 >100 75.5 >100 <10 >100 
M14 21.5 NA <10 >100 <10 23.0 
MDA-MB-435 <10 NA <10 0.01 <10 <0.01 
SK-MEL-2 26.9 4.24 55.5 >100 <10 30.5 
SK-MEL-28 >1000 6.33 NA NA NA 60.7 
SK-MEL-5 12.6 0.35 26.7 0.32 <10 0.02 
UACC-62 157 4.61 <10 >100 >1000 >100 
Ovarian Cancer  
IGROV1 64.8 >100 50.9 >100 <10 21.5 
OVCAR-3 10.8 0.04 24.4 >100 <10 <0.01 
OVCAR-4 77.4 >100 NA >100 <10 >100 
NCI/ADR-RES 23.1 66.1 <10 0.08 <10 17.5 
SK-OV-3 75.0 97.7 45.8 >100 <10 40.3 
Renal Cancer 
786-0 42.8 >100 15.3 >100 <10 19.4 
A498 33.2 6.69 <10 NA <10 <0.01 
ACHN 81.3 >100 145 >100 <10 62.5 
CAKI-1 42.6 >100 50.2 >100 <10 >100 
UO-31 92.3 >100 20.0 >100 <10 25.1 
Prostate Cancer  
PC-3 45.8 >100 41.5 >100 <10 35.2 
DU-145 26.6 NA 44.8 >100 <10 NA 
Breast Cancer 
 MCF7 26.9 >100 24.5 >100 <10 >100 
MDA-MB-
231/ATCC 94.7 >100 46.0 >100 <10 >100 
HS 578T NA >100 40.9 >100 <10 >100 
MDA-MB-468 34.6 26.0 23.3 0.08 <10 22.4 
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Table 4.6: Growth Inhibition (GI50/µM) and Total Growth Inhibition (TGI/µM) data for 
compounds ST-282, ST-482, ST-452 against NCI human cancer cells. 
 
Table 4.6 (continued) 
Panel/cell line 
ST-282 ST-482 ST-452 
GI50 
(nM) 
TGI 
(µM) 
GI50 
(nM) 
TGI 
(µM) 
GI50 
(µM) 
TGI 
(µM) 
Leukemia 
CCRF-CEM 33.7 >100 282 >100 
3.38 >100 
HL-60(TB) 18.9 0.08 201 NA 5.75 >100 
K-562 <10 >100 49.6 >100 5.50 >100 
MOLT-4 39.9 11.6 572 51.8 4.23 >100 
RPMI-8226 32.5 11.0 326 22.1 10.7 >100 
SR <10 24.0 43.6 11.6 5.43 >100 
Non-Small Cell  
Lung  Cancer  
A549/ATCC 
22.9 22.6 289 50.9 
4.85 >100 
HOP-62 18.2 19.3 336 >100 5.32 >100 
HOP-92 <10 0.54 122 1.59 3.28 >100 
NCI-H23 48.0 41.7 767 >100 9.13 >100 
NCI-H460 24.6 20.0 335 28.7 3.67 >100 
Colon Cancer  
COLO 205 26.7 0.07 311 1.30 
2.89 >100 
HCC-2998 39.4 17.5 >1000 24.6 9.16 >100 
HCT-116 <10 0.81 181 15.6 2.89 >100 
HCT-15 <10 >100 125 >100 2.93 >100 
HT29 25.3 12.3 392 12.5 4.56 >100 
KM12 <10 11.2 70.0 11.9 6.87 >100 
SW-620 <10 >100 105 >100 4.40 >100 
CNS Cancer 
SF-268 68.5 >100 >1000 >100 
7.36 >100 
SF-295 <10 42.8 98.9 3.61 3.01 >100 
SF-539 <10 NA 181 0.54 NA >100 
SNB-19 29.4 >100 501 >100 7.75 >100 
SNB-75 <10 21.9 82.4 NA 1.58 >100 
U251 20.1 22.7 302 11.2 5.35 >100 
Melanoma 
LOX IMVI 17.5 37.8 545 87.1 
4.83 >100 
M14 <10 NA NA 12.0 14.3 >100 
MDA-MB-435 <10 NA 94.8 NA 2.20 >100 
SK-MEL-2 <10 18.1 23.6 55.7 6.52 >100 
SK-MEL-28 >100 34.8 244 43.5 5.39 >100 
SK-MEL-5 <10 0.16 >1000 11.9 7.89 >100 
UACC-62 >100 21.2 >1000 30.8 3.35 >100 
Ovarian Cancer  
IGROV1 33.2 30.3 >1000 >100 
5.94 >100 
OVCAR-3 <10 <0.01 432 0.37 3.38 >100 
OVCAR-4 33.6 57.2 76.3 >100 3.04 >100 
NCI/ADR-RES <10 69.7 84.9 24.0 3.92 >100 
SK-OV-3 <10 12.7 486 93.2 2.72 >100 
Renal Cancer 
786-0 <10 13.5 618 63.5 
2.75 >100 
A498 10.4 1.50 343 9.32 3.18 >100 
ACHN <10 >100 705 >100 1.75 >100 
CAKI-1 <10 >100 316 >100 8.42 >100 
UO-31 <10 24.6 661 72.7 6.84 >100 
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Table 4.6 (continued) 
Prostate Cancer  
PC-3 18.4 39.4 255 43.7 
4.50 >100 
DU-145 25.0 >100 346 >100 1.41 >100 
Breast Cancer 
 MCF7 <10 37.9 76.8 >100 
2.58 >100 
MDA-MB-
231/ATCC 44.4 >100 529 31.5 
5.89 >100 
HS 578T 668 64.2 442 >100 11.6 >100 
MDA-MB-468 14.7 30.5 226 25.8 3.20 >100 
 
 
 
 
4.5.2 Anticancer evaluation of ST-145(b) versus 9LSF rat gliosarcoma cells via 
colony formation assay 
 
9LSF cells were acquired from the laboratory of Dennis Deen, Ph.D. (Brain Tumor 
Research Center, University of California, San Francisco).  Cells were exposed to ST-
145(b) at concentrations of 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 1 µM, or 10 µM for 24 
hours prior to seeding of the colony formation assay.  Cells were then trypsinized, 
counted, seeded into 25 cm2 flasks, and incubated at 37°C to form colonies (Borrelli, 
Stafford et al. 1998). All conditions were seeded in triplicate. Flasks that were plated with 
less than 50,000 cells were previously plated with 50,000 lethally irradiated A549 cells to 
serve as feeders (Borrelli, Thompson et al. 1989). Flasks were removed from incubation 
when colonies were large enough to count (>50 cells).  Colonies were then fixed and 
stained with crystal violet, rinsed, allowed to dry, and counted. LD50 was determined as 
7.5 nM using SigmaPlot Figure 4.4. The colony formation assay was conducted by 
Kevin Howk at Dr. Borelli’s lab. 
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Figure 4.4: Dose response study of ST-145(b) against 9LSF cells. 
 
4.6 Conclusion 
In summary, we have developed a new facile procedure for the synthesis of 4,5-diaryl-
2H-1,2,3-triazoles bearing a broad range of aryl moieties from their corresponding (Z)-
2,3-diarylacrylonitriles. The method does not require an inert atmosphere, is economical, 
can be applied to a wide range of aryl groups and aromatic ring substitutions, and is a 
viable alternative to the Huisgen cycloaddition reaction of alkynes with azides.  
The 2H-triazole CA-4 analogues do not undergo cis-trans isomerization and are stable in 
aqueous solution. They also have a better water-solubility profile compared to the parent 
CA-4 precursor molecules. With the exception of ST-452, all the compounds in this 
sublibrary had LC50 values >100μM against most of the human cancer cell lines in the 
NCI panel, implying that these compounds are anti-proliferative agents.  It is noteworthy 
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that ST-467 had impressive GI50 values of less than 10nM against almost all the cancer 
cell lines in the panel, except for melanoma cancer cell line UACC-62, and colon cancer 
cell lines COLO 205 and HCC-2998. ST-467 also exhibited potent TGI values of <10nM 
against CNS cancer cell line SF-539, melanoma cell MDA-MB-435, ovarian cancer cell 
line OVCAR-3 and renal cancer cell line A498. Analogues ST-124(a) and ST-282 
exhibited GI50 values of <10nM against leukemia cancer cell lines K-562 and SR, non-
small lung cancer cell line HOP-92, colon cancer cell lines HCT-116 and HCT-15, 
melanoma cancer lines M14 and UACC-62, ovarian cancer cell line NCI/ADR-RES and 
renal cancer cell line A498. Melanoma cancer cell line MDA-MB-435 and ovarian cancer 
cell line OVCAR-3 appeared to be the most sensitive to the growth inhibitory effects of 
124(a) and ST-467, exhibiting TGI values of <10 nM. Also, analogue ST-145(b) was 
very effective in the colony formation assay against 9LSF rat gliosarcoma cells, 
exhibiting an LD50 value of 7.5 nM. 
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Figure 4.5: Lead 4,5-diaryl-2H-1,2,3-triazoles as potent CA-4 analogs. 
 
Thus, analogues ST-467, ST-124(a), ST-282 and ST-145(b) can be considered as lead 
anticancer agents from the 2H-triazole series of compounds and further investigation is 
warranted to determine their potential as clinically effective therapeutic agents.  
Copyright © Nikhil Reddy Madadi 201 
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Chapter 5 
Resveratrol derivatives as selective, high affinity cannabinoid receptor ligands and 
correlation with their anti-cancer properties 
5.1 Introduction 
The psychotropic and therapeutic actions of cannabis extracts have been known for 
centuries. By 1940, the concerns about the danger of abuse has led to the banning of 
medical marijuana world-wide (Pisanti, Malfitano et al. 2009). However, increasing 
evidence of biologically beneficial aspects of cannabinoids associated with cancer, 
inflammation, obesity and brain damage is awakening renewed interest in cannabinoid 
receptor studies (Munson, Harris et al. 1975, Cridge and Rosengren 2013).  
CB1 and CB2 receptors are the two major cannabinoid-specific receptors which have 
been characterized from mammalian tissues. CB1 receptors (CB1R) are abundantly 
expressed in the CNS (Pertwee 2006).  These receptors are also expressed in peripheral 
nerve terminals and in many extra-neuronal sites. CB1R activation is responsible for 
most of the pharmacological effects of cannabinoids in the nervous system. In contrast, 
CB2 receptors (CB2R) are known to be expressed in other tissues, predominantly in cells 
of the immune system (Sarfaraz, Adhami et al. 2008). Interestingly, many types of cancer 
cells express relatively high densities of CB1 and CB2 receptors, and most recent studies 
report that cannabinoids can reduce tumor growth and progression in several animal 
models of cancer (Sanchez, de Ceballos et al. 2001, Sarfaraz, Adhami et al. 2008, Wasik, 
Christensson et al. 2011). 
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Cannabinoids can be classified into three structurally distinct groups: endocannabinoids, 
phytocannabinoids, and synthetic cannabinoids (Franks, Ford et al. 2014). 
Endocannabinoids are endogenous compounds synthesized in the body (example: 
Anandamide (Figure 5.1)). Phytocannabinoids are plant-derived compounds that are 
often structurally similar to Δ9-THC (Figure 5.1). Lastly, synthetic cannabinoids are 
compounds specifically designed with high affinity for CB1 and CB2 receptors to alter 
receptor and/or endocannabinoid function. 
To develop cannabinoids with improved therapeutic properties, we synthesized of a novel 
class of cannabinoid receptor inhibitors, the indolequinuclidines (Figure 5.1) that bind 
with high nanomolar affinity to both types of cannabinoid receptors, and we have 
characterized the intrinsic activity of such compounds (Madadi, Penthala et al. 2013, 
Franks, Ford et al. 2014). 
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Figure 5.1 Structures of Anandamide, Tetrahydrocannabinol, N-benzyl 
indolequinuclidinones, Carboxamido-5-aryl-isoxazole. 
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Qamri and co-workers have demonstrated that synthetic cannabinoid receptor agonists 
JWH-133 and WIN-55 (Figure 5.2) inhibit cell proliferation against breast cancer cell 
lines (MDA-MB231, MDA-MB468). Interestingly, these results were reversed when 
breast cancer cells were treated with CB1R and CB2R antagonists AM 251 and SR 44528 
(Figure 5.2), indicating the likely involvement of CB1 and CB2 receptors in tumor 
growth and metastasis (Qamri, Preet et al. 2009).   
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Figure 5.2 Structures of synthetic cannabinoids JWH-133, WIN 55, SR 144528 and 
AM252. 
 
Recently, much attention has focused on potential chemotherapeutic uses for the naturally 
occurring plant stilbenoid, resveratrol, and resveratrol analogs such as the prenylated 
stilbenoids have been reported to have improved affinity for cannabinoid receptors 
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(Brents, Medina-Bolivar et al. 2012). In this regard, identifying selective and high affinity 
ligands for both CB1 and CB2 receptors is a worthwhile goal, since most cannabinoid 
drugs have been associated with potential addictive properties and other unwanted side 
effects due to their lack of selectivity. 
HO
HO
OH
HO
HO
OH
OHtrans-arachidin-1 trans-arachidin-3  
Figure 5.3 Structures of prenylated stilbenoids trans-arachidin-1 and trans-arachidin-3. 
 Based on the above mentioned literature review, we hypothesized that the anticancer 
activity of the synthesized resveratrol analogs may partly be mediated through their 
interaction with cannabinoid receptors. Thus, we wanted to find a correlation between 
cannabinoid receptor affinity and anticancer activity for our resveratrol derivatives. We 
initiated a study to identify selective CB1 and CB2 receptor ligands from the library of 
novel stilbene scaffolds structurally related to the resveratrol molecule.  From our SAR 
studies we have discovered that incorporating a 3,4-methylenedioxy group into the 
phenyl moieties and introducing a cyano substituent onto the stilbene double bond not 
only improved affinity of these novel stilbenes for CB1 and CB2 cannabinoid receptors, 
but also afforded selectivity at CB1 and CB2 receptors. 
5.2 Standard Operating Procedure for cannabinoid affinity screening 
Membrane homogenates of either whole mouse brain (50 µg) (CB1R) or Chinese hamster 
ovary (CHO)-hCB2 cells (25 µg) (CB2R) were incubated for 90 min at room temperature 
with 0.2 nM [3H]CP-55, 940, 5 mM MgCl2, and either increasing sample concentrations 
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(10 fM–10 µM), 1 µM WIN 55212-2 (to define non-specific binding) or vehicle (to 
determine total binding). Each ligand concentration was examined in duplicate, in a final 
volume of 1 mL of buffer containing 50 mM Tris, 0.05% bovine serum albumin (BSA) 
and 0.1% ethanol/0.1% dimethyl sulfoxide as vehicle. Reactions were terminated by 
rapid vacuum filtration through Whatman GF/B glass fiber filters, followed by five 
washes with ice-cold buffer (50 mM Tris, 0.05% BSA). Filters were immediately placed 
into 7 mL scintillation vials to which 4 mL of scintillation fluid was added. Bound 
radioactivity was determined after overnight incubation at room temperature by liquid 
scintillation spectrophotometry. Specific binding was expressed as total minus 
nonspecific binding and graphed for each data point as a percentage of specific binding 
occurring in the absence of any competitor. The affinity of IQDs for CB1Rs and CB2Rs 
was derived by employing the Cheng–Prusoff (Cheng and Prusoff 1973) equation to 
convert the observed IC50 values to Ki values from 3 to 4 separate competition receptor 
binding curves for each ligand. 
5.3 CB1 and CB2 receptor competitive binding data from screening assay with 
resveratrol analogs 
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Figure 5.4: Structures of TMR, ST-124, ST-179, ST-165 and ST-160. 
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By comparing the CB1 and CB2 receptor competitive binding data for TMR and ST-124 
(Figure 6.1), it was found that incorporating a cyano group into the double bond of the 
stilbene moiety markedly improved the receptor affinity for both CB1 and CB2 receptors 
compared to the parent compound. Subsequently, a variety of cyanostilbenes were 
screened, and it was discovered that 3,4-methylenedioxy cyanostilbenes ST-179, ST-165 
and ST-160 (Figure 6.1) not only exhibited improved receptor affinity but also afforded 
compounds that were selective  ligands at both CB1 and CB2 receptors.  
Figure 5.5: CB1 and CB2 competitive binding screen at 1µM concentration with TMR, 
ST-124, ST-179, ST-165 and ST-160. 
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Initially, all twenty four 3,4-methylenedioxy cyanostilbenes synthesized were screened at 
1µM in CB1 and CB2 competitive receptor binding studies, and several compounds 
showed promising affinities towards both CB1 and CB2 receptors (full screening results 
are given in the Appendix; Figure 8.1-Figure 8.6). However, only compounds with high 
affinity and/or selectivity were selected for subsequent evaluation utilizing complete 
binding curves to derive Ki values. Three compounds (ST-179, ST-165 and ST-160)  
were identified as selective for CB1 and CB2 receptors with relatively high affinities 
(Table 5.1 and Figure 5.3). 
Table 5.1:  Ki values for compounds ST-179, ST-165, and ST-160 for CB1 and CB2 
receptors.  
Ki values (nM) 
               Comp. CB1 CB2 CB1/CB2 
               ST-179 13290 284 47 
ST-165 717 327 2 
ST-160 400 780 0.5 
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Figure. 5.6: Affinity (Ki) of compounds ST-179(A), ST-165(B) and ST-160(C) for 
mouse brain CB1Rs (mCB1) and human CB2Rs (hCB2). 
 
5.4 Discussion and Conclusion 
Twenty four novel 3,4-methylenedioxy substituted stilbene analogs were synthesized 
(Chapter 2). Several showed promising affinities in cannabinoid receptor binding assays, 
and some were selective for both CB1 and CB2 cannabinoid receptors. Two compounds 
were identified as selective receptor ligands. Compound  ST-179 had 47-fold selectivity 
for CB2 receptors (Ki = 284 nM) compared to CB1 receptors, while compound ST-160 
was 2-fold selective for CB1 receptors (Ki = 400 nM) compared to the CB2 receptors. 
Current studies are ongoing to determine the intrinsic activity of these high affinity 
cannabinoid ligands.  
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Compounds ST-179 and ST-165 were screened at a single dose (10-5 M) at NCI to 
determine their growth inhibition properties against various cancer cell lines. To our 
dissapointment compound ST-160 was not selected for single dose screening in the NCI 
panel of human cancer cell lines. Based on the single dose screening results, Compound 
ST-179 was selected for full five dose response study against the NCI 60 cell panel of 
human tumor cell lines. The anticancer study results are presented in Chapter 3. 
Unfortunately, no direct correlation could be derived between the anticancer activity and 
the cannabinoid affinity results for ST-179, ST-165 and ST-160. Thus, further studies 
need to be conducted on these resveratrol analogs to establish if any correlation between 
cannabinoid affinities and anticancer activities exists.  
In conclusion, we have identified 3,4-methylenedioxy cyanostilbenes as a novel class of 
selective cannabinoid ligands that have the potential for development as novel 
cannabinoid therapeutics for treatment of obesity and/or drug dependency. The 
cannabinoid receptor activities of the molecules does not appear to correlate with their 
anticancer activities against human cancer cell lines. 
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Chapter 6 
 
Summary 
Herein, two medicinal chemistry projects related to the natural products resveratrol and 
combretastatin-A4, which possess anticancer properties, are presented. Resveratrol 
(3,5,4-trihydroxystilbene) is a well-known phytoalexin found in grapes, peanuts, red wine 
and other foods. It has been reported as a potential chemotherapeutic agent due to its 
striking inhibitory effects on cellular events associated with cancer initiation, promotion, 
and progression. However, resveratrol has some limitations which preclude its use in 
cancer treatment. It cannot be used as an antitumor drug due to its low bioavailability 
caused by rapid metabolism.  
We have synthesized 184 compounds related to resveratrol with chemical alterations 
designed to make the molecule more potent and drug-like (presented in Chapter 2). 
Thus, the majority of the aromatic hydroxyl groups were defunctionalized by O-
methylation and novel functional groups where added to the stilbene scaffold to improve 
anticancer potency. The resulting resveratrol analogs were divided into four groups based 
on the nature and position of the functional group introduced into the stilbene skeleton, 
i.e. simple stilbenes, C2-substituted stilbenes, cyanostilbenes and tetrazole stilbenes. All 
184 resveratrol analogues were submitted to the NCI anticancer screening program and 
evaluated against a panel of 60 human tumor cells. Eighty five of these analogues were 
selected for single dose screening at 10µM concentration. NCI selects compounds based 
on drug-likeliness of the structures analyzed by the algorithm software COMPARE, and 
does not accept compounds which have been previously submitted. From the 85 
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compounds selected for single dose screening, 25 resveratrol analogs showed promising 
anticancer activity and were selected for full five-dose studies. We have identified a 
tetrazole resveratrol analog ST-145(a) [(Z)-5-(2-(1H-tetrazol-5-yl)-2-
(3,4,5trimethoxyphenyl)vinyl)-2-methoxyphenol] as a lead anticancer agent from the 
resveratrol analog series. ST-145(a) had impressive GI50 values of less than 10nM 
against almost all 60 cell lines in the  NCI panel of human cancer cells, except for colon 
cancer cell lines HT29 and COLO 205. ST-145 also showed potent TGI (Total Growth 
Inhibition) values of <10nM against Non-small cell lung cancer cell line NCI-H522, CNS 
cancer cell line SF-539, Melanoma cell line MDA-MB-435 and renal cancer cell line 
A498. The full anticancer activitiesof the synthesized resveratrol analogs are presented in 
Chapter 3. 
In a separate study we aimed to test the hypothesis that the limited bioavailability of 
resveratrol, can be improved by synthesizing analogs which would be glucuronidated at a 
lower rate than resveratrol itself. From our library of resveratrol analogs we have selected 
three compounds (ST-05, ST-12(a) and DNR-1) hypothesizing that the functional 
moieties that were introduced into the molecule would slow the rate of glucuronidation 
and could constitute useful scaffolds for the subsequent design of resveratrol analogs with 
improved bioavailability. In the current study we demonstrated that ST-05 [(E)-2,4-
dimethoxy-6-(4-methoxystyryl)benzaldehyde oxime) and ST-12(a) [(E)-3-(3-hydroxy-4-
methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)acrylic acid] were substrates for recombinant 
UGT enzymes and human hepatic and intestinal microsomes. In conclusion, the 
glucuronidation of the novel stilbenoids studied in this study revealed that these 
compounds exhibit lower glucuronidation profiles when compared to resveratrol, and 
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likely represent useful scaffolds for the design of efficacious resveratrol analogs with 
improved bioavailability. The glucuronidation study results are discussed in Data set 1 
(Appendices). 
 
Recently, resveratrol analogs such as prenylated stilbenoids have been reported to have 
improved affinity for cannabinoid receptors. In this regard, identifying selective and high 
affinity ligands for both CB1 and CB2 cannabinoid receptors is a worthwhile goal, since 
most cannabinoid drugs have been associated with potential addictive properties and 
other unwanted side effects due to their lack of selectivity. We initiated a new discovery 
program at UAMS to identify selective CB1 and CB2 receptor ligands from the library of 
novel stilbene scaffolds structurally related to the resveratrol molecule. Several of these 
compounds showed promising affinities in cannabinoid receptor binding assays, and 
some were selective for both CB1 and CB2 cannabinoid receptors. From the screened 
resveratrol analogs, two compounds were identified as selective CB2 and CB1 ligands, 
compound ST-179 exhibited 47-fold selectivity for CB2 (Ki = 284 nM) compared to CB1 
receptors. Compound ST-160 was 2-fold selective for CB1 receptors (Ki = 400 nM) 
compared to the CB2 receptors. These structural analogs may have potential for the 
development as novel cannabinoid therapeutics for treatment of obesity and/or drug 
dependency. The cannabinoid receptor affinity studies with the stilbenes are presented in 
Chapter 5) 
Combretastatin A4 (CA-4) is a cis-stilbene originating from the South African willow 
tree Combretum caffrum. It is one of the most potent antiangiogenic and antimitotic 
agents of natural origin. Its O-phosphate prodrug (CA-4P) is currently in phase 3 clinical 
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trial for the treatment of anaplastic thyroid cancer, and successfully retards tumor growth 
in wide spectrum of solid tumor models. However, recent studies have reported the 
chemical instability of CA-4 in solution due to cis- trans isomerization to the more 
thermodynamically stable, but less potent trans-CA-4 isomer. To circumvent this 
problem, introduced an aromatic triazole ring in place of the double bond of the cis-
stilbene moiety of CA-4 to constrain molecule to the cis-configuration and to make 
moecule more stable more water-soluble. We have developed a facile procedure for the 
general synthesis of 4,5-diaryl-2H-1,2,3-triazoles as CA-4 analogs that incorporate a 
broad range of aryl moieties from their corresponding (Z)-2,3-diarylacrylonitriles. This 
method does not require an inert atmosphere, is economical, can be applied to a wide 
range of aryl groups and aromatic ring substitutions, and is a viable alternative to the 
Huisgen cycloaddition reaction of alkynes with azides. The methodology, development 
and design of these 4,5 disubstitutes-2H-1,2,3-triazoles is discussed in Chapter 4. 
A total of twenty three 4,5-diaryl-2H-1,2,3-triazoles as CA-4 analogs were synthesized 
and submitted to the NCI panel of 60 human tumor cells for anticancer screening. Of 
these, twelve analogs were selected for single dose screening at 10µM concentration. 
From the 12 compounds selected for single dose screening, six of these CA-4 analogs 
showed promising anticancer activity and were selected for full five dose-studies. From 
these CA-4 analogs, ST-467 (4-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-2H-
1,2,3-triazole) had impressive GI50 values of less than 10nM against almost all the cell 
lines in the panel, except for melanoma cancer cell line UACC-62, and colon cancer cell 
lines COLO 205 and HCC-2998. Compound ST-467 also showed potent TGI values of 
<10nM against CNS cancer cell line SF-539, melanoma cell line MDA-MB-435, ovarian 
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cancer cell line OVCAR-3, and renal cancer cell line A498. Also, compound ST-145(b) 
(2-methoxy-5-(5-(3,4,5-trimethoxyphenyl)-2H-1,2,3-triazol-4-yl)phenol), another triazole 
CA-4 analogue, was very effective in the colony formation assay against 9LSF rat 
gliosarcoma cells, exhibiting an LD50 of 7.5 nM. Both ST-467 and ST-145(b) can be 
considered as lead anticancer agents from the triazole CA-4 series and further 
investigation into their in vivo effects in various solid tumor xenograph models in nude 
mice may provide additional data on their potential as therapeutic agents for treatment of 
a variety of solid tumors. The anticancer activity results of the triazole CA4 analogs are 
presented in Chapter 4. 
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Appendices 
Data set 1 
Novel Resveratrol-Based Substrates for Human Hepatic, Renal, and Intestinal UDP-
Glucuronosyltransferases 
7.1 Introduction 
Resveratrol is a well-known, natural polyphenol known to be a potent antioxidant, 
coronary protective, hepatic protective, neuroprotective, cardiovascular protective, anti-
inflammatory and anti-carcinogenic agent (Pace-Asciak, Rounova et al. 1996, Jang, Kang 
et al. 1999, Aggarwal, Bhardwaj et al. 2004, Kim, Zhu et al. 2006). Although initial 
preclinical data was encouraging, resveratrol could not be used as a drug because of its 
low bioavailability. Resveratrol was found to have a short half-life of 8-10 min after oral 
administration and was extensively metabolized to both O-sulfate and O-glucuronide 
conjugates (Marier, Vachon et al. 2002).  
The human hepatic and intestinal UDP-glucuronosyltransferases (UGTs) actively 
transform resveratrol to its O-glucuronide conjugate (Sabolovic, Humbert et al. 2006). To 
circumvent this unfavorable metabolism of resveratrol, the search for resveratrol analogs 
with chemical stability, enhanced bioavailability and more promising metabolic stability, 
is of great importance.  
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Recently, Dr. Radominska’s group at UAMS have discovered that prenylated resveratrol 
analogues, trans-arachidin-1 and trans-arachidin-3 (Figure 7.1) had O-glucuronidation 
rates that were slower in comparison to resveratrol (Brents, Medina-Bolivar et al. 2012). 
From our library of resveratrol analogs, three compounds were selected (ST-05, ST-12(a) 
and DNR-1, Figure 5.1) that were hypothesized to have a slow rate of O-glucuronidation 
and might represent a useful scaffold for the design of potent resveratrol analogs with 
improved bioavailability and which could be developed as chemotherapeutic agents with 
clinical potential. The glucoronate studies were carried out by members of Dr. 
Radominska’s research group. 
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Figure 7.1: Structures of resveratrol analogs trans-arachidin-1, trans-arachidin-3, ST-
05, DNR-1 and ST-12(a). 
 
The three compounds selected for the study had the majority phenolic groups blocked by 
O-methylation or incorporated a hydroxylamine, carboxylic acid or aromatic nitro group 
on the stilbene scaffold.  
The study was designed to elucidate: 
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1) If the above three chemically synthesized stilbene derivatives are substrates for human 
recombinant UGTs. 
2) If the rate of glucuronidation of the three analogues was comparable to resveratrol 
itself. 
Twelve major recombinant human UGT1A and UGT2B enzymes were utilized to 
determine their capability to metabolize these three reseveratrol analogs. 
HPLC−UV−VIS analysis was used to identify the formation of glucuronide conjugates. 
LC−MS/MS and β-glucuronidase hydrolysis was used to elucidate the structures of the 
metabolites. 
7.2 Source of Human Microsomes and Recombinant UGTs. 
Human hepatic microsomes were acquired from ten contributors, and human intestinal 
microsomes were acquired from thirteen contributors. Recombinant proteins UGT1A1, 
1A3, 1A4, and 1A6−1A10 were cloned and expressed in baculovirus-infected insect cells 
(Kurkela, Garcia-Horsman et al. 2003, Kuuranne, Kurkela et al. 2003). Human UGT2B4, 
2B7, 2B15, and 2B17 were purchased from BD Biosciences (Woburn, MA) and the 
manufacturer’s protocols were used to carry out the assays.  
7.3 Screening of Human Microsomes and Recombinant UGTs 
Screening trials for glucuronidation were conducted with human hepatic and intestinal 
microsomes from 10 and 13 donors, respectively, one pooled liver sample, and 
commercially available hepatosomes. A 250 µL aliquot of substrate was dissolved in 
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ethanol solution and added to the incubation tube. The resveratrol analogs were sonicated 
to ensure solubilization. Reaction buffer and human microsomes (50 mg of total protein) 
or recombinant UGT membranes (5 mg of total protein) were then added. UDP-GlcUA in 
molar excess was added, and the samples containing the analogs were incubated at 37 °C 
for one hour. Final reaction concentrations were as follows: 100 μM Tris−HCl (pH 7.4)/5 
mM MgCl2/5 mM saccharolactone/2% DMSO/250 μM substrate/2 micromolar 
UDPGA/50 or 5 μg of total protein, respectively. The total reaction volume was 30 µL. 
Controls were run under the same reaction conditions in the absence of substrate 
molecules. The glucuronidation rate with these enzymes has been shown to be linear for a 
maximum of 3 hours. The reactions were finally stopped by addition of 30 µL of ethanol. 
Later, centrifugation of the samples was carried out at 14 000 rpm for 8 min to collect the 
protein. The supernatants were investigated by HPLC using an HP1050 HPLC system 
equipped with a UV−VIS diode array detector. Instrument function and data acquisition 
were assessed using Agilent ChemStation software. 
7.4 Enzyme Kinetics Assays.  
Kinetic parameters were calculated by incubating recombinant UGT protein with 
different concentrations of ST-12a (10−1000 μM) or ST-05 (1−1000 μM) with a molar 
excess of UDP-GlcUA for 1 hour. All kinetic assays were conducted in duplicate under 
conditions identical to those employed for screening assays. 
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7.5 Data Analysis.  
Kinetic data analysis for the glucuronidation of ST-12(a) and ST-05 by UGTs were 
estimated by plotting the measured initial reaction velocity values as a function of 
substrate concentration. Graph-Pad Prism v4.0b (GraphPad Software, Inc., San Diego, 
CA) was utilized for conducting curve-fitting and statistical analyses. Kinetic constants 
were obtained by fitting the experimental data to the following kinetic models using the 
nonlinear regression (Curve Fit) function. 
1. Michaelis−Menten (M−M) equation used for the one-enzyme model. 
𝑣𝑣 =
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚  ×  [𝑆𝑆]
𝐾𝐾𝑚𝑚 +  [𝑆𝑆]
 
 
2. Hill equation reflects the extent of cooperativity among multiple binding sites 
(Weiss 1997). 
𝑣𝑣 =
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚  ×  [𝑆𝑆]𝑛𝑛
𝑆𝑆50𝑛𝑛 +  [𝑆𝑆]𝑛𝑛
 
 
3. Uncompetitive substrate inhibition (USI) model, where Ki is the inhibition 
constant describing the rate reduction. 
 
𝑣𝑣 =
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
1 + 𝐾𝐾𝑚𝑚[𝑆𝑆] +
[𝑆𝑆]
𝐾𝐾𝑖𝑖
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7.6 Glucuronide Product Analysis 
A HP1050 LC system equipped with a variable wavelength UV-DAD detector was used 
for HPLC-UV analyses of supernatants. Agilent ChemStation software was used for 
instrument control and data collection. A reversed-phase 5 µm Suplex pKb-100 analytical 
column (0.46 cm x 25 cm, C18) was used for HPLC separations. The temperature was 
maintained at 25 ˚C. A flow rate of 1 ml/min with a linear gradient from 15-80% 
methanol in ammonium formate buffer (0.05 M, pH 3.4) for 25 min, followed by a linear 
gradient from 80-100% methanol in ammonium formate for 3 min was utilized. The 
elution of each metabolite of ST-12(a) was monitored at 335 nm, whereas the elution of 
the metabolite of ST-05 was monitored at 325 nm. 
7.7 Analysis of Glucuronide Product Structures by ESI-HPLC-MS 
An Acquity uHPLC system interfaced to a Quattro Premier triple quadrupole mass 
analyzer (Waters Corporation, Beverly, MA) with an electrospray probe operating in the 
positive ion mode was used for HPLC-MS analysis of the glucuronide and structural 
identification of glucuronide products. Liquid chromatography settings were identical to 
those used for LC-UV analysis, and 10 µL of sample was injected onto the column. The 
nitrogen flow rate was 600 L/h and was maintained at 500°C. The source temperature 
was 150°C. 
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Figure 7.2. Metabolism of ST-12(a) and ST-05 with human liver microsomes. 
Representative HPLC analyses are shown from 60 min incubations of 50 μg of human 
liver proteins with 0.25 mM substrate and 3 mM UDP-GlcUA. DNR-1 was not 
metabolized under the similar conditions. 
 
 
7.8 Glucuronide Metabolite Analysis by HPLC−UV−VIS and HPLC−MS/MS 
UGT1A and UGT2B enzymes were used for preliminary studies on the glucuronidation 
of ST-05, DNR-1, and ST-12(a). Glucuronidation products for ST-05 and ST-12(a) were 
detected, identified and quantitated, but no glucuronidation product of DNR-1 was 
formed. Two metabolites at tR = 17.6 and tR = 17.8 min for ST-12(a) and one metabolic 
product at tR 23.2 min for ST-05 were identified (Figure 7.3). 
LC− (+)-ESI−MS analysis (Figure 5.4), indicated that the two glucuronides of ST-12(a) 
(tR = 16.0 and 16.3 min) had an [M + NH4] + peak m/z 554, and suspected to be COO- 
and O-conjugated glucuronides. The enzyme β-glucuronidase selectively hydrolyzes only 
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O-glucuronides, and this enzyme was used to identify which of the two possible 
glucuronide metabolites were present. It was determined that the peak at tR = 16.0 min in 
the HPLC chromatogram was an acyl glucuronide. 
In Figure 7.4, ammonium adducts of ST-05 glucuronides were not observed; however, 
the proton adduct [M + H]+) was observed with a retention time of 23.2 min and an m/z 
490. We suspected the glucuronide product to be a C=N-O-glucuronide. The different LC 
systems with unique system dead volumes can be attributed to the different retention 
times on LC-MS and LC-UV runs. 
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Figure 7.3. Extracted ion chromatogram (m/z 361) and (+)-ESI mass spectra of ST-12(a) 
and its glucuronide conjugate NH4+ adducts. Spectra of ST-12(a) glucuronides (two 
isomers of tR = 16.0 and 16.3 min) showed an [M + NH4] + peak (m/z 554) plus a 
fragment ion resulting from neutral loss of the glucuronide moiety (m/z 361). 
 
 
 
 
Figure 7.4. Structures and Mass spectra of ST-05 and its glucuronide conjugates. 
Spectrum of ST-05 glucuronide (tR = 21.4 min) showed an [M+ H]+ peak (m/z 490) plus 
a major peak corresponding to the ST-05 substrate (m/z 314). 
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7.9 Screening of Recombinant UGTs for glucuronidation of ST-12a and ST-05. 
Eight human recombinant UGT1 enzymes and UGT2B4, 2B7, 2B15, and 2B17 were 
acquired from BD Biosciences and were evaluated for their ability to glucuronidate ST-
12a and ST-05. β-Glucuronidase hydrolysis was used to differentiate between COO- and 
O-glucuronides in ST-12(a) (Figure 7.5). 
For ST-12(a), treatment with human recombinant UGT1A3 led to both COO- and O-
glucuronide formation. When UGT1A1 was utilized only the carboxyl metabolite was 
produced, whereas UGTs 1A7−1A10 formed only the O-glucuronide. None of the 
UGT2B enzymes, UGT1A4 and 1A6 were active toward this compound. 
For compound ST-05, treatment with human recombinant UGT1A1, 1A9, and 1A10 
resulted in the formation of the C=N−O-glucuronide. All of the other UGTs remained 
inactive. 
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Figure 7.5. Glucuronidation of NI-12a and ST-05 by human recombinant UGTs. 
UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, 2B17 (5 μg of 
protein) were evaluated for their ability to glucuronidate DNR-1, ST-12(a), and ST-05. 
No activity was observed toward DNR-1, and UGT2B7, 2B4, 2B15, and 2B17 were not 
active toward any compound. Activities are expressed in nanomoles per milligram of 
protein per minute. 
 
7.10 Glucuronidation of ST-12(a) and ST-05 by Human Hepatic and Intestinal 
Microsomes. 
 
Screening assays for glucuronidation activity were conducted with HLM (Human Liver 
Microsomes) and HIM (Human Intestine Microsomes) from 10 and 13 contributors, one 
pooled liver sample, and commercial hepatosomes (Figure 7.6).  Both ST-12(a) and ST-
05 were shown to be glucuronidated with all the hepatic samples utilized, producing two 
metabolites of ST-12(a) and one metabolic product from ST-05. 
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Intestinal samples HI27, HI28, HI29 and HI54 failed to display glucuronidation activity 
toward ST-12(a). Contributors HI34, HI36, HI40 and HI41 produced only the O-
glucuronide. The remaining contributors with activity produced both COO- and O-
glucuronide metabolites. In the case of ST-05, donors HI27, HI29, and HI30 did not 
display any glucuronidation activity, but all other donors produced the C=N−O-
glucuronide. 
 
 
 
 
Figure 7.6.  Glucuronidation activities of Human Liver Microsomes and Human 
Intestinal Microsomes toward NI-12a and NI-ST-05.  Human liver microsomes from 10 
different donors, a pooled liver sample, and hepatosomes and human intestine 
microsomes from 13 different donors were analyzed. Each substrate concentration was 
0.25 mM for HIM, with a molar excess of UDP-GlcUA; the reactions were incubated for 
60 minutes. Activities are expressed in nmol/mg protein/min. 
 
7.11 Kinetic Analysis of NI-12a and NI-ST-05 with selected recombinant UGTs  
Based on the activity screening data human recombinant UGT isoforms (UGT 1A7 to 
1A10 for ST-12(a) and UGT1A1, 1A9, and 1A10 for ST-05) were subjected to kinetic 
analysis and the results presented in Table 1 and Figure 7.8,7.9 In the case of ST-12(a), 
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human recombinant isoform UGT1A9 was the most active with Vmax = 8.3 nm /mg 
protein/min. UGT1A7 showed the greatest affinity for ST-12(a) with Km = 62 μM, and 
UGT1A10 had the lowest affinity with Km = 500 μM. Because of the high Vmax, the 
catalytic efficiency of UGT1A9 toward ST-12(a), measured by the ratio Vmax/Km (35 
μL/min/mg), was also the highest. Data generated for UGT1A7 and 1A8 fits an 
uncompetitive substrate inhibition kinetic model, which suggests the existence of 
multiple binding sites on these UGT isoforms.   
For ST-05, because of the very small amount of product formation (C=N-O-
glucuronidation) and the low sensitivity of our HPLC-UV/VIS detection capabilities, our 
ability to perform kinetic analyses was limited. Assuming michaelis–menten  kinetics 
UGT1A1 activities at concentrations above 5 µM were used to estimate a Vmax value of 
0.2 nmol/mg/min. Cooperative binding was indicated for UGT1A10 which fit to the Hill 
equation. Also, data generated with isoform UGT1A9 did not fit any of the kinetic 
models tested. 
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Table 7.1.  Glucuronidation Kinetics for NI-12(a) and NI-ST-05 
Metabolites. Glucuronidation activities of selected recombinant UGTs were measured by 
incubating membrane fractions with increasing concentrations of substrate (see Figures 
7.7 and 7.8) at a constant concentration of UDP-GlcUA (3 mM). Reactions were 
centrifuged, supernatants separated by HPLC, and curve fits and kinetic constants 
determined using GraphPad Prism 4 software. *Values estimated based on an incomplete 
data set. 
 
 UGT1A1 UGT1A7 UGT1A8 UGT1A9 UGT1A10 
ST-12(a)      
ST-12a-O-Gluc Not Produced     
Km (μM)   62 ± 43 240 ± 76 240 ± 40 500 ± 75 
Vmax 
(nmol/mg/min)   2.2 ± 0.77 6.0 ± 1.3 8.3 ± 0.52 3.5 ± 0.24 
Ks (μM)  242 ± 133 950 ± 449   
CLint  or CLmax 
(µL/mg/min)   35 25 35 7 
Kinetic Model   USI USI M-M M-M 
R2   0.82 0.98 0.97 0.98 
ST-12a-COO-Gluc Too low to be assessed 
Not 
Produced 
Not 
Produced Not Produced 
Not 
Produced 
ST-05       
ST-05-N-O-Gluc  Not Produced 
Not 
Produced   
Km  or S50 (µM)  <5*   <5* 6.2 ± 0.35 
Vmax 
(nmol/mg/min)  0.21 ± 0.02*   Undetermined 
0.65 ± 
0.017 
n     3.4 
CLint  or CLmax 
(µL/mg/min)      105 
Kinetic Model  M-M*   Undetermined Hill 
R2  0.61*    0.87 
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Figure 7.7. Steady state kinetic curves for the glucuronidation of NI-12a by selected 
human recombinant UGTs. Glucuronidation activities for wildtype UGT1A7, 1A8, 1A9, 
and 1A10 were measured by incubating membrane fractions containing recombinant 
UGTs with increasing concentrations (shown in figure) of the substrates at a constant 
concentration of UDP-GlcUA (3 mM) for 60 min at 37 °C. Curve fits and kinetic 
constants were determined using GraphPad Prism 4 software. The graphical fits of the 
data (mean ± SD) are shown. 
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Figure 7.8. Steady state kinetic curves for the glucuronidation of ST-05 by selected 
human recombinant UGTs. Glucuronidation activities for wildtype UGT1A1, 1A9, and 
1A10 were measured by incubating membrane fractions containing recombinant UGTs 
with increasing concentrations (shown in figure) of the substrates at a constant 
concentration of UDP-GlcUA (3 mM) for 60 min at 37 °C. Curve fits and kinetic 
constants were determined using GraphPad Prism 4 software. The graphical fits of the 
data (mean ± SD) are shown. 
 
5.12 Conclusion 
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Figure 7.9. Glucuronidation rates of resveratrol, ST-05 and ST-12(a). 
 
The current study was designed to test the hypothesis that the limited bioavailability of 
resveratrol can be improved by synthesizing analogs that will be glucuronidated at a 
lower rate than resveratrol itself. The analogs selected for the study: ST-05, DNR-1, and 
ST-12(a), had aromatic hydroxylamine, hydroxyl, nitro and carboxylic acid moieties 
incorporated into their structures and were assumed to be less susceptible to 
glucuronidation, thereby improving their bioavailability. In the current study we 
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demonstrated that ST-05 and ST-12(a) were substrates for recombinant UGT enzymes 
and human hepatic and intestinal microsomes. Because of the presence of sterically 
hindering aromatic nitro groups in the molecule, O-glucuronidation of DNR-1 was not 
observed. Glucuronidation experiments with ST-12(a) resulted in different products and 
atypical reaction kinetics specific for each enzyme (Table 1), which indicates a complex 
mechanism of metabolism for this analog. The results from the kinetic parameters 
discussed earlier indicate that ST-12(a) will have improved bioavailability compared to 
that of resveratrol. Glucuronidation experiments with ST-05 resulted in the formation of 
a rare C=N−O -glucuronide, and the rate of this reaction was significantly lower than that 
for O-glucuronidation of resveratrol. 
In conclusion, the glucuronidation of the novel stilbenoids utilized in this study revealed 
that these compounds exhibit lower glucuronidation profiles as compared to resveratrol. 
Compound ST-12(a) and related stilbenes have been reported to be effective antitubulin 
agents (Borrel, Thoret et al. 2005), and based of these data, the synthesized stilbenoids 
likely represent a useful scaffold for the design of efficacious resveratrol analogs with 
improved bioavailability over resveratrol. 
This data set has been reproduced with permission from the following publication: 
copyright ACS publications: Greer, A. K., N. R. Madadi, S. M. Bratton, S. D. Eddy, Z. 
Mazerska, H. Hendrickson, P. A. Crooks and A. Radominska-Pandya (2014). "Novel 
Resveratrol-Based Substrates for Human Hepatic, Renal and Intestinal UDP-
Glucuronosyltransferases." Chem. Res. Toxicol., 2014, 27 (4), pp 536–545. 
Copyright © Nikhil Reddy Madadi 2014 
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Data Set 2 
 NCI single dose percentage growth results for the simple stilbene analogues. 
Table 8.1. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-191, ST-192, ST-193, ST-194, ST-197, ST-198 and ST-209 at 10µM concentration. 
 
Table 8.1 (continued) 
Cancer cell type ST-191 ST-192 ST-193 ST-194 ST-197 ST-198 ST-209 
Leukemia 
CCRF-CEM 96.6 86.2 NA 82.9 NA NA NA 
HL-60(TB) 119.6 89.2 101.1 47.0 91.7 -18.8 88.1 
K-562 129.1 150.9 146.2 21.8 105.5 17.6 NA 
MOLT-4 108.6 92.0 82.8 50.4 114.1 16.1 118.8 
RPMI-8226 95.3 75.2 NA 44.6 92.9 49.8 95.6 
SR 103.6 100.4 108.4 40.8 91.1 9.6 94.9 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 122.8 88.4 98.0 67.6 108.7 32.5 116.6 
HOP-62 99.9 97.8 99.9 80.6 88.6 46.6 92.3 
HOP-92 120.6 114.2 NA NA NA NA NA 
NCI-H226 95.2 92.8 94.6 74.3 89.9 34.5 123.9 
NCI-H23 96.5 89.2 101.9 74.0 86.8 40.0 97.5 
NCI-
H322M 83.1 95.6 94.1 87.0 85.7 52.7 97.2 
NCI-H460 104.4 103.7 97.9 93.7 102.2 14.1 99.8 
NCI-H522 95.6 98.0 102.9 59.8 98.6 32.5 103.3 
Colon 
Cancer 
COLO 205 104.6 85.9 99.7 71.5 89.6 0.6 98.7 
HCC-2998 99.6 97.4 106.0 90.7 111.6 9.8 105.5 
HCT-116 97.0 97.3 101.3 68.7 95.4 9.9 103.0 
HCT-15 102.7 99.5 96.4 63.1 85.4 20.2 102.3 
HT29 98.7 92.7 109.2 60.0 98.1 12.6 104.8 
KM12 99.9 91.2 98.5 64.0 100.2 16.1 103.7 
SW-620 100.6 104.9 91.9 64.7 99.3 28.2 100.9 
CNS 
Cancer 
SF-268 103.3 94.7 101.9 81.3 96.9 39.0 107.8 
SF-295 97.3 104.2 106.3 78.9 93.7 6.6 101.1 
SF-539 102.0 97.9 94.2 83.2 100.5 -2.9 108.8 
SNB-19 98.4 85.4 94.5 70.0 74.0 54.3 104.9 
SNB-75 56.0 100.7 NA 57.8 103.6 NA NA 
U251 108.6 97.1 98.2 76.7 98.3 29.0 121.9 
Melanoma 
LOX IMVI 106.1 124.4 115.0 77.6 95.4 35.1 109.3 
MALME-
3M 100.8 93.3 102.7 59.3 96.2 61.9 99.8 
M14 102.2 88.5 96.5 64.4 91.9 20.4 94.3 
MDA-MB-
435 103.4 115.6 105.0 2.4 103.7 -26.4 90.6 
SK-MEL-2 123.2 94.7 115.0 69.6 90.4 62.5 112.8 
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Table 8.1 (continued) 
SK-MEL-28 104.8 98.3 101.9 74.5 87.8 55.7 94.7 
SK-MEL-5 96.9 92.9 96.9 57.0 114.9 27.0 101.3 
UACC-257 NA NA NA 49.3 72.6 NA 78.1 
UACC-62 95.7 74.2 115.8 51.6 93.6 28.3 104.3 
Ovarian 
Cancer 
IGROV1 91.1 96.0 91.1 85.0 101.1 43.5 104.1 
OVCAR-3 104.5 103.9 91.5 NA NA -13.4 NA 
OVCAR-4 85.8 93.7 98.5 75.5 80.0 45.9 90.1 
OVCAR-5 97.9 103.2 90.2 87.1 91.4 50.9 97.5 
OVCAR-8 104.2 103.0 94.7 85.3 NA 28.0 NA 
NCI/ADR-
RES 107.1 95.0 107.7 63.3 86.9 12.7 109.0 
SK-OV-3 104.0 95.7 108.5 84.3 98.5 26.8 97.1 
Renal 
Cancer 
786-0 102.8 105.0 97.5 88.1 101.6 51.2 106.4 
A498 90.6 80.5 102.1 56.4 83.3 -4.3 80.7 
ACHN 110.9 105.6 72.8 84.0 101.1 46.0 106.2 
CAKI-1 94.7 94.3 99.0 62.6 92.4 43.8 100.7 
RXF 393 104.1 112.2 92.7 89.5 95.0 -7.0 116.6 
SN12C 99.0 91.4 103.0 78.9 85.5 23.9 100.8 
TK-10 132.4 90.9 89.9 74.1 115.6 76.2 104.1 
UO-31 89.7 79.8 147.5 51.2 71.8 42.6 92.2 
Prostate 
Cancer 
PC-3 98.6 83.4 67.0 59.6 93.4 49.2 103.1 
DU-145 105.2 100.3 110.7 90.7 94.8 12.1 109.6 
Breast 
Cancer 
MCF7 88.8 89.3 80.9 42.2 96.9 1.8 90.2 
MDA-MB-
231 99.4 102.6 87.4 66.9 94.1 18.2 129.3 
HS 578T 119.2 94.3 109.0 76.4 98.6 12.0 131.0 
BT-549 92.5 91.2 81.4 69.0 85.8 38.9 100.3 
T-47D 86.2 87.2 84.0 64.1 101.3 56.3 94.6 
MDA-MB-
468 100.6 90.4 101.5 NA NA 16.7 NA 
 
 
Table 8.2. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-212, ST-220, ST-226, ST-227, ST-233, ST-234 and ST-236 at 10µM concentration. 
  
Table 8.2 (continued) 
Cancer cell type ST-212 ST-220 ST-226 ST-227 ST-233 ST-234 ST-236 
Leukemia 
CCRF-CEM 93.6 88.5 98.9 106.5 89.5 98.8 85.4 
HL-60(TB) 73.1 78.2 NA NA 79.2 96.6 86.2 
K-562 92.2 101.0 98.9 114.2 89.3 99.4 30.6 
MOLT-4 82.6 79.8 89.5 91.7 74.0 84.1 79.5 
RPMI-8226 86.2 74.4 109.7 102.1 103.0 100.7 99.1 
SR 84.9 95.9 91.8 108.0 69.5 77.4 44.8 
Non-Small A549/ATCC 83.7 87.7 96.4 100.3 97.0 102.0 85.2 
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Table 8.2 (continued) 
Cell Lung 
Cancer 
HOP-62 83.5 100.8 118.1 92.1 84.4 90.4 85.0 
HOP-92 NA NA 90.6 94.6 86.1 NA 79.7 
NCI-H226 104.5 97.7 103.7 110.0 85.8 101.5 100.3 
NCI-H23 98.6 94.4 95.4 104.4 95.3 90.5 92.0 
NCI-
H322M 95.1 100.4 104.5 98.7 103.1 108.9 112.6 
NCI-H460 97.4 99.9 106.2 125.3 103.7 105.4 104.1 
NCI-H522 74.3 77.4 76.5 106.7 67.0 72.8 29.1 
Colon 
Cancer 
COLO 205 100.3 107.4 98.6 91.9 97.4 100.7 98.6 
HCC-2998 103.4 111.0 103.3 100.2 95.3 96.7 92.4 
HCT-116 98.4 91.9 99.4 111.1 98.7 91.8 79.3 
HCT-15 91.9 90.1 95.0 94.7 92.6 96.0 74.6 
HT29 79.9 88.7 90.7 102.3 88.3 86.2 75.2 
KM12 99.5 91.5 97.5 94.1 93.8 91.4 75.3 
SW-620 93.3 97.2 106.3 116.0 100.5 103.3 80.2 
CNS 
Cancer 
SF-268 106.0 104.3 110.7 116.0 83.2 99.8 90.7 
SF-295 91.1 98.8 111.5 107.1 94.2 101.5 74.6 
SF-539 99.0 99.5 100.0 98.4 97.1 97.6 94.9 
SNB-19 99.8 97.3 107.1 96.5 98.3 109.9 92.9 
SNB-75 94.1 89.0 88.3 111.0 80.2 84.2 87.8 
U251 95.2 95.6 109.6 95.6 90.5 103.0 79.8 
Melanoma 
LOX IMVI 100.9 103.3 98.0 98.7 88.6 90.3 84.4 
MALME-
3M 100.9 109.6 114.0 101.4 97.1 99.8 56.0 
M14 99.0 97.2 108.4 120.1 92.3 93.6 73.1 
MDA-MB-
435 92.5 96.1 102.9 103.6 95.9 103.0 3.6 
SK-MEL-2 97.8 98.8 101.4 105.5 85.8 83.0 81.7 
SK-MEL-28 97.6 100.3 100.6 99.8 95.5 98.8 79.1 
SK-MEL-5 96.9 99.1 104.0 111.4 90.9 96.4 85.8 
UACC-257 72.0 71.7 117.9 105.5 101.0 105.1 88.5 
UACC-62 94.9 104.5 78.2 94.6 63.9 67.1 58.5 
Ovarian 
Cancer 
IGROV1 104.4 104.6 109.0 102.5 98.2 101.8 94.0 
OVCAR-3 NA NA NA NA NA NA NA 
OVCAR-4 83.7 88.7 94.6 115.5 100.6 102.3 102.2 
OVCAR-5 82.5 95.1 100.0 99.9 93.1 95.2 95.2 
OVCAR-8 101.2 101.8 113.3 115.5 93.0 101.9 101.6 
NCI/ADR-
RES 99.7 109.5 106.8 109.5 89.4 101.2 63.7 
SK-OV-3 99.9 99.4 101.3 103.8 96.5 93.1 95.7 
Renal 
Cancer 
786-0 97.0 104.0 100.4 98.4 90.9 104.1 90.9 
A498 83.2 80.7 106.0 104.8 74.1 92.6 66.7 
ACHN 92.1 97.0 105.4 106.0 94.9 102.1 94.8 
CAKI-1 92.1 91.7 99.5 98.6 94.5 106.5 71.7 
RXF 393 108.5 110.1 118.9 111.5 100.4 104.4 87.3 
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Table 8.2 (continued) 
SN12C 95.4 98.7 102.0 110.6 81.8 98.3 87.8 
TK-10 78.6 110.4 95.0 95.9 88.3 100.5 78.1 
UO-31 82.9 86.6 93.5 94.7 71.6 107.1 87.9 
Prostate 
Cancer 
PC-3 93.2 93.2 87.5 103.6 87.3 90.8 90.2 
DU-145 93.2 97.6 101.4 102.2 90.6 101.3 98.6 
Breast 
Cancer 
MCF7 87.0 87.0 60.6 100.4 98.0 105.4 58.0 
MDA-MB-
231 108.8 94.4 120.3 118.9 89.9 95.4 88.5 
HS 578T 103.8 104.7 118.2 117.6 100.3 106.6 92.4 
BT-549 94.6 98.9 104.0 98.2 82.1 82.3 106.6 
T-47D 82.3 84.6 73.8 103.1 86.5 64.4 81.2 
MDA-MB-
468 NA NA 98.7 109.8 96.5 100.4 92.6 
 
 
Table 8.3. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-239, ST-247, ST-294, ST-297, ST-309, ST-315 and ST-320 at 10µM concentration. 
 
Table 8.3 (continued) 
Cancer cell type ST-239 ST-247 ST-294 ST-297 ST-309 ST-315 ST-320 
Leukemia 
CCRF-CEM 95.1 91.5 97.6 99.6 97.0 99.7 71.4 
HL-60(TB) 100.5 98.8 NA NA NA NA NA 
K-562 107.5 94.8 95.6 68.9 73.0 81.0 22.3 
MOLT-4 90.8 79.2 89.6 60.2 74.2 90.7 71.1 
RPMI-8226 92.1 102.0 92.9 71.9 83.8 81.3 84.4 
SR 88.3 73.3 95.9 64.8 77.9 79.6 43.0 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 95.7 94.7 88.2 79.0 79.5 92.0 91.4 
HOP-62 95.0 89.4 86.2 93.3 96.6 97.3 97.6 
HOP-92 101.3 NA 122.6 90.4 73.7 82.8 80.2 
NCI-H226 96.8 89.7 74.6 95.8 98.4 103.3 98.1 
NCI-H23 101.2 90.1 83.3 104.4 91.7 97.5 91.7 
NCI-
H322M 104.1 88.2 95.3 100.9 78.7 91.5 88.9 
NCI-H460 103.6 87.0 98.3 100.4 104.7 104.3 99.3 
NCI-H522 84.2 76.0 81.1 59.9 59.8 76.3 76.1 
Colon 
Cancer 
COLO 205 100.5 96.4 98.2 88.6 91.4 91.5 98.3 
HCC-2998 101.3 84.8 102.7 92.7 89.7 103.7 99.8 
HCT-116 97.0 86.9 91.7 89.3 87.2 93.5 88.2 
HCT-15 101.8 90.7 83.4 76.0 66.1 89.4 62.2 
HT29 101.2 85.5 89.1 68.3 77.6 79.5 73.2 
KM12 101.2 81.7 87.2 100.0 89.2 94.1 79.0 
SW-620 106.1 98.8 95.5 99.7 91.9 105.1 81.4 
CNS SF-268 102.7 101.7 98.7 85.2 81.3 94.8 91.9 
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Table 8.3 (continued) 
Cancer SF-295 NA 102.1 105.8 96.6 90.0 89.3 95.4 
SF-539 99.9 98.0 89.9 94.2 96.6 93.7 86.3 
SNB-19 111.4 105.0 103.2 77.1 74.9 79.6 84.1 
SNB-75 99.4 80.2 84.9 91.8 72.0 81.9 92.3 
U251 97.0 91.9 87.9 88.7 81.4 96.2 87.0 
Melanoma 
LOX IMVI 99.9 93.8 89.1 101.4 97.6 97.9 91.0 
MALME-
3M 93.1 83.0 91.0 83.6 120.3 97.7 75.4 
M14 99.4 88.4 86.6 86.7 92.7 91.0 80.1 
MDA-MB-
435 109.9 100.6 102.1 86.3 92.1 85.9 28.9 
SK-MEL-2 101.0 95.6 99.7 94.1 79.4 90.2 89.2 
SK-MEL-28 107.2 103.1 111.1 95.3 92.5 99.7 93.8 
SK-MEL-5 101.7 93.8 93.9 87.8 87.1 93.0 90.5 
UACC-257 118.0 103.5 116.5 95.4 95.9 102.8 93.4 
UACC-62 101.2 82.4 91.9 80.3 70.5 74.7 75.3 
Ovarian 
Cancer 
IGROV1 97.0 88.8 77.6 96.5 87.1 101.5 86.1 
OVCAR-3 NA NA NA NA NA NA NA 
OVCAR-4 102.5 82.4 78.2 97.1 89.4 83.6 84.9 
OVCAR-5 103.4 96.0 109.1 91.0 91.4 91.4 94.2 
OVCAR-8 105.4 99.8 103.7 95.6 93.5 96.0 96.5 
NCI/ADR-
RES 113.6 106.6 104.7 90.7 73.5 94.5 89.0 
SK-OV-3 102.2 88.4 99.9 101.0 106.8 104.3 90.9 
Renal 
Cancer 
786-0 97.1 100.2 97.0 89.8 82.4 94.1 91.8 
A498 111.5 97.8 86.2 69.3 81.0 67.8 66.8 
ACHN 108.9 96.5 94.2 89.4 79.1 93.9 98.8 
CAKI-1 NA 98.0 85.1 88.9 71.6 100.6 86.3 
RXF 393 114.0 110.2 NA 98.3 88.5 107.2 87.4 
SN12C 105.5 98.1 101.9 80.9 75.8 87.1 91.8 
TK-10 114.1 103.9 131.1 74.8 61.2 65.0 82.6 
UO-31 92.2 81.6 69.5 65.2 59.1 63.5 74.8 
Prostate 
Cancer 
PC-3 100.8 94.2 92.4 64.4 61.5 77.3 80.8 
DU-145 104.1 105.9 99.2 92.7 87.9 94.0 99.2 
Breast 
Cancer 
MCF7 83.6 15.8 66.7 88.2 84.5 89.6 65.3 
MDA-MB-
231 102.0 95.9 77.5 102.8 90.7 93.9 84.6 
HS 578T 111.6 101.8 102.0 112.7 100.5 112.1 118.1 
BT-549 97.1 86.6 89.1 83.3 73.3 82.7 92.9 
T-47D 87.9 58.6 56.3 69.0 62.5 86.2 82.0 
MDA-MB-
468 108.4 7.7 78.6 94.5 85.2 101.7 90.3 
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Table 8.4. Percentage growth inhibition of NCI 60 human cancer cells by compound ST-
321 a 10µM concentration. 
 
Table 8.4 (continued) 
                       Cancer             Cell type ST-321 
Leukemia 
CCRF-CEM 95.2 
HL-60(TB) NA 
K-562 NA 
MOLT-4 83.2 
RPMI-8226 88.8 
SR 107.9 
Non-Small Cell Lung 
Cancer 
A549/ATCC 95.0 
HOP-62 93.2 
HOP-92 84.5 
NCI-H226 87.0 
NCI-H23 95.3 
NCI-H322M 94.1 
NCI-H460 102.8 
NCI-H522 75.2 
Colon Cancer 
COLO 205 91.8 
HCC-2998 NA 
HCT-116 92.3 
HCT-15 91.5 
HT29 85.6 
KM12 96.2 
SW-620 97.5 
CNS Cancer 
SF-268 101.3 
SF-295 102.7 
SF-539 92.6 
SNB-19 92.8 
SNB-75 84.4 
U251 92.0 
Melanoma 
LOX IMVI 93.2 
MALME-3M 83.1 
M14 90.0 
MDA-MB-435 97.9 
SK-MEL-2 93.8 
SK-MEL-28 97.8 
SK-MEL-5 91.2 
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Table 8.4 (continued) 
UACC-257 91.8 
UACC-62 72.7 
Ovarian Cancer 
IGROV1 96.7 
OVCAR-3 NA 
OVCAR-4 96.5 
OVCAR-5 95.5 
OVCAR-8 93.9 
NCI/ADR-RES 106.0 
SK-OV-3 92.3 
Renal Cancer 
786-0 102.0 
A498 102.8 
ACHN 92.2 
CAKI-1 87.8 
RXF 393 94.2 
SN12C 94.0 
TK-10 114.2 
UO-31 82.2 
Prostate Cancer 
PC-3 86.6 
DU-145 104.0 
Breast Cancer 
MCF7 70.1 
MDA-MB-231 88.4 
HS 578T 106.1 
BT-549 105.6 
T-47D 83.0 
MDA-MB-468 101.2 
 
 
NCI single dose percentage growth results for the resveratrol analogues with 
substitutions at the C2 position on the stilbene. 
 
Table 8.5. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
RES-14, RES-17, RES-18, RES-27, RES-16 and RES-54 at 10µM concentration. 
 
Table 8.5 (continued) 
Cancer Cell line RES-14 RES-17 RES-18 RES-27 RES-16 RES-54 
Leukemia 
CCRF-CEM 82.6 -36.0 74.0 91.8 81.2 NA 
HL-60(TB) 100.5 -12.4 79.8 93.0 104.4 94.2 
MOLT-4 84.6 -66.5 77.5 82.5 87.8 95.8 
RPMI-8226 83.3 40.1 75.4 87.4 77.5 NA 
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Table 8.5 (continued) 
SR 88.6 27.9 70.8 71.7 74.3 NA 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 99.0 63.9 94.2 104.7 104.0 100.2 
EKVX 101.8 59.0 79.9 75.5 92.1 105.1 
HOP-62 97.5 85.9 103.1 113.4 121.5 104.4 
NCI-H226 109.6 76.5 93.5 98.5 103.0 104.6 
NCI-H23 93.9 55.1 87.4 93.9 91.0 103.9 
NCI-H322M NA 41.5 108.7 116.1 109.4 108.4 
NCI-H460 105.3 76.1 88.6 99.3 110.8 112.5 
NCI-H522 86.5 25.3 64.3 74.0 78.2 98.5 
Colon 
Cancer 
HCC-2998 100.9 -100.0 98.1 108.0 111.6 103.6 
HCT-116 102.6 12.7 75.6 91.8 107.8 103.0 
HCT-15 96.4 8.4 93.5 97.9 91.7 100.6 
HT29 104.4 27.9 86.5 106.1 107.2 107.3 
KM12 109.3 25.7 94.5 104.3 106.7 101.5 
SW-620 97.1 -23.5 86.8 93.7 108.0 107.7 
CNS 
Cancer 
SF-268 99.0 -29.5 89.5 96.5 103.9 109.2 
SF-295 100.0 53.7 84.8 88.4 87.1 103.4 
SF-539 101.4 95.2 96.5 101.2 102.9 113.3 
SNB-19 89.8 71.6 81.7 103.2 96.0 107.9 
SNB-75 79.0 83.5 72.7 78.6 96.5 91.3 
U251 100.4 86.0 79.4 99.2 104.1 111.1 
Melanoma 
MALME-3M NA 126.2 134.1 120.3 123.7 100.6 
M14 108.5 82.6 99.6 107.1 106.1 123.7 
MDA-MB-435 93.9 84.9 67.6 75.3 99.3 107.9 
SK-MEL-2 121.2 74.1 102.4 105.9 100.3 99.7 
SK-MEL-28 103.0 91.3 96.6 103.0 107.6 112.5 
SK-MEL-5 114.5 85.2 86.2 103.0 94.0 109.2 
UACC-257 104.1 86.9 113.3 114.8 141.5 106.3 
UACC-62 88.3 48.1 86.0 88.4 87.2 104.8 
Ovarian 
Cancer 
IGROV1 NA 84.4 105.7 110.6 123.3 102.7 
OVCAR-3 106.2 93.6 95.1 110.2 113.2 115.1 
OVCAR-4 136.7 93.8 90.4 86.1 110.5 105.0 
OVCAR-5 107.2 91.9 99.2 95.0 115.2 103.3 
OVCAR-8 102.7 74.2 95.8 99.9 122.9 111.8 
NCI/ADR-RES 99.6 67.0 96.2 98.9 98.9 105.5 
SK-OV-3 108.0 19.2 106.4 125.6 118.9 109.0 
Renal 
Cancer 
786-0 99.8 89.6 94.6 103.0 93.1 100.7 
A498 90.8 94.0 68.7 87.8 90.1 103.0 
ACHN 108.3 52.1 97.4 100.1 107.6 106.5 
CAKI-1 NA 81.2 115.2 120.5 125.3 106.3 
RXF 393 109.3 90.0 104.2 99.4 106.1 99.9 
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Table 8.5 (continued) 
SN12C 93.3 15.3 86.8 104.4 99.4 102.4 
TK-10 128.9 70.6 93.1 131.7 92.3 112.2 
UO-31 NA 76.8 79.9 97.4 93.5 95.8 
Prostate 
Cancer 
PC-3 97.3 45.4 76.0 93.8 119.7 100.2 
DU-145 115.7 53.7 113.1 116.1 115.6 109.0 
Breast 
Cancer 
MCF7 74.8 15.4 72.3 78.2 91.8 100.7 
MDA-MB-
231/ATCC 97.6 67.5 86.0 100.8 88.6 112.9 
HS 578T 106.4 78.4 89.8 93.1 106.9 108.3 
BT-549 89.4 96.0 89.4 86.4 96.1 112.3 
T-47D 83.7 35.0 85.8 91.8 95.6 102.8 
MDA-MB-468 107.2 55.6 91.0 111.9 115.2 110.8 
 
 
Table 8.6. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
RES-57, RES-11, RES-75, RES-59, RES-80 and RES-62 at 10µM concentration. 
 
Table 8.6 (continued) 
Cancer Cell line RES-57 RES-11 RES-75 RES-59 RES-80 RES-62 
Leukemia 
CCRF-CEM NA NA NA NA NA NA 
HL-60(TB) 85.8 NA NA NA 95.2 NA 
MOLT-4 101.9 NA NA NA 100.4 NA 
RPMI-8226 NA NA NA NA NA NA 
SR NA NA NA NA NA NA 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 110.4 33.9 87.5 51.9 100.6 89.4 
EKVX 111.5 64.5 95.0 82.9 103.5 76.3 
HOP-62 118.3 31.5 95.7 51.9 104.1 88.5 
NCI-H226 108.8 50.1 104.6 83.4 107.9 91.7 
NCI-H23 106.6 41.2 91.0 52.3 104.9 83.7 
NCI-H322M 102.4 69.5 98.0 88.4 105.7 97.0 
NCI-H460 108.8 17.5 97.1 21.4 110.0 101.6 
NCI-H522 96.6 -18.5 78.0 -11.8 107.6 67.0 
Colon 
Cancer 
HCC-2998 105.4 53.1 98.8 65.4 105.3 89.3 
HCT-116 103.4 31.1 93.0 19.7 106.2 81.1 
HCT-15 106.5 38.4 86.9 45.6 100.4 86.1 
HT29 108.9 6.0 101.2 9.9 112.9 89.7 
KM12 105.7 26.0 86.6 19.7 105.4 65.7 
SW-620 103.7 28.8 91.4 26.0 105.8 84.7 
CNS 
Cancer 
SF-268 109.7 53.7 82.6 44.6 112.6 89.6 
SF-295 102.9 6.6 89.9 23.6 98.8 68.0 
SF-539 113.1 4.5 88.6 36.4 110.7 85.8 
SNB-19 103.9 48.2 89.0 54.4 108.5 87.2 
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Table 8.6 (continued) 
SNB-75 103.7 -13.5 77.5 6.4 101.3 73.7 
U251 105.1 21.2 86.0 29.2 104.0 88.0 
Melanoma 
MALME-3M 98.1 39.0 89.1 39.7 99.6 81.5 
M14 99.0 NA NA NA NA NA 
MDA-MB-435 115.5 26.1 84.6 27.1 110.2 69.3 
SK-MEL-2 99.5 -27.7 79.3 -6.3 99.0 13.1 
SK-MEL-28 107.7 39.2 102.6 25.7 112.2 108.7 
SK-MEL-5 110.4 67.1 102.1 58.0 117.6 83.5 
UACC-257 109.3 14.2 74.3 25.6 106.5 60.5 
UACC-62 95.2 51.1 75.8 71.8 105.8 83.9 
Ovarian 
Cancer 
IGROV1 99.1 39.2 62.8 40.1 99.9 61.3 
OVCAR-3 109.3 55.4 107.3 62.7 111.1 73.0 
OVCAR-4 113.6 -23.0 90.4 -12.4 116.2 93.5 
OVCAR-5 111.1 54.2 90.8 76.7 114.8 97.6 
OVCAR-8 111.4 60.6 102.9 84.6 114.7 96.8 
NCI/ADR-RES 101.3 34.0 86.2 60.6 106.4 94.4 
SK-OV-3 112.4 24.2 86.3 7.6 107.9 76.2 
Renal 
Cancer 
786-0 104.1 17.2 92.9 51.8 100.4 88.7 
A498 104.0 44.0 82.7 42.0 107.5 101.6 
ACHN 103.3 19.1 66.9 43.7 98.1 61.8 
CAKI-1 101.6 58.4 73.1 60.4 105.4 90.2 
RXF 393 97.6 33.5 92.2 57.7 94.1 61.7 
SN12C 101.4 47.6 83.1 62.2 108.2 85.8 
TK-10 112.1 50.6 103.5 71.9 115.0 110.8 
UO-31 90.3 50.7 72.8 62.3 97.8 74.8 
Prostate 
Cancer 
PC-3 102.9 29.5 93.7 54.1 99.2 78.1 
DU-145 110.9 24.8 86.2 66.7 114.0 102.0 
Breast 
Cancer 
MCF7 100.6 34.9 130.0 34.6 97.7 67.1 
MDA-MB-
231/ATCC 104.4 33.4 77.1 43.4 106.8 65.2 
HS 578T 112.6 45.6 86.9 51.9 106.2 74.4 
BT-549 104.2 33.5 77.4 52.2 104.6 95.2 
T-47D 103.8 36.2 82.5 58.4 103.2 73.9 
MDA-MB-468 108.3 -3.6 80.1 6.2 100.2 71.4 
 
 
Table 8.7. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-132(a), ST-127, ST-128 and ST-138 at 10µM concentration. 
 
Table 8.7 (continued) 
Cancer cell type ST-132(a) ST-127 ST-128 ST-138 
Leukemia CCRF-CEM 40.1 NA NA NA 
210 
 
Table 8.7 (continued) 
HL-60(TB) 86.0 24.2 100.6 90.1 
K-562 86.9 15.8 86.8 95.0 
MOLT-4 62.7 44.7 86.0 92.2 
RPMI-8226 89.8 54.2 72.6 74.5 
SR 74.7 15.7 84.1 86.1 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 98.1 NA NA NA 
HOP-62 93.6 59.7 97.7 101.8 
HOP-92 61.1 48.7 76.9 73.3 
NCI-H226 87.1 87.2 78.8 97.8 
NCI-H23 84.9 82.1 79.9 92.2 
NCI-H322M 110.7 92.2 97.6 99.7 
NCI-H460 96.1 75.1 101.4 101.6 
NCI-H522 68.3 NA NA NA 
Colon Cancer 
COLO 205 118.2 72.9 89.0 101.8 
HCC-2998 95.1 76.2 107.3 107.4 
HCT-116 90.0 36.3 76.1 92.8 
HCT-15 90.3 31.7 87.3 86.7 
HT29 94.3 15.0 87.0 102.6 
KM12 88.1 34.0 86.2 88.2 
SW-620 96.5 42.3 100.3 109.8 
CNS Cancer 
SF-268 101.9 66.6 94.4 90.5 
SF-295 94.1 57.1 103.8 94.0 
SF-539 88.1 55.3 98.2 92.6 
SNB-19 89.3 80.1 99.6 91.5 
SNB-75 92.2 49.9 78.7 70.0 
U251 94.1 47.5 96.1 91.0 
Melanoma 
LOX IMVI 98.1 52.7 86.8 87.0 
MALME-3M 85.2 45.6 90.9 80.1 
M14 84.4 42.4 81.5 81.8 
MDA-MB-
435 59.2 -18.1 100.6 89.4 
SK-MEL-2 86.0 30.1 83.6 73.5 
SK-MEL-28 92.6 60.4 101.2 97.4 
SK-MEL-5 97.6 50.3 95.3 90.8 
UACC-257 96.4 NA NA NA 
UACC-62 61.7 66.7 84.5 84.5 
Ovarian 
Cancer 
IGROV1 95.4 51.7 79.6 104.3 
OVCAR-3 108.6 50.7 95.6 98.9 
OVCAR-4 95.4 88.1 95.0 88.4 
OVCAR-5 84.5 82.0 98.4 111.0 
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Table 8.7 (continued) 
OVCAR-8 102.0 74.5 97.8 85.9 
NCI/ADR-
RES 89.0 24.3 83.5 86.2 
SK-OV-3 92.0 65.0 85.7 97.4 
Renal Cancer 
786-0 98.5 68.4 93.5 92.4 
A498 76.3 51.5 112.5 83.1 
ACHN 89.8 59.8 92.3 68.8 
CAKI-1 91.8 52.3 71.2 91.3 
RXF 393 95.7 58.8 101.8 81.6 
SN12C 90.7 80.4 97.2 96.2 
TK-10 116.7 68.6 135.2 104.4 
UO-31 84.6 68.5 76.0 77.3 
Prostate 
Cancer 
PC-3 86.6 57.8 84.5 90.2 
DU-145 102.4 80.6 104.5 95.9 
Breast 
Cancer 
MCF7 94.8 25.0 72.8 103.2 
MDA-MB-
231 82.0 64.0 100.6 93.6 
HS 578T 88.8 74.7 98.8 105.3 
BT-549 100.1 37.7 83.4 73.6 
T-47D 86.5 43.7 56.4 83.7 
MDA-MB-
468 NA 61.3 107.0 85.4 
 
 
Table 8.8. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-139, ST-98, ST-100 and ST-89 at 10µM concentration. 
 
Table 8.8 (continued) 
Cancer cell type ST-139 ST-98 ST-100 ST-89 
Leukemia 
CCRF-CEM NA 85.5 3.0 68.9 
HL-60(TB) 99.9 99.8 5.7 58.1 
K-562 87.5 77.0 13.4 45.5 
MOLT-4 73.2 64.5 1.9 54.5 
RPMI-8226 72.5 81.9 7.7 53.9 
SR 79.7 62.5 2.7 59.2 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC NA 103.9 20.1 78.9 
HOP-62 103.1 117.3 26.9 85.1 
HOP-92 73.0 73.4 58.3 64.7 
NCI-H226 92.3 83.4 65.7 80.3 
NCI-H23 84.3 91.2 31.1 79.5 
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Table 8.8 (continued) 
NCI-H322M 98.4 92.4 42.1 93.5 
NCI-H460 94.2 98.5 11.5 86.4 
NCI-H522 NA 75.5 -28.8 55.9 
Colon 
Cancer 
COLO 205 87.0 121.8 -24.6 101.3 
HCC-2998 96.3 99.0 40.6 72.0 
HCT-116 79.1 90.5 14.3 61.3 
HCT-15 82.1 91.4 24.6 74.1 
HT29 78.3 94.8 5.1 63.3 
KM12 88.9 93.9 25.3 82.4 
SW-620 95.7 96.9 26.9 87.6 
CNS 
Cancer 
SF-268 92.2 90.2 41.9 94.7 
SF-295 101.6 88.9 36.8 83.1 
SF-539 96.8 NA NA NA 
SNB-19 101.8 99.1 49.5 79.6 
SNB-75 74.0 87.6 -1.9 77.5 
U251 84.3 94.3 17.1 67.7 
Melanoma 
LOX IMVI 88.9 67.2 42.6 59.5 
MALME-3M 88.2 101.4 24.9 63.7 
M14 90.6 103.6 16.8 84.9 
MDA-MB-435 93.2 94.1 -19.6 81.0 
SK-MEL-2 83.6 98.9 25.3 86.0 
SK-MEL-28 91.1 107.6 42.4 95.3 
SK-MEL-5 102.6 92.5 6.9 75.7 
UACC-257 NA 105.6 41.7 85.1 
UACC-62 88.3 75.0 31.8 81.3 
Ovarian 
Cancer 
IGROV1 84.5 100.3 53.4 66.7 
OVCAR-3 99.1 97.9 -21.6 76.3 
OVCAR-4 93.7 102.4 58.0 95.5 
OVCAR-5 95.3 104.5 61.8 90.4 
OVCAR-8 92.4 103.8 21.6 75.8 
NCI/ADR-RES 89.1 90.1 11.7 66.9 
SK-OV-3 93.1 101.8 6.3 88.8 
Renal 
Cancer 
786-0 96.6 90.2 48.3 86.4 
A498 92.3 88.6 5.6 66.9 
ACHN 90.0 87.2 54.6 74.1 
CAKI-1 91.2 80.6 43.9 79.7 
RXF 393 107.6 84.2 -29.6 85.6 
SN12C 99.1 95.7 47.3 81.0 
TK-10 112.6 86.4 57.2 94.5 
UO-31 80.3 71.2 35.7 49.3 
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Table 8.8 (continued) 
Prostate 
Cancer 
PC-3 84.5 81.0 35.7 66.3 
DU-145 97.2 99.0 14.7 100.2 
Breast 
Cancer 
MCF7 74.0 84.6 14.7 69.6 
MDA-MB-231 95.0 89.7 36.5 73.4 
HS 578T 99.4 92.8 19.4 86.7 
BT-549 85.6 96.2 57.2 67.1 
T-47D 65.1 79.7 37.4 64.1 
MDA-MB-468 106.8 80.7 16.0 64.3 
 
 
 
NCI single dose percentage growth results for (E/Z)-2,3-diaryl substituted 
acrylonitriles  
Table 8.9. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-101, ST-113, ST-148, ST-147, ST-145, ST-145(a) and ST-161 at 10µM 
concentration. 
 
Table 8.9 (continued) 
Cancer cell type ST-101 ST-113 ST-148 ST-147 ST-145 
ST-
145(a) 
ST-
161 
Leukemia 
CCRF-CEM 107.4 3.3 7.9 25.2 6.4 10.8 73.2 
HL-60(TB) 104.5 -33.3 -44.8 -4.3 -25.1 105.5 57.9 
K-562 89.4 9.9 3.9 8.1 11.9 99.3 24.9 
MOLT-4 105.1 -1.0 -12.4 64.5 2.0 94.9 67.7 
RPMI-8226 107.7 -7.6 6.2 60.4 5.2 8.5 75.2 
SR 93.7 1.4 7.5 11.1 1.3 NA 26.2 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 93.7 10.1 28.0 37.9 15.3 25.9 59.5 
HOP-62 113.2 21.8 27.0 42.1 30.2 19.5 76.7 
HOP-92 103.0 -1.1 17.0 57.0 NA 17.2 94.2 
NCI-H226 99.7 21.5 33.8 73.8 48.4 33.0 94.9 
NCI-H23 113.5 12.1 22.6 84.1 24.9 21.8 83.2 
NCI-
H322M 98.8 10.6 37.6 80.0 21.6 48.4 106.1 
NCI-H460 101.9 4.0 4.9 79.5 6.4 2.7 83.6 
NCI-H522 87.6 -45.4 -21.9 17.3 -22.1 -6.3 76.4 
Colon 
Cancer 
COLO 205 112.1 -57.3 -67.3 27.3 52.7 33.1 59.8 
HCC-2998 102.5 14.2 6.2 66.9 5.1 20.3 72.3 
HCT-116 104.3 4.6 3.6 24.1 5.5 5.3 57.5 
HCT-15 98.0 14.1 7.0 33.0 15.9 15.1 43.9 
HT29 107.9 -12.6 0.7 11.9 24.2 38.8 39.6 
KM12 105.6 8.1 4.2 NA 2.1 -1.7 42.2 
SW-620 105.9 22.7 26.2 33.4 27.8 26.1 42.9 
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Table 8.9 (continued) 
CNS 
Cancer 
SF-268 103.3 32.8 19.7 63.9 31.9 15.2 81.2 
SF-295 95.3 -12.5 14.2 NA -0.2 4.5 76.5 
SF-539 110.9 -5.6 -32.7 28.9 -17.7 -2.0 79.4 
SNB-19 101.3 47.9 56.3 75.8 116.9 70.7 95.9 
SNB-75 102.3 13.0 45.5 41.2 27.2 54.9 94.3 
U251 105.5 5.4 11.5 56.4 -26.9 10.5 77.2 
Melanoma 
LOX IMVI 97.5 7.4 22.6 34.4 31.3 24.9 65.1 
MALME-
3M 96.1 23.3 85.6 66.5 67.0 123.7 69.0 
M14 110.0 21.3 19.9 29.1 18.1 18.6 50.8 
MDA-MB-
435 105.8 -44.1 -13.0 -35.9 -43.3 -8.4 -5.7 
SK-MEL-2 110.4 -2.3 20.8 31.4 NA 26.2 63.5 
SK-MEL-28 113.9 52.2 74.3 66.4 56.9 74.4 88.5 
SK-MEL-5 101.3 -5.9 -49.8 28.1 0.6 -54.1 75.9 
UACC-257 105.4 58.8 80.9 70.7 62.1 72.8 80.2 
UACC-62 99.0 27.7 36.6 47.8 44.9 44.2 69.4 
Ovarian 
Cancer 
IGROV1 111.0 -45.2 34.5 59.9 12.5 37.5 66.1 
OVCAR-3 111.1 -12.9 -21.7 29.3 0.8 -8.5 71.7 
OVCAR-4 119.4 40.4 61.2 84.2 47.5 68.4 89.7 
OVCAR-5 104.4 37.8 34.3 91.2 51.9 55.9 97.9 
OVCAR-8 103.8 -3.4 24.7 68.2 8.6 21.2 83.8 
NCI/ADR-
RES 107.3 9.8 12.8 29.5 11.1 11.9 41.0 
SK-OV-3 104.6 11.8 22.6 46.9 19.4 16.3 85.5 
Renal 
Cancer 
786-0 100.0 14.9 24.6 46.0 24.2 21.9 90.0 
A498 88.3 -17.0 -7.1 57.5 -6.5 -3.5 73.7 
ACHN 129.3 28.4 21.5 53.9 23.7 24.9 96.2 
CAKI-1 92.4 7.1 28.6 NA 17.0 33.0 66.8 
RXF 393 92.8 13.3 41.2 69.3 62.7 43.7 94.7 
SN12C 96.7 21.4 22.0 56.9 27.2 31.6 90.7 
TK-10 NA NA 53.8 65.0 47.4 73.4 91.0 
UO-31 100.3 19.0 32.1 41.1 21.1 32.8 86.7 
Prostate 
Cancer 
PC-3 108.8 5.6 25.5 58.0 16.3 33.5 70.2 
DU-145 103.6 -14.0 -9.3 94.7 -8.4 3.4 92.5 
Breast 
Cancer 
MCF7 95.4 10.8 14.7 25.5 8.8 10.7 23.9 
MDA-MB-
231 111.4 2.0 7.3 80.3 6.5 27.0 66.8 
HS 578T 94.0 26.7 32.2 69.3 41.0 34.4 89.7 
BT-549 96.2 52.4 24.9 45.2 21.3 39.8 49.6 
T-47D 99.5 7.5 73.7 32.1 58.2 53.8 67.7 
MDA-MB-
468 NA NA 8.9 37.2 29.6 6.1 54.9 
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Table 8.10. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-162, ST-163, ST-164, ST-165, ST-168, ST-169 and ST-170 at 10µM concentration. 
 
Table 8.10 (continued) 
Cancer cell type ST-162 ST-163 ST-164 ST-165 ST-168 ST-169 ST-170 
Leukemia 
CCRF-CEM 96.5 21.6 83.4 89.4 75.4 86.7 91.9 
HL-60(TB) 88.6 0.1 64.5 72.0 62.9 75.0 83.1 
K-562 80.4 15.8 98.7 94.8 96.2 77.5 94.8 
MOLT-4 87.2 19.5 67.2 85.2 66.6 61.2 72.2 
RPMI-8226 88.5 18.9 89.4 96.9 76.6 84.4 80.1 
SR 83.5 11.8 82.0 83.0 79.0 77.0 77.7 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 93.6 32.3 84.6 96.6 79.9 79.9 70.0 
HOP-62 92.2 43.8 92.3 97.6 103.6 90.6 88.0 
HOP-92 NA 40.4 NA 110.2 112.6 NA NA 
NCI-H226 100.9 71.8 99.8 114.5 114.9 111.0 98.9 
NCI-H23 94.5 43.2 96.6 97.1 91.5 93.7 88.0 
NCI-
H322M 103.8 35.7 89.5 96.8 91.4 102.2 74.1 
NCI-H460 107.1 15.5 101.8 105.7 99.4 101.5 84.7 
NCI-H522 85.8 -2.4 87.9 94.5 76.3 65.4 82.7 
Colon 
Cancer 
COLO 205 103.6 11.9 97.7 106.0 105.6 99.6 93.2 
HCC-2998 91.3 49.4 102.3 106.1 90.7 89.9 92.1 
HCT-116 99.4 17.4 96.3 104.6 82.1 89.7 70.1 
HCT-15 85.7 17.8 102.4 99.8 92.6 92.6 88.7 
HT29 88.8 6.0 92.4 106.1 91.1 93.7 101.6 
KM12 93.8 30.0 94.6 96.2 92.4 95.2 91.7 
SW-620 98.9 19.6 102.1 107.2 100.9 99.9 89.8 
CNS 
Cancer 
SF-268 94.4 38.5 95.5 99.5 93.5 101.5 80.9 
SF-295 96.1 11.2 99.2 105.0 96.4 95.6 77.0 
SF-539 92.4 -13.8 103.8 102.6 94.4 97.9 86.9 
SNB-19 93.8 46.0 100.7 105.1 108.8 106.3 105.3 
SNB-75 114.5 2.2 68.9 87.5 77.3 51.5 20.3 
U251 96.6 16.5 93.7 102.3 99.9 89.0 86.3 
Melanoma 
LOX IMVI 108.9 33.3 103.2 100.9 97.1 98.9 62.7 
MALME-
3M 98.9 24.3 95.7 103.0 84.0 56.1 NA 
M14 95.0 10.5 99.5 106.1 92.8 89.7 96.5 
MDA-MB-
435 74.7 -29.1 100.2 96.1 98.7 63.5 93.7 
SK-MEL-2 90.2 -17.7 94.4 102.1 88.7 90.6 89.7 
SK-MEL-28 97.6 40.7 105.9 115.8 98.9 104.2 105.1 
SK-MEL-5 92.2 16.4 97.3 102.6 95.4 93.5 98.4 
UACC-257 97.5 23.0 97.0 118.3 100.0 99.8 86.3 
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Table 8.10 (continued) 
UACC-62 87.6 37.5 86.4 113.5 85.4 86.4 108.3 
Ovarian 
Cancer 
IGROV1 95.3 46.3 87.1 96.9 85.1 85.6 67.2 
OVCAR-3 108.3 4.9 102.6 108.7 102.6 97.7 97.7 
OVCAR-4 89.2 67.3 82.9 109.6 81.3 79.9 26.1 
OVCAR-5 99.7 49.6 111.4 104.2 100.1 103.2 99.3 
OVCAR-8 96.3 26.7 92.3 103.8 107.7 92.6 70.9 
NCI/ADR-
RES 93.9 11.6 99.7 101.7 94.9 103.1 79.3 
SK-OV-3 102.7 28.8 101.3 104.8 94.4 97.9 70.6 
Renal 
Cancer 
786-0 96.5 50.3 94.5 103.2 98.2 95.6 72.4 
A498 81.8 -6.2 88.9 96.5 90.4 82.7 94.3 
ACHN 96.0 45.7 107.7 110.8 96.1 103.4 49.1 
CAKI-1 86.6 24.8 96.5 101.6 88.1 83.2 87.4 
RXF 393 100.0 23.3 106.2 111.0 95.5 96.1 94.4 
SN12C 95.4 37.2 95.3 103.2 94.7 95.9 93.5 
TK-10 98.1 32.2 95.6 96.5 96.1 81.0 90.2 
UO-31 67.1 28.0 78.6 88.0 76.5 80.1 73.7 
Prostate 
Cancer 
PC-3 88.7 21.2 97.3 100.4 89.2 94.3 91.5 
DU-145 107.2 28.3 94.4 104.2 94.2 99.3 94.1 
Breast 
Cancer 
MCF7 NA 20.7 85.5 87.2 82.3 93.7 79.9 
MDA-MB-
231 88.2 49.6 92.5 106.5 89.9 95.8 80.5 
HS 578T 100.2 27.2 115.1 114.1 112.0 101.0 81.3 
BT-549 82.1 30.3 86.4 91.8 91.4 100.4 94.1 
T-47D 70.7 35.8 75.6 88.7 82.0 83.8 74.7 
MDA-MB-
468 99.6 1.2 98.7 104.0 103.3 84.9 101.0 
 
Table 8.11. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-171, ST-173, ST-174, ST-175, ST-176, ST-177 and ST-178 at 10µM concentration. 
 
Table 8.11 (continued) 
Cancer cell type ST-171 ST-173 ST-174 ST-175 ST-176 ST-177 ST-178 
Leukemia 
CCRF-CEM 97.7 27.0 93.3 104.5 93.7 NA 52.3 
HL-60(TB) 108.4 7.1 87.3 83.5 83.8 NA NA 
K-562 105.7 15.9 76.2 105.2 112.9 39.2 21.7 
MOLT-4 83.1 22.7 79.2 79.7 NA NA NA 
RPMI-8226 94.7 58.1 84.6 103.5 89.3 NA 77.0 
SR 84.6 15.5 68.7 86.5 92.8 51.1 23.8 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 100.5 36.4 92.3 92.1 102.6 84.7 55.9 
HOP-62 91.9 54.0 88.0 94.5 102.9 87.2 75.9 
HOP-92 124.6 NA 99.9 NA NA NA NA 
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Table 8.11 (continued) 
NCI-H226 102.1 73.8 113.1 101.0 98.9 85.0 83.0 
NCI-H23 102.8 59.1 96.3 106.0 97.2 85.0 77.7 
NCI-
H322M 121.0 67.6 86.4 90.6 97.0 97.8 90.5 
NCI-H460 102.7 36.0 103.4 104.3 101.6 92.6 77.8 
NCI-H522 132.5 43.3 75.8 95.4 71.7 66.0 47.6 
Colon 
Cancer 
COLO 205 105.3 25.4 99.0 101.1 112.0 85.0 56.0 
HCC-2998 94.6 60.5 94.8 106.1 107.0 76.9 68.8 
HCT-116 97.1 19.3 99.5 102.2 94.0 71.4 32.7 
HCT-15 99.4 24.4 82.9 106.6 98.8 63.9 40.6 
HT29 108.6 10.0 89.7 102.2 106.1 70.3 23.5 
KM12 97.6 28.1 76.0 94.6 108.8 69.2 39.2 
SW-620 104.8 31.9 105.8 108.7 94.8 62.3 35.2 
CNS 
Cancer 
SF-268 101.1 53.1 94.4 101.5 108.9 98.2 71.0 
SF-295 98.5 27.1 97.5 100.9 109.6 91.1 68.2 
SF-539 97.8 19.0 93.8 105.4 99.8 91.8 67.9 
SNB-19 109.7 55.6 99.8 101.1 101.3 89.6 82.1 
SNB-75 111.8 12.8 76.2 67.7 102.3 73.5 61.6 
U251 107.8 29.2 91.1 93.7 95.8 95.5 47.3 
Melanoma 
LOX IMVI 104.6 41.0 102.9 111.6 103.1 77.3 65.2 
MALME-
3M 116.4 49.3 76.4 113.5 106.8 79.1 73.3 
M14 99.0 16.4 88.7 105.3 94.9 72.4 37.9 
MDA-MB-
435 98.2 -28.6 50.7 107.4 97.1 15.3 -28.5 
SK-MEL-2 119.3 2.7 98.9 106.2 98.9 80.1 59.8 
SK-MEL-28 115.1 50.2 98.3 113.0 113.1 91.0 64.6 
SK-MEL-5 104.7 31.7 98.9 102.4 92.2 85.0 66.2 
UACC-257 104.5 44.7 93.8 110.5 111.9 106.5 103.0 
UACC-62 105.7 39.7 81.9 106.5 85.7 56.6 44.7 
Ovarian 
Cancer 
IGROV1 121.0 45.1 97.9 96.4 113.4 77.1 68.8 
OVCAR-3 109.4 15.3 98.4 103.4 115.4 100.5 46.8 
OVCAR-4 106.6 73.7 88.7 91.0 100.0 98.6 68.9 
OVCAR-5 102.9 81.6 105.9 115.2 105.9 92.8 98.2 
OVCAR-8 96.7 63.1 104.0 90.8 56.2 100.1 99.0 
NCI/ADR-
RES 105.6 20.3 100.5 113.4 100.6 60.5 36.5 
SK-OV-3 102.3 33.2 97.3 102.2 103.2 89.2 61.9 
Renal 
Cancer 
786-0 94.6 52.1 91.4 96.7 94.0 84.8 77.1 
A498 111.3 26.5 100.9 103.3 90.7 72.5 35.7 
ACHN 109.3 59.1 101.5 112.1 108.7 92.3 79.3 
CAKI-1 94.2 40.0 86.9 97.3 102.6 79.3 61.2 
RXF 393 98.5 40.3 100.6 101.2 98.3 78.3 64.3 
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Table 8.11 (continued) 
SN12C 106.5 53.3 101.8 103.5 91.7 83.5 75.9 
TK-10 118.9 49.7 90.7 104.1 105.6 87.6 78.2 
UO-31 104.1 46.7 75.1 84.6 87.6 74.9 80.3 
Prostate 
Cancer 
PC-3 101.2 47.0 93.4 110.2 100.9 NA 80.1 
DU-145 109.0 63.9 99.3 98.5 114.6 103.9 77.7 
Breast 
Cancer 
MCF7 88.4 NA 109.5 87.1 112.1 71.6 26.1 
MDA-MB-
231 102.2 48.9 119.0 102.8 99.8 82.3 48.3 
HS 578T 121.7 43.8 135.0 118.8 128.9 81.9 65.5 
BT-549 94.5 35.3 86.4 96.5 88.5 64.1 51.8 
T-47D 102.0 43.5 76.3 90.7 93.4 65.1 67.9 
MDA-MB-
468 102.5 8.3 82.1 105.1 93.7 48.8 25.9 
 
Table 8.12. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-179, ST-180, ST-181, ST-183, ST-152, ST-153 and ST-112 at 10µM concentration. 
 
Table 8.12 (continued) 
Cancer cell type ST-179 ST-180 ST-181 ST-183 ST-152 ST-153 ST-112 
Leukemia 
CCRF-CEM 21.6 16.8 87.7 89.7 90.1 72.1 79.8 
HL-60(TB) 7.8 0.5 70.8 87.1 93.7 66.6 82.0 
K-562 19.1 18.8 64.2 70.3 89.9 37.9 41.3 
MOLT-4 26.8 17.4 71.5 78.5 73.0 70.4 70.2 
RPMI-8226 5.3 9.3 73.2 84.9 81.0 64.7 81.8 
SR 18.4 13.5 50.1 60.5 81.2 39.3 28.3 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 31.7 17.2 77.4 56.8 88.9 71.2 87.4 
HOP-62 44.4 58.5 88.1 69.7 97.4 86.6 105.2 
HOP-92 NA 60.8 64.9 90.2 54.1 93.0 83.5 
NCI-H226 38.5 28.7 93.3 70.8 72.5 86.6 91.8 
NCI-H23 49.9 31.1 93.7 58.8 77.3 96.1 89.2 
NCI-
H322M 34.3 40.9 98.3 66.6 94.3 94.7 99.6 
NCI-H460 13.2 9.7 95.2 24.7 96.8 64.3 98.3 
NCI-H522 1.4 -20.5 79.8 58.8 58.7 90.5 56.7 
Colon 
Cancer 
COLO 205 7.6 -33.9 97.6 103.5 103.9 76.2 114.2 
HCC-2998 45.7 6.4 93.2 95.1 101.8 80.0 79.1 
HCT-116 21.1 11.6 82.6 20.5 70.3 64.9 86.1 
HCT-15 21.4 20.4 78.0 79.7 74.9 59.0 76.2 
HT29 10.0 5.0 63.8 71.9 84.8 64.5 85.6 
KM12 21.0 6.0 63.9 86.8 89.0 63.6 63.0 
SW-620 10.6 21.0 86.1 89.9 73.1 84.9 83.5 
CNS SF-268 34.0 23.8 91.0 62.5 98.4 92.0 96.9 
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Table 8.12 (continued) 
Cancer SF-295 5.6 2.9 89.3 64.0 95.6 80.8 94.7 
SF-539 -42.9 -10.1 83.1 69.6 90.8 83.7 NA 
SNB-19 36.1 46.4 96.4 34.7 96.4 49.4 93.0 
SNB-75 -3.1 0.5 57.0 5.4 32.2 80.8 85.0 
U251 18.7 18.4 84.5 26.7 69.6 80.9 88.5 
Melanoma 
LOX IMVI 35.2 19.9 95.6 59.5 99.8 101.9 77.0 
MALME-
3M 37.9 55.1 90.6 68.3 90.6 79.9 85.1 
M14 16.2 20.6 91.1 90.3 88.4 10.4 88.7 
MDA-MB-
435 -26.3 -37.2 37.2 48.3 97.8 77.9 22.7 
SK-MEL-2 13.1 29.2 93.2 87.1 83.2 90.1 84.1 
SK-MEL-28 43.6 60.6 95.1 88.6 104.6 81.4 84.0 
SK-MEL-5 19.1 16.6 84.1 95.3 88.7 91.4 88.5 
UACC-257 41.0 72.8 89.4 NA NA NA 103.5 
UACC-62 25.1 24.0 79.9 86.8 64.2 69.2 76.0 
Ovarian 
Cancer 
IGROV1 36.3 34.3 90.6 55.1 70.5 84.6 84.0 
OVCAR-3 -21.2 -29.5 100.0 63.0 82.3 88.7 101.7 
OVCAR-4 49.7 60.2 81.6 45.0 65.6 76.4 106.1 
OVCAR-5 55.7 50.4 95.0 81.1 98.7 93.9 112.6 
OVCAR-8 29.0 14.0 90.1 60.8 92.8 94.7 86.2 
NCI/ADR-
RES 10.5 -1.9 86.0 64.3 89.0 75.3 72.1 
SK-OV-3 26.9 20.7 83.1 25.8 91.1 88.6 91.3 
Renal 
Cancer 
786-0 40.2 44.7 106.6 51.9 99.9 95.4 98.2 
A498 -8.4 -7.5 70.8 54.1 83.7 63.3 91.0 
ACHN 44.7 38.8 93.4 41.4 86.5 95.3 86.5 
CAKI-1 30.8 41.2 75.3 76.0 71.8 78.2 88.8 
RXF 393 -17.7 -2.6 86.5 80.0 84.1 91.4 92.7 
SN12C 38.6 25.3 92.6 73.0 89.6 84.3 93.7 
TK-10 43.8 42.7 80.4 45.0 122.7 85.7 103.8 
UO-31 42.1 34.9 82.3 72.8 70.1 72.8 79.6 
Prostate 
Cancer 
PC-3 36.1 25.8 77.9 77.5 79.2 81.0 82.9 
DU-145 14.9 5.1 97.4 81.3 100.0 95.0 102.9 
Breast 
Cancer 
MCF7 12.1 16.3 83.5 84.6 49.6 60.8 71.4 
MDA-MB-
231 39.4 24.3 75.6 50.2 69.5 68.7 87.5 
HS 578T -14.1 -5.4 100.7 34.8 105.2 92.4 97.1 
BT-549 26.6 56.4 81.0 86.1 80.0 74.7 84.0 
T-47D 38.2 70.4 81.0 69.4 45.4 70.0 82.5 
MDA-MB-
468 -14.5 14.1 60.8 77.8 64.6 48.6 81.6 
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Table 8.13. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
TMR-03, TMR-01, ST-252, ST-253, ST-257, ST-260 and ST-261 at 10µM 
concentration.  
 
Table 8.13 (continued) 
Cancer cell type 
TMR-
03 
TMR-
01 ST-252 ST-253 ST-257 ST-260 ST-261 
Leukemia 
CCRF-CEM NA NA 58.7 0.4 6.4 3.7 1.3 
HL-60(TB) 97.4 33.1 38.0 -46.3 -15.7 -41.3 -47.7 
K-562 93.9 14.3 18.7 7.5 11.6 5.3 3.4 
MOLT-4 98.9 65.1 32.2 -14.3 19.6 -15.8 -12.8 
RPMI-8226 86.2 63.4 80.8 39.2 57.1 67.1 50.3 
SR 80.0 10.9 -1.3 -11.0 1.8 -9.0 -16.5 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 86.5 38.0 41.5 21.1 40.0 18.1 19.1 
HOP-62 56.3 82.7 68.3 40.8 36.9 38.5 30.6 
HOP-92 NA NA 89.0 -1.7 39.3 6.5 NA 
NCI-H226 88.2 78.2 81.2 43.9 71.1 47.4 42.9 
NCI-H23 74.9 64.1 78.3 20.7 46.8 22.3 21.1 
NCI-
H322M 94.6 95.7 77.5 24.2 34.5 19.5 27.1 
NCI-H460 81.8 49.6 33.4 5.2 12.4 4.5 3.3 
NCI-H522 62.8 55.5 39.3 -27.0 -30.1 -42.2 -44.8 
Colon 
Cancer 
COLO 205 112.8 67.9 50.5 -74.4 -1.3 -51.6 -70.0 
HCC-2998 107.1 69.8 55.7 14.9 60.1 14.9 14.6 
HCT-116 83.2 74.1 38.8 -12.3 22.3 -12.6 -31.0 
HCT-15 95.1 47.4 43.4 16.5 31.6 14.3 10.5 
HT29 103.2 48.2 21.8 0.4 6.6 -17.8 -17.8 
KM12 99.5 54.6 27.8 2.0 30.6 0.7 -10.7 
SW-620 95.4 60.2 28.8 25.2 15.5 22.8 21.6 
CNS 
Cancer 
SF-268 74.6 82.5 71.9 24.6 53.2 26.8 20.5 
SF-295 91.5 66.3 66.7 -8.0 -14.0 -20.2 -21.2 
SF-539 NA NA 63.7 2.5 5.6 -2.4 -19.9 
SNB-19 101.3 80.9 83.3 51.2 53.2 55.4 50.2 
SNB-75 72.3 85.0 61.1 17.1 2.2 5.8 15.2 
U251 88.7 71.0 36.3 8.1 19.9 5.6 4.7 
Melanoma 
LOX IMVI NA NA 56.7 24.7 44.9 21.3 25.3 
MALME-
3M 91.2 66.1 64.6 64.3 51.8 45.2 64.2 
M14 94.7 12.6 38.5 5.7 19.7 1.2 -15.0 
MDA-MB-
435 97.5 53.0 -29.8 -22.2 -17.6 -34.5 -26.3 
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Table 8.13 (continued) 
SK-MEL-2 88.4 66.3 36.0 24.1 19.4 10.5 2.2 
SK-MEL-28 86.7 43.8 75.3 63.0 61.7 64.1 62.0 
SK-MEL-5 81.4 79.8 45.0 -38.0 16.8 -1.5 -31.8 
UACC-257 91.3 50.8 76.7 76.0 66.7 72.8 76.7 
UACC-62 77.2 68.3 53.7 45.4 43.7 38.2 42.3 
Ovarian 
Cancer 
IGROV1 98.3 95.1 71.3 25.5 49.5 26.2 31.4 
OVCAR-3 103.1 64.8 NA NA NA NA NA 
OVCAR-4 63.2 86.4 94.6 44.9 69.3 40.9 33.2 
OVCAR-5 105.4 82.4 88.0 49.1 73.5 42.5 43.5 
OVCAR-8 69.1 48.1 77.1 10.4 30.1 6.2 2.4 
NCI/ADR-
RES 81.0 76.0 34.4 17.0 24.5 2.5 15.2 
SK-OV-3 69.8 82.5 81.0 17.6 20.0 15.9 3.5 
Renal 
Cancer 
786-0 95.0 -10.6 80.2 14.8 39.3 17.2 10.7 
A498 87.8 74.9 70.9 -11.0 -4.1 -1.3 -10.1 
ACHN 83.5 62.9 87.7 34.4 51.3 34.8 27.1 
CAKI-1 88.2 60.4 64.2 20.0 17.6 8.5 0.5 
RXF 393 96.3 82.2 77.3 41.8 14.9 19.2 27.1 
SN12C 87.5 83.5 72.1 34.5 56.7 34.1 27.1 
TK-10 124.6 66.7 65.2 48.5 45.7 41.7 50.2 
UO-31 83.8 63.6 73.2 23.9 41.8 26.9 31.4 
Prostate 
Cancer 
PC-3 80.9 91.8 70.9 26.5 21.3 16.5 16.3 
DU-145 100.0 63.4 84.7 6.7 20.7 6.5 0.3 
Breast 
Cancer 
MCF7 63.3 40.3 24.4 14.6 20.1 13.8 11.5 
MDA-MB-
231 74.2 73.0 68.4 13.7 63.0 16.9 13.7 
HS 578T 72.9 63.2 79.6 18.7 16.3 17.2 11.0 
BT-549 70.9 82.6 56.6 -17.2 19.2 -16.9 -37.9 
T-47D NA NA 40.4 84.4 31.0 79.3 83.1 
MDA-MB-
468 51.7 50.1 14.8 -15.1 -11.4 2.0 0.3 
 
Table 8.14. Percentage growth inhibition of NCI 60 human cancer cells by compounds 
ST-287, ST-288, ST-507, ST-507(A), ST-509, ST-510 and ST-124 at 10µM 
concentration. 
 
Table 8.14 (continued) 
Cancer cell type ST-287 ST-288 ST-507 
ST-
507(A) 
ST-
509 
ST-
510 
ST-
124 
Leukemia 
CCRF-CEM 83.4 88.3 14.5 18.1 17.6 7.9 NA 
HL-60(TB) 41.8 92.3 -3.9 2.5 5.4 5.4 NA 
K-562 NA NA 12.3 14.5 11.7 14.3 NA 
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Table 8.14 (continued) 
MOLT-4 84.3 83.5 15.1 19.9 15.9 8.0 NA 
RPMI-8226 87.1 79.9 37.1 38.3 25.1 12.8 NA 
SR 37.5 88.7 7.1 8.9 9.6 19.0 NA 
Non-Small 
Cell Lung 
Cancer 
A549/ATCC 44.7 86.9 19.4 25.2 22.4 35.8 88.7 
HOP-62 84.5 94.1 41.5 48.2 33.4 49.2 89.8 
HOP-92 55.8 64.1 77.9 47.9 35.4 15.3 111.5 
NCI-H226 94.2 83.4 77.3 72.0 67.7 33.3 100.3 
NCI-H23 89.1 88.7 27.8 28.0 20.1 4.1 101.6 
NCI-
H322M 91.7 93.9 49.9 49.0 40.2 -35.6 95.5 
NCI-H460 79.7 99.0 6.6 8.3 9.5 6.1 100.5 
NCI-H522 66.8 71.8 -24.2 -8.3 -30.6 14.1 92.1 
Colon 
Cancer 
COLO 205 79.3 103.2 97.9 92.3 57.2 6.0 NA 
HCC-2998 93.6 102.3 23.9 26.7 22.6 8.4 97.8 
HCT-116 92.4 97.5 6.3 2.5 2.8 8.9 103.2 
HCT-15 67.8 81.1 13.8 13.6 13.6 10.0 98.3 
HT29 72.4 87.7 81.6 87.9 58.0 22.5 101.8 
KM12 68.4 109.8 16.6 16.1 16.0 22.5 103.5 
SW-620 80.9 102.0 28.5 35.3 36.1 6.2 104.5 
CNS 
Cancer 
SF-268 95.4 94.3 41.7 42.6 36.1 -24.8 108.1 
SF-295 87.6 98.7 19.6 28.1 18.6 22.7 96.8 
SF-539 93.7 101.4 8.4 -1.2 -6.0 61.0 96.2 
SNB-19 90.3 90.0 55.7 62.8 56.8 4.9 108.2 
SNB-75 67.2 89.5 49.2 59.0 70.1 19.2 106.4 
U251 82.1 79.4 13.4 9.6 1.0 70.5 92.8 
Melanoma 
LOX IMVI 93.0 102.0 29.6 33.7 34.2 11.2 NA 
MALME-
3M 78.4 103.7 85.4 80.4 74.5 -13.4 113.7 
M14 91.8 104.6 19.3 13.3 11.4 25.0 NA 
MDA-MB-
435 19.5 96.2 1.9 7.8 5.2 53.7 99.0 
SK-MEL-2 86.9 97.8 28.7 48.5 27.9 -47.2 90.4 
SK-MEL-28 86.8 99.0 47.9 47.4 58.6 46.9 107.2 
SK-MEL-5 66.5 94.6 -20.8 -51.9 -64.1 10.5 116.1 
UACC-257 82.8 91.6 82.6 91.4 63.3 27.0 105.1 
UACC-62 68.7 81.4 47.8 54.6 44.9 1.5 106.7 
Ovarian 
Cancer 
IGROV1 87.5 99.6 41.4 37.6 33.6 38.4 81.4 
OVCAR-3 NA NA NA NA NA NA 104.6 
OVCAR-4 75.0 76.0 10.4 15.0 14.6 7.4 118.2 
OVCAR-5 83.6 97.1 66.4 67.0 55.9 0.7 111.9 
OVCAR-8 85.8 93.6 42.9 50.4 34.8 2.0 102.9 
NCI/ADR-
RES 76.6 99.7 19.7 19.3 12.9 19.2 98.7 
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Table 8.14 (continued) 
SK-OV-3 86.7 105.3 22.2 25.2 24.9 -15.2 89.7 
Renal 
Cancer 
786-0 92.7 97.1 33.5 40.8 23.0 22.7 107.7 
A498 14.4 74.0 30.0 21.4 15.5 22.9 108.0 
ACHN 76.0 88.5 36.2 36.4 8.1 22.2 89.1 
CAKI-1 73.6 92.8 27.7 26.7 29.6 24.6 97.2 
RXF 393 NA NA 41.6 39.5 33.7 55.0 78.5 
SN12C 86.1 91.7 45.5 41.2 42.9 34.1 96.3 
TK-10 78.6 89.0 86.4 87.9 78.2 29.0 116.6 
UO-31 72.5 84.3 47.0 45.4 35.2 10.4 83.2 
Prostate 
Cancer 
PC-3 87.9 86.5 26.4 29.2 35.5 10.5 97.3 
DU-145 101.3 NA 15.5 14.9 16.2 5.9 111.7 
Breast 
Cancer 
MCF7 77.9 103.1 19.4 24.2 22.1 40.1 89.7 
MDA-MB-
231 76.9 98.4 25.8 27.4 33.9 3.5 80.3 
HS 578T 88.7 101.2 44.0 59.7 49.3 61.6 94.6 
BT-549 84.0 93.6 NA NA NA NA 120.2 
T-47D 75.2 80.1 NA NA NA NA 92.7 
MDA-MB-
468 64.6 89.1 32.5 38.5 8.3 -5.9 65.1 
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Data Set 3 
CB1 and CB2 competitive binding screening at 1µM concentration. 
Figure 8.1: CB1 and CB2 competitive binding screen at 1µM concentration with ST-
179, ST-173, ST-165, ST-172, ST-171 and ST-167. 
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Figure 8.2: CB1 and CB2 competitive binding screen at 1µM concentration with ST-
177, ST-162, ST-164, ST-184, ST-178 and ST-161 
 
 
 
 
 
 
 
 
 
226 
 
 
 
Figure 8.3: CB1 and CB2 competitive binding screen at 1µM concentration with ST-
190, ST-175, ST-181, ST-185, ST-169 and ST-183. 
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Figure 8.4: CB1 and CB2 competitive binding screen at 1µM concentration with ST-
192, ST-193, ST-194, ST-195, ST-196 and ST-197. 
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Figure 8.5: CB1 and CB2 competitive binding screen at 1µM concentration with ST-
198, ST-179(repeat), ST-188, ST-166, ST-176 and ST-191 
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Figure 8.6: CB1 and CB2 competitive binding screen at 1µM concentration with ST-
153, ST-155, ST-147(a) and ST-156. 
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Data Set 4 
NMR spectral data of selected compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.7 1H NMR spectral data of compound ST-145(a) 
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Figure 8.8 1D NOE spectral data of compound ST-145(a). Blue circled hydrogen is 
excited. 
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Figure 8.9 1D NOE spectral data of compound ST-145(a). Blue circled hydrogen is 
excited. 
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Figure 8.10 1H NMR spectral data of compound ST-145 
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Figure 8.11 13C NMR spectral data of compound ST-145 
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Figure 8.12 1H NMR spectral data of compound ST-510 
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Figure 8.13 13C NMR spectral data of compound ST-510 
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Figure 8.14 1H NMR spectral data of compound ST-467 
 
H3CO
H3CO OCH3 OCH3
ST-467
N
H
N
N
238 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.15 13C NMR spectral data of compound ST-467 
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Figure 8.17 13C NMR spectral data of compound ST-145(b) 
 
Figure 8.16 1H NMR spectral data of compound ST-145(b) 
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Figure 8.17 13C NMR spectral data of compound ST-145(b) 
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